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ABSTRACT
Myelinated axons are essential for the normal functioning of the brain. Since myelinated 
axons, like grey matter, are dependent on a continuous supply of energy, it is likely that 
ischaemic injury compromises axonal function as well as that of the neuronal cell 
bodies. Axonal injury following cerebral ischaemia has attracted less attention than 
damage in grey matter. However, it is becoming increasingly recognised that axons are 
highly vulnerable to focal ischaemia. Since white matter does not contain neuronal cell 
bodies or synapses it is likely that the mechanisms of injury and strategies for its 
protection are different from those in grey matter.
To define markers of axonal injury appropriate for use in the assessment of 
axonal pathology consequent to focal cerebral ischaemia, immunocytochemical methods 
were employed. Antibodies to a synaptosomal associated protein of 25 kDa (SNAP25), 
which is transported by fast anterograde transport; the 68-kDa neurofilament subunit 
(NF68kD) and microtubule-associated protein 5 (MAP5), were investigated on sections 
from rats subjected to 30 minutes, 1, 2, and 4 h of ischaemia induced by permanent 
middle cerebral artery (MCA) occlusion. After 4 h of occlusion, there was increased 
SNAP25 immunoreactivity which was bulbous in appearance, reminiscent of axonal 
swellings which occur following blunt head injury. Increased SNAP25 
immunoreactivity was present in circumscribed zones in the subcortical white matter 
and in the axonal tracts at the border of infarction, a pattern similar to that previously 
described for amyloid precursor protein. Although less marked, similar changes in 
immunoreactivity in axons were evident following 2 h of ischaemia. MAP5 and 
NF68kD had striking changes in immunoreactivity in axonal tracts permeating the 
caudate nucleus within the MCA territory at 4 h. The appearance was roughened and
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disorganised compared to the smooth regular staining in axons within the non-ischaemic 
areas. Profiles reminiscent of axonal bulbs were evident in MAP5 stained sections. The 
changes seen with NF68kD and MAP5 were also evident at 2 h but were more subtle at 
1 h. There were no changes in axonal immunoreactivity with SNAP25 or NF68kD at 30 
minutes post MCA occlusion. Altered immunoreactivity following ischaemia using 
SNAP25, MAP5 and NF68kD provide further evidence for the progressive breakdown 
of the axonal cytoskeleton following an ischaemic insult. NF68kD and MAP5 appear to 
be sensitive markers of the structural disruption of the cytoskeleton, which precedes the 
subsequent accumulation of SNAP25 within the damaged axons. Axonal cytoskeletal 
breakdown and disruption of fast axonal transport, which are well recognised features of 
traumatic brain injury, are also sequelae of an ischaemic insult.
To allow future assessments of protection of white matter by therapeutic 
interventions, a method by which axonal injury can be quantified is required. For this 
purpose, immunocytochemical methods using amyloid precursor protein (APP) were 
investigated following permanent MCA occlusion in the rat. APP is transported by fast 
anterograde axonal transport and has been shown to accumulate following a variety of 
insults to axons, indicative of dysfunction of axonal transport. The topographical 
relationship between APP accumulation and region of infarction was mapped using 
immunocytochemistry and image analysis techniques. Additionally, using a semi- 
quantitative scoring system in the rat, a relationship was demonstrated between the 
amount of APP accumulation and the volume of infarction following middle cerebral 
artery occlusion.
A number of studies have shown certain drugs to be neuroprotective following 
focal cerebral ischaemia in the rat and cat. However, the effect of neuroprotection has 
often been assessed by a reduction in neuronal necrosis volume; the effect on axons
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being largely ignored. Since APP has been shown to be a good marker of axonal injury, 
and a method of semi-quantitative analysis was developed, the method was utilised to 
determine whether BW619C89 or MK-801 protects axons following focal cerebral 
ischaemia in the rat. Both drugs failed to significantly reduce the APP score. However, 
in the rat brain the volume of white matter is relatively small compared to the volume of 
grey matter. Therefore the possibility that neuroprotective drugs such as MK-801 are 
saving white matter but that this protection is unable to be detected in the rat, was 
addressed.
The cat brain offers several advantages over the rat for the purpose of assessment 
of axonal injury. Conceivably, a shift in the boundary and a change in the quantity of 
APP accumulation could be more readily appreciated following neuroprotection in the 
cat. The study undertaken in the cat demonstrated that increased APP immunoreactivity 
is a consistent outcome in white matter after focal cerebral ischaemia. Secondly, using 
two different scoring systems for APP, which were developed to overcome the 
limitations encountered in the rat tissue, it was found that the larger the volume of the 
ischaemic lesion, the greater the extent of APP immunoreactivity. Once these two facts 
had been established, it was possible to assess whether MK-801 protects axons 
following focal cerebral ischaemia. MK-801 failed to reduce the APP score in the cat 
following MCA occlusion. Further analysis suggested that following MK-801 
administration, the axonal injury:neuronal necrosis ratio was higher than in vehicle 
treated animals. That is, MK-801 failed to protect axons. The potential implications for 
drug development are huge. The failure of many recent drug trials and the findings of 
the present study, suggest that the success of future strategies may be dependant on the 
protection of the brain as a whole.
IV
LIST OF CONTENTS
ABSTRACT..........................................................................................................................II
LIST OF CONTENTS.......................................................................................................... V
LIST OF FIGURES........................................................................................................... IX
LIST OF TABLES.............................................................................................................. XI
LIST OF ABBREVIATIONS........................................................................................XIII
ACKNOWLEDGEMENT...............................................................................................XIV
PREFACE AND DECLARATION.................................................................................X V
CHAPTER 1 .......................................................................................................................... 1
INTRODUCTION.................................................................................................................1
1.1 GENERAL INTRODUCTION..................................................................................................1
1.2 ACUTE BRAIN INJURY.......................................................................................................... 3
1.2.1 Stroke.......................................................................................................................................................... 3
1.2.2 Traumatic brain injury..............................................................................................................................4
1.3 FUNCTIONAL ANATOMY OF CEREBRAL WHITE MATTER............................... 5
1.4 MYELINATED AXONS - STRUCTURE AND FUNCTION..........................................5
1.4.1 Neurofilaments.......................................................................................................................................... 7
1.4.2 Microtubules..............................................................................................................................................8
1.4.3 Microfilaments.......................................................................................................................................... 9
1.4.4 Axonal transport...................................................................................................................................... 10
1.4.5 Axonal ion channels..............................................................................................................................11
1.5 MECHANISMS OF NERVE INJURY................................................................................. 13
1.5.1 Introduction.............................................................................................................................................. 13
1.5.2 Glutamate-receptor-mediated neuronal cell body damage............................................................... 13
1.5.3 White matter injury.................................................................................................................................19
1.5.4 Action o f calcium....................................................................................................................................26
1.6 NEUROPROTECTION WITH GLUTAMATE ANTAGONISTS................................31
1.6.1 Introduction..............................................................................................................................................31
1.6.2 Blockade o f postsynaptic action of glutamate....................................................................................31
1.6.3 Prevention o f glutamate release........................................................................................................... 34
1.7 ASSESSMENT OF WHITE MATTER INJURY IN VTVO............................................35
1.7.1 Introduction..............................................................................................................................................35
1.7.2 Immunohistochemistry...........................................................................................................................35
1.7.3 Evoked potentials....................................................................................................................................41
1.7.4 MRI........................................................................................................................................................... 42
1.8 AIMS OF THESIS......................................................................................................................47
V
CHAPTER 2 ......................................................................................................................... 48
MATERIALS AND METHODS........................................................................................ 48
2.1 FOCAL CEREBRAL ISCHAEMIA IN THE R A T ...........................................................48
2.1.1 Source and Strain.................................................................................................................................... 48
2.1.2 Anaesthesia...............................................................................................................................................49
2.1.3 Middle cerebral artery occlusion...........................................................................................................52
2.1.4 Transcardiac perfusion and subsequent tissue processing.................................................................54
2.2 FOCAL CEREBRAL ISCHAEMIA IN THE C A T ...........................................................56
2.2.1 Source........................................................................................................................................................56
2.2.2 Anaesthesia...............................................................................................................................................56
2.2.3 Middle cerebral artery occlusion...........................................................................................................57
2.3 LIGHT MICROSCOPE IMMUNOHISTOCHEMISTRY..............................................58
2.3.1 FAM fixed material................................................................................................................................. 58
2.3.2 PAM fixed sections................................................................................................................................. 60
2.3.3 Tissue pretreatments................................................................................................................................ 60
2.3.4 Antibody concentrations........................................................................................................................ 61
2.4 HISTOLOGICAL PROCEDURES....................................................................................... 64
2.5 MEASUREMENT OF VOLUME OF INFARCTION.......................................................64
2.5.1 Determination in the rat.......................................................................................................................... 64
2.5.2 Determination in the cat......................................................................................................................... 64
2.6 ELECTRON MICROSCOPE IMMUNOHISTOCHEMISTRY....................................69
2.6.1 Correlated light and electron microscopy............................................................................................ 69
2.6.2 Antibody concentrations........................................................................................................................ 71
CHAPTER 3 ..........................................................................................................................73
MARKERS OF AXONAL INJURY...................................................................................73
3.1 INTRODUCTION...................................................................................................................... 73
3.2 LIGHT MICROSCOPIC STUDIES...................................................................................... 74
3.2.1 Animal preparation.................................................................................................................................. 74
3.2.2 Analysis o f  material................................................................................................................................. 75
3.2.3 Results........................................................................................................................................................75
3.3 ELECTRON MICROSCOPE STUDIES..............................................................................88
3.3.1 Animal Preparation................................................................................................................................. 88
3.3.2 Results........................................................................................................................................................88
3.4 DISCUSSION............................................................................................................................... 95
CHAPTER 4 ......................................................................................................................... 99
QUANTITATIVE ANALYSIS OF AXONAL INJURYIN THE RAT ...........................99
4.1 INTRODUCTION......................................   99
4.2 M ETHOD....................................................................................................................................100
4.2.1 Anaesthesia and MCA occlusion......................................................................................................... 100
4.2.2 Mapping areas o f infarction.................................................................................................................102
4.2.3 Immunocytochemistry...........................................................................................................................103
4.2.4 Topography o f increased APP immunoreactivity............................................................................. 103
4.2.5 Quantitative analysis o f APP immunoreactivity............................................................................... 104
VI
4.3 RESULTS...........................................................................................................................   110
4.3.1 APP immimocytochemistry after middle cerebral artery occlusion.............................................. 110
4.3.2 Reproducibility o f semi-quantitative analysis..................................................................................110
4.3.3 Relationship between ischaemia and APP accumulation............................................................... I l l
4.4 DISCUSSION............................................................................................................................ 117
CHAPTER 5 ...................................................................................................................... 118
QUANTITATIVE ANALYSIS OF APP FOLLOWING DRUG INTERVENTION IN  
THERAT........................................................................................................................... 118
5.1 INTRODUCTION................................................................................................................... 118
5.2 M ETHOD...................................................................................................................................119
5.2.1 MK-801 treated animals...................................................................................................................... 119
5.2.2 BW619C89 treated animals................................................................................................................120
5.2.3 Tissue processing and APP analysis...................................................................................................120
5.3 RESULTS OF MK-801 STUDY........................................................................................... 122
5.3.1 Physiology.............................................................................................................................................. 122
5.3.2 APP immunocytochemistry after MCA occlusion........................................................................... 122
5.3.3 Effect o f MK-801 on ischaemic damage...........................................................................................122
5.3.4 Effect o f MK-801 on APP accumulation..........................................................................................123
5.4 RESULTS OF BW619C89 STUDY.....................................................................................135
5.4.1 APP immunocytochemistry after MCA occlusion........................................................................... 135
5.4.2 Effect o f  BW619C89 on ischaemic damage..................................................................................... 135
5.4.3 Effect o f BW619C89 on APP accumulation.................................................................................... 135
5.5 DISCUSSION............................................................................................................................ 147
CHAPTER 6 ...................................................................................................................... 151
QUANTITA TIVEANAL YSIS OF APP FOLLOWING DRUG INTERVENTION IN  
THE CAT,...........................................................................................................................151
6.1 INTRODUCTION....................................................................................................................151
6.2 M ETHOD................................................................................................................................... 154
6.2.1 Anaesthesia, MCA occlusion and tissue processing........................................................................154
6.2.2 Topographical analysis o f APP immunoreactivity.......................................................................... 159
6.2.3 Quantification o f  APP immunoreactivity..........................................................................................163
6.3 RESULTS................................................................................................................................... 171
6.3.1 APP immunocytochemistry after MCA occlusion........................................................................... 171
6.3.2 Relationship between ischaemia and APP accumulation............................................................... 171
6.3.3 Effect o f MK-801 on APP accumulation..........................................................................................171
6.3.4 Semi-quantitative analysis versus point-counting technique of APP............................................ 173
6.4 DISCUSSION............................................................................................................................ 185
6.4.1 The species issue...................................................................................................................................185
6.4.2 Semi-quantitative versus quantitative analysis o f APP................................................................... 185
6.4.3 MK-801 and the protection of axons................................................................................................. 186
VII
CHAPTER 7......................................................................................................................188
DISCUSSION....................................................................................................................188
7.1 INTRODUCTION................................................................................................................... 188
7.2 THE SEARCH FOR A MARKER OF AXONAL INJURY..........................................190
7.2.1 MAP5, SNAP25, NF68kD and APP....................................................................................... 190
7.2.2 Does APP accumulation reflect irreversible injury to axons?................................................. 198
7.2.3 Axonal injury: Common mechanisms following head injury and focal cerebral ischaemia... 199
7.3 QUANTIFICATION OF AXONAL INJURY................................................................. 202
7.4 NEUROPROTECTION: BRAIN PROTECTION?........................................................207
7.4.1 Glutamate antagonists in clinical trials....................................................................................207
7.4.2 Cerebral white matter is highly vulnerable to ischaemia.........................................................210
7.4.3 NMDA antagonists: preservation of white matter?.................................................................210
7.5 THE FUTURE......................................................................................................................... 213
APPENDIX 1.....................................................................................................................216
Sources o f commonly used materials............................................................................................216
APPENDIX 2.....................................................................................................................217
Stock solutions and buffers.......................... ,................................................................................. 217
Materials for electron microscopy................................................................................................. 218
APPENDIX 3.....................................................................................................................219
Haematoxylin and eosin staining for paraffin sections.............................................................. 219
Luxol fast blue staining for paraffin sections...............................................................................219
APPENDIX 4.....................................................................................................................220
DENSITOMETRIC ANALYSIS OF APP IN THE RAT.............................................220
A4.1 M ETHOD...............................................................................................................................220
A4.2 RESULTS...............................................................................................................................226
A4.2.1 Reproducibility of quantitative analysis...............................................................................226
A4.2.2 Relationship between ischaemia and APP accumulation...................................................... 229
A4.3 DISCUSSION........................................................................................................................ 229
REFERENCES................................................................................................................ 232
ABSTRACTS AND PAPERS...........................................................................................257
VIII
LIST OF FIGURES
CHAPTER 1
Figure 1.1 The components o f the cytoskeleton............................................................................... 7
Figure 1.2 Illustration o f movement o f membrane-associated material in fast axonal
transport.................................................................................................................................................11
Figure 1.3 Glutamate mediated neuronal damage.......................................................................... 17
Figure 1.4 The NMDA receptor-ion channel complex...................................................................18
Figure 1.5 Anoxia-induced calcium accumulation in myelinated CNS axons.......................... 23
Figure 1.6 Anoxia induced GABA release......................................................................................25
Figure 1.7 Mechanisms of grey and white matter injury compared............................................ 30
Figure 1.8 Neuroprotection in the cat brain following MK-801 administration....................... 33
Figure 1.9 Semi-quantitative analysis o f amyloid precursor protein in man..............................40
CHAPTER 2
Figure 2.1 Incidence and topography of infarction in different rat strains................................. 51
Figure 2.2 Middle cerebral artery in the rat..................................................................................... 53
Figure 2.3 Negative controls for immunocytochemistry...............................................................59
Figure 2.4 Eight coronal levels in the rat brain.............................................................................. 66
Figure 2.5 Transcription o f area o f infarction onto line diagrams.............................................. 67
Figure 2.6 Sixteen coronal levels in the cat brain..........................................................................68
Figure 2.7 Correlated light and electron microscopy.................................................................... 72
CHAPTER 3
Figure 3.1 MAP2, H&E and LFB following 4h MCA occlusion.................................................80
Figure 3.2 MAP2 immunoreactivity at different time points following MCA occlusion 81
Figure 3.3 Diagrammatic representation o f MAP5,SNAP25 andNF68kD immunoreactivity 
following MCA occlusion..................................................................................................................82
Figure 3.4 SNAP25 immunoreactivity in the caudate nucleus following MCA occlusion......83
Figure 3.5 SNAP25 immunoreactivity in the subcortical white matter following MCA 
occlusion............................................................................................................................................... 84
Figure 3.6 NF68kD immunoreactivity in the subcortical white matter following MCA 
occlusion............................................................................................................................................... 85
Figure 3.7 NF68kD immunoreactivity in the caudate nucleus following MCA occlusion......86
Figure 3.8 MAP5 immunoreactivity in the caudate nucleus following MCA occlusion.........87
Figure 3.9 Ultrastructural analysis o f NF68kD immunoreactivity - low magnification 90
Figure 3.10 Ultrastructural analysis o f NF68kD immunoreactivity - high magnification.......91
Figure 3.11 Ultrastructural analysis o f APP immunoreactivity...................................................92
IX
Figure 3.12 Axotomy following MCA occlusion.......................................................................... 93
Figure 3.13 Accumulation of APP and organelles following MCA occlusion......................... 94
CHAPTER 4
Figure 4.1 Incidence and topography o f infarction and APP accumulation.............................107
Figure 4.2 Transcription of APP onto line diagrams................................................................... 108
Figure 4.3 APP accumulation score............................................................................................... 109
Figure 4.4 Reproducibility o f semi-quantitative APP analysis..................................................112
Figure 4.5 APP immunoreactivity following MCA occlusion...................................................113
Figure 4.6 Location o f increased APP immunoreactivity.......................................................... 114
Figure 4.7 Relationship o f total APP accumulation score to volume o f infarction.................115
Figure 4.8 Relationship o f APP score and infarction at each coronal level.............................116
CHAPTER 5
Figure 5.1 Topographical map o f APP accumulation in vehicle and MK-801 treated
animals............................................................................................................................................... 125
Figure 5.1 cont...................................................................................................................................126
Figure 5.2 Effect o f MK-801 on total volume o f ischaemic damage and total APP score 
following MCA occlusion...............................................................................................................131
Figure 5.3 Effect o f MK-801 on area o f ischaemic damage and mean APP score at eight 
defined coronal levels following MCA occlusion....................................................................... 132
Figure 5.4 Relationship o f volume o f ischaemic damage and APP accumulation score: effect 
of MK-801......................................................................................................................................... 133
Figure 5.5 APP accumulation score in MK-801 treated animals: subgroup analysis............ 134
Figure 5.6 Topographical map of APP accumulation in vehicle and BW619C89 treated 
animals................................................................................................................................................137
Figure 5.6 cont...................................................................................................................................138
Figure 5.7 Effect o f BW619C89 on total volume o f ischaemic damage and total APP score 
following MCA occlusion...............................................................................................................143
Figure 5.8 Effect o f BW619C89 on area o f ischaemic damage and mean APP score at eight 
defined coronal levels following MCA occlusion........................................................................144
Figure 5.9 Volume of ischaemic damage and APP accumulation score: BW619C89........... 145
Figure 5.10 APP accumulation score in BW619C89 treated animals:..................................... 146
subgroup analysis.............................................................................................................................. 146
CHAPTER 6
Figure 6.1 Tissue salvage following NMDA blockade in the cat and rat................................ 153
Figure 6.2 Plasma MK-801 concentration analysis..................................................................... 157
Figure 6.3 APP immunoreactivity in the ca t................................................................................ 160
X
Figure 6.4 Topography o f APP immunoreactivity: vehicle group.............................................161
Figure 6.4 Topography of APP immunoreactivity: MK-801 group...........................................162
Figure 6.5 Scoring o f APP in the cat.............................................................................................. 165
Figure 6.6 Reproducibility o f the semi-quantitative APP analysis............................................167
Figure 6.7 Method of quantitative APP analysis.......................................................................... 168
Figure 6.8 Reproducibility o f quantitative APP analysis............................................................ 170
Figure 6.9 Effect o f MK-801 on total volume o f ischaemic damage and total APP score 
following MCA occlusion................................................................................................................179
Figure 6.10 Effect o f MK-801 on area o f ischaemic damage and mean APP score at eight 
defined coronal levels following MCA occlusion in the cat.......................................................180
Figure 6.11 Volume o f ischaemic damage and semi-quantitative APP accumulation score 181
Figure 6.12 Volume o f ischaemic damage and quantitative APP accumulation score.........182
Figure 6.13 White matter injury:grey matter injury ratio following MCA occlusion.............184
CHAPTER 7
Figure 7.1 Axonal bulb formation following head injury and ischaemia..................................195
Figure 7.2 Mechanisms of axonal injury following traumatic brain injury and ischaemia... 201
APPENDIX 4
Figure A4.1 Spatial - Distance Calibration...................................................................................223
Figure A4.2 Quantitative analysis o f increased APP immunoreactivity.................................. 224
Figure A4.3 Assessment o f reproducibility for quantitative APP analysis..............................225
Figure A4.4 Relationship o f area o f APP immunoreactivity to volume o f infarction............ 228
LIST OF TABLES
CHAPTER 1
Table 1.1 Clinical conditions resulting in axonal injury................................................................. 2
CHAPTER 2
Table 2.1 Concentration curves for immunocytochemistry on FAM fixed rat material.......... 61
Table 2.2 Concentration curves for immunocytochemistiy on PAM fixed rat material.......... 62
Table 2.3 Cat tissue concentration curves for amyloid precursor protein.................................. 63
Table 2.4 Concentration curves for immunocytochemistry on material for electron 
microscopy............................................................................................................................................ 71
CHAPTER 3
Table 3.1 Immunoreactivity of SNAP25, NF68kD and MAP5 at different time points 
following MCA occlusion in the rat.................................................................................................. 76
XI
CHAPTER 4
Table 4.1 Physiological variables prior to and following middle cerebral artery occlusion. 101
Table 4.2 Hemispheric infarction and APP accumulation score............................................... 105
Table 4.3 APP score for each coronal level................................................................................. 106
CHAPTER 5
Table 5.1 Physiological variables prior to and following MCA occlusion in MK-801 study 124
Table 5.2 Ischaemic damage following MCA occlusion: vehicle group................................. 127
Table 5.2 Ischaemic damage following MCA occlusion: MK-801 group..............................128
Table 5.3 Influence o f MK-801 upon the volume o f ischaemic damage and APP score after 
MCA occlusion..................................................................................................................................129
Table 5.4 APP score for each coronal level in vehicle and MK-801 treated animals............ 130
Table 5.5 Ischaemic damage following MCA occlusion: vehicle group.................................139
Table 5.5 cont... Ischaemic damage following MCA occlusion: BW619C89 group.............140
Table 5.6 Influence o f BW619C89 upon the volume o f ischaemic damage and APP score 
after MCA occlusion........................................................................................................................ 141
Table 5.7 APP score for each coronal level in vehicle and BW6119C89 reated animals.... 142 
CHAPTER 6
Table 6.1 Plasma MK-801 concentration analysis.......................................................................156
Table 6.2 Physiological variables prior to and following MCA occlusion in the ca t.............158
Table 6.3 Semi-quantitative APP score for vehicle and MK-801 treated cats.......................166
Table 6.4 Quantitative APP score for vehicle and MK-801 treated cats.................................. 169
Table 6.5 Ischaemic damage following MCA occlusion in the cat: vehicle group................. 174
Table 6.5 cont... Ischaemic damage following MCA occlusion in the cat: vehicle group... 175
Table 6.5 cont... Ischaemic damage following MCA occlusion in the cat: MK-801 group. 176
Table 6.5 cont... Ischaemic damage following MCA occlusion in the cat: MK-801 group. 177
Table 6.6 Influence o f MK-801 upon the volume o f ischaemic damage and APP score in the 
cat after MCA occlusion...................................................................................................................178
Table 6.7 White matter injury:grey matter injury ratio following MCA occlusion................183
CHAPTER 7
Table 7.1 Glutamate antagonists and clinical trials..................................................................... 209
APPENDIX 4
Table A4.1 Linear regression analysis o f repeated measures.....................................................227
XII
LIST OF ABBREVIATIONS
APP Amyloid precursor protein
BOLD Blood oxygen level dependant
CAP Compound action potential
CNS Central nervous system
DAI Diffuse axonal injury
EM Electron microscopy
FAM Formaldehyde, acetic acid, methanol
MABP Mean arterial blood pressure
MAP5 Microtubule associated protein 5
MCA Middle cerebral artery
MCID Microcomputer Imaging Device
MRI Magnetic resonance imaging
MT Microtubules
NMDA N-methyl-D-aspartate
NF Neurofilaments
NF68kD Neurofilament subunit of 68-kDa
PAM Paraformaldehyde
PBS Phosphate buffered saline
PKC Protein kinase C
SHRSP Spontaneously Hypertensive Rat, Stroke Prone
SNAP25 Synaptosomal associated protein of 25 kDa
TBI Traumatic brain injury
XIII
ACKNOWLEDGEMENT
During the last three years I have had the pleasure of working with a number of 
distinguished people. These include Tei Takasago, Laurence Dunn, Rammanjit Gill, Jim 
Patterson, David Maxwell and Leonard Miller. Some of the highlights of my PhD have 
included the chance to meet people from other departments; a special mention must go 
to Professor David Graham and Dr. Will Maxwell with whom I have had the 
opportunity on several occasions to ‘talk science’ and seek advice. I must also thank the 
staff at the Wellcome for their technical support, in particular Joan Stewart and Eileen 
Harrop; and the excellent and forthcoming help from animal nurses, Christine Stirton 
and Julie Summerhill. Most of all, my thanks must go to Professor Jim McCulloch. I 
could never have anticipated what an all round education I was to get at the Wellcome. 
His enthusiasm for Neuroscience goes without saying; it was other subjects ranging 
from American histoiy, geometry and Greek philosophy that took me by surprise. When 
I first started my PhD I attended a course on supervisor-student relations. One exercise 
entailed describing the ideal attributes of a supervisor. Apart from myself, I wonder how 
many other students who attended that course can reflect on their good fortune to have 
had a supervisor who fulfilled so many of those attributes? Jim’s enthusiasm, insight, 
humour and availability to discuss matters, together with his ability to calm my anxiety, 
will not be forgotten.
XIV
PREFACE AND DECLARATION
This thesis presents results from investigations conducted within 4 broadly defined 
areas.
1. To define markers of axonal injury appropriate for use in the assessment of axonal 
pathology consequent to focal cerebral ischaemia
2. To develop quantitative techniques for the assessment of axonal injury
3. To apply a suitable marker of axonal injury and a method of quantification of axonal 
injury in the rat following focal cerebral ischaemia
4. To explore the utility of techniques of quantification of axonal injury in species 
where there is a larger volume of white matter compared to that in the rat brain.
The thesis comprises my own original work and has not been presented previously as a 
thesis in any form. Mr. L. Dunn performed the middle cerebral artery occlusions in the 
cats and Dr. T. Takasago performed the middle cerebral artery occlusions in the rat 
study described in Chapter 4.
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CHAPTER 1
INTRODUCTION
1.1 GENERAL INTRODUCTION
A number of prevalent clinical conditions, including stroke, expose the central nervous 
system (CNS) to anoxic/ischaemic damage. Neurons of the brain and spinal cord rely on 
axonal connections for signal transmission. Both cell bodies and axons are therefore 
critical for normal operation of the CNS, and understanding the basic mechanisms of 
injury in both grey and white matter is essential for the rational design of therapeutic 
intervention for optimal protection of the brain. Many neurological diseases result in 
damage to the myelinated, subcortical fibre tracts, ranging from demyelination as seen 
with multiple sclerosis to ischaemic injury occurring with strokes. There is a large body 
of work dealing with anoxic/ischaemic injury of grey matter (Haddad and Jiang, 1993; 
Choi, 1990; Siesjo, 1986), but until recently, virtually no information was available on 
the mechanisms of anoxic/ischaemic damage in central white matter tracts. Given the 
drastically different structure of grey and white matter regions of the mammalian CNS, 
it is reasonable to expect that these mechanisms might be different. During the last few 
years experimental investigation of white matter following ischaemia/anoxia has 
revealed that it is vulnerable to this type of injury (Follis et al. 1993; Pantoni et al. 1996) 
(Table 1.1) and in vitro studies have started to unravel the fundamental cellular 
mechanisms involved. The recognition of white matter injury following ischaemic 
insults, and an understanding of the pathological mechanisms involved, is crucial for the 
efficient and logical designs of therapeutic interventions in diseases in which white 
matter is a prominent target.
Table 1.1 Clinical conditions resulting in axonal injury
Condition Description
Central
Stroke Both white and grey matter injury in artery 
territory infarcts, or more selective white matter 
damage in lacunar stroke syndromes
Spinal cord injury A significant portion of axonal damage may occur 
on a vascular basis
Ischaemic optic neuropathy Arteritic or nonarteritic
Traumatic optic neuropathy Secondary ischaemic injury from vasospasm and 
optic nerve swelling
Radiation-induced white matter 
necrosis
Evidence for selective ischaemic injury to white 
matter
Vascular dementia Chronic anoxia/ischaemia of subcortical white 
matter
Neonatal leukomalacia Preferential injury to white matter in neonates as a 
result of hypotension and ischaemia
Peripheral
Diabetic neuropathy Pathogenesis may be partly due to decreased 
blood flow and endoneurial hypoxia
Vasculitis May result in multiple mononeuropathy, or 
symmetric or asymmetric polyneuropathy
Compression Combination of mechanical deformation and 
ischaemia from damaged intraneural blood vessels
Examples of conditions in which anoxia/ischaemia is implicated as an important or 
major mechanism of axonal dysfunction and injury. (Adapted from Stys et al., 1995).
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1.2 ACUTE BRAIN INJURY
1.2.1 Stroke
Stroke is the third major cause of death and an important cause of hospital admission 
and long term disability in most industrialised populations. In Scotland, about 7% of all 
hospital bed days are accounted for by stroke patients; this bed usage is greater than all 
other conditions with the exception o f ‘mental disorders’ and ‘mental handicap’. In 
financial terms, stroke absorbs 6% of hospital running costs and 4.6% of all National 
Health Service costs and these figures have remained much the same for a decade (Isard 
and Forbes, 1992). The World Health Organisation definition of stroke is, ‘rapidly 
developing clinical signs of focal (or global) disturbance of cerebral function, with 
symptoms lasting 24 hours or longer leading to death, with no apparent cause other than 
of vascular origin’, although this definition is probably no longer adequate. Stroke 
accounts for 10-12% of all deaths in industrialised countries; about 88% of the deaths 
attributed to stroke are among people over 65 years (Bonita, 1992). About 20% of 
strokes result from intracerebral and subarachnoid haemorrhage and about 80% are due 
to blood vessel occlusion by a blood clot originating from the heart or atherosclerotic 
plaque. Multiple risk factors are associated with ischaemic stroke in man. These include 
age, diabetes mellitus, cigarette smoking, diet and alcohol, obesity and hypertension 
(Marmot and Poulter, 1992). Strokes restricted to white matter have also been identified 
as a major class of neurological injury, comprising approximately 1/4 of strokes seen 
clinically (Bamford et al. 1987; Fisher, 1982). These so called lacunar syndromes are 
defined clinically and are highly predictive of small deep lesions affecting the motor and 
sensory pathways i.e. in the corona radiata, internal capsule, thalamus, cerebral peduncle 
and pons (For review see Warlow, 1993).
1.2.2 Trau matic brain inj ury
The problems posed by head injuries are vast, varied and vext (Teasdale, 1995). Head 
injury accounts for 1% of all deaths but for 15-20% between the ages of 5 and 35 years. 
In the UK, one million patients per annum attend hospital after sustaining a head injury. 
Males outnumber females by more than two to one and almost half of the cases are 
children less than 15 years old.
Brain damage after head injury can be classified by pattern and by time course. 
The patterns are essentially separated into focal and diffuse varieties. In time course, the 
differentiation is between primary damage (such as free radical formation, calcium flux 
and inflammation), developing at the moment of impact, and secondary damage due to 
subsequent complications (including ischaemia, raised intracranial pressure, seizures or 
infection). The eventual outcome is dependent on the overall effect of all these 
described parameters (Graham, 1996).
In the context of this thesis, traumatic brain injury is of interest since diffuse 
axonal injury (DAI) is the single most important lesion to result (Adams et al. 1989). 
DAI can be defined as the occurrence of diffuse damage to axons in the cerebral 
hemispheres, corpus callosum, brain stem and sometimes also in the cerebellum 
resulting from head injury (Adams et al. 1989). This is of importance since it has been 
suggested that in both man (Adams et al. 1980; 1982; 1983; 1977) and a non-human 
primate model (Gennarelli et al. 1982) that there is a direct link between the extent of 
DAI and the extent of ensuing patient morbidity. DAI consists of scattered damage of 
axons throughout the white matter of the brain. Injury to individual axons can be 
recognised only by microscopy on fatal cases; silver stains show ‘retraction balls’ which 
represent swollen blobs of axoplasm. More recently, a variety of other markers have 
been investigated in order to define the responses of axons to injury including amyloid
precursor protein (APP) (Sherriff et al. 1994a; Gentleman et al. 1993; Gentleman et al.
1995), neurofilament subunits (Ng et al. 1994; Christman et al. 1994; Grady et al. 1993) 
and ubiquitin (Gultekin and Smith, 1994).
1.3 FUNCTIONAL ANATOMY OF CEREBRAL WHITE 
MATTER
White matter occupies nearly one half the volume of the adult cerebral hemispheres in 
man, and myelinated tracts connect grey matter structures throughout the brain. In the 
cerebrum, three groups of white matter pathways are recognised: projection fibres 
convey sensory and motor information to and from the cortex; commissural fibres, 
primarily via the corpus callosum, mediate interhemispheric communication; and 
association fibres connect various cortical areas. Short association fibres, also known as 
U or arcuate fibres connect remote intrahemispheric zones. The blood supply of the 
hemispheric white matter comes primarily from long penetrating arteries arising from 
large vessels at the base of the brain. Prominent among these are the lenticulostriate 
arteries that originate from the middle cerebral artery. Additional blood supply comes 
from the recurrent artery of Heubner (medial striate artery) and the anterior choroidal 
artery (Filley, 1998).
1.4 MYELINATED AXONS - STRUCTURE AND FUNCTION
In the CNS, the myelinated axon originates from the neuronal perikaryon. It may extend 
for a considerable distance but has a characteristic constant diameter throughout its 
length. Most axons do not branch or form synaptic contacts before their termination. 
Almost all axons with diameters above 0.2pm in the CNS are myelinated and the
segments of myelin are separated by nodes of Ranvier along the length of the axon. The 
myelin is composed of layers of protein and lipid. In myelinated axons, the excitable 
axonal membrane is exposed to the extracellular space only at the nodes of Ranvier; this 
is the location of sodium channels (section 1.5.3) and impulse propagation jumps from 
node to node. The intemode length is generally proportional to the axon diameter. In the 
CNS it is the oligodendroglial cells which form the myelin, and each glial cell can 
myelinate many separate axons. The axon contains fewer organelles as compared to the 
soma, because it does not have Golgi apparatus or rough endoplasmic reticulum. It is 
surrounded by the axolemma which is about 8 nm thick and appears morphologically 
similar to the plasma membrane of the neuronal soma. The axoplasm itself is specialised 
to maintain its tube-like shape and considerable length. The cytoskeleton is a  highly 
dynamic character, involved in many essential cellular processes including oeli 
movement, process elongation and intracellular transport. The cytoskeleton, which 
imparts structure to the axon cylinder and serves to maintain the required distribution of 
channels (Salzer, 1997), is unique to eukaryotic cells and consists of three major classes 
of cytoskeletal fibres: neurofilaments (NF’s), microtubules (MT’s) and microfilaments 
(Ludin and Matus, 1993) (Fig. 1.1).
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Figure 1.1 The components of the cytoskeleton
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1.4.1 Neurofilaments
Neurofilaments are members o f the intermediate filament family, whose name derives 
from the characteristic diameter o f 8-10 nm, which is intermediate between actin 
filaments (6 nm) and microtubules (24 nm). N F’s are long, unbranched filaments that in 
large myelinated axons accumulate as the most abundant structures (Lee and Cleveland, 
1996). N F’s are composed from three subunit polypeptides, the so-called 'neurofilament 
triplet’ (Hoffman and Lasek, 1975). In mammals these distinct polypeptides are NFH 
(180-200 kDa), NFM (130-170 kDa) and NFL (60-70 kDa) with each being encoded by 
a separate gene. The size difference between the NF proteins occurs mainly in the length 
o f the carboxy-terminal tail sequences. NF-M and NF-H are phosphorylated at many 
sites, mostly in the carboxy-terminal tail region o f the molecule with a few other sites in 
the amino-terminal head region. Biochemically purified N F’s from various sources have
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in general been found to contain NFL, NFM, and NFH in a ratio of about 5:2:1. In 
neurons, it is primarily the NFH, and to a lesser degree NFM polypeptides, which 
participate in a cross linking function between filaments (Hirokawa et al. 1984).
NF’s are moved into and through axons via slow axonal transport although the 
mechanism remains unsettled. Despite the traditional view that NF’s are static, evidence 
suggests that they can be highly dynamic structures (Okabe et al. 1993). Both the level 
and phosphorylation state of NFH have been proposed to regulate the rate of NF 
transport and axonal calibre. Phosphorylation may slow NFH transport by the formation 
of cross bridges between NFH’s (Hirokawa et al. 1984) or by causing dissociation of 
NF’s from the axonal transport machinery (Hisanaga et al. 1990). After arriving at the 
nerve terminal, it is believed that NF’s are degraded.
NF accumulation, although detectable during neurite elongation, becomes robust 
only after synapse formation and is concomitant with myelination (Lee and Cleveland,
1996). Therefore, NF’s are suggested to play a critical role in determining axonal calibre 
(Hoffman et al. 1984). Earlier evidence had shown a linear relationship between NF 
number and cross-sectional area throughout radial growth and regrowth following 
axonal injury (Hoffman et al. 1985; Friede and Samorajski, 1970). This increase in 
axonal diameter is important for normal nerve function because calibre is a principal 
determinant of the speed at which nerve impulses are propagated along the axon 
(Gillespi and Stein, 1983).
1.4.2 Microtubules
Microtubules provide a structural framework for axons and dendrites, tracks for 
organelle traffic and have a role during neuronal growth and development. They are 24 
nm in diameter, cylindrical structures with walls made up of 12-14 protofilaments (for
review see Hammerschlag et al. 1994). Microtubules are arranged haphazardly in the 
perikaryon but longitudinally in axons and dendrites and may reach lengths of 100pm. 
Distinct domains exist within microtubules that vary in composition and degrees of 
stability. The primary polypeptides of microtubules are a  and p tubulins. These are 
subject to a variety of post-translational modifications which may relate to microtubule 
stability although this is uncertain. Microtubules in vivo include a members of 
heterogeneous set of polypeptides known as microtubule associated proteins (MAP’s). 
MAP’s interact with microtubules maintaining a constant stoichiometry with the tubulin 
through cycles of assembly and disassembly. MAP’s may stimulate microtubule 
formation and stabilise existing microtubules in vivo (Pedrotti et al. 1996). Despite the 
crosslinks formed by MAP’s, microtubules can slide relative to one another.
1.4.3 Microfilaments
Microfilaments comprise of actin subunits arranged like two strings of pearls 
intertwined to form fibrils 4-6 nm in diameter. Actin microfilaments can be found 
throughout neurons and glia but are concentrated in presynaptic terminals, dendritic 
spines, growth cones and subplasmalemmal cortex. In the axon, microfilaments are most 
apparent in the vicinity of microtubules and near the plasma membrane. Microfilaments 
and associated proteins e.g. spectrin, a protein which binds actin filaments and links 
them to the plasma membrane (Bennett, 1985), form the membrane cytoskeleton which 
is important for cell shape, cell to cell interactions and distribution of membrane 
proteins. At the leading edge of the elongating process is the growth cone which, 
through controlled polymerisation and rearrangement of the actin fibres, is responsible 
for process extension.
1.4.4 Axonal transport
In mature neurons, the extreme asymmetry of the neuron with its small cell body relative 
to the long lengths of its axons and dendrites and the restriction of the non- 
mitochondrial protein synthetic machinery to the cell body has led to the development of 
a specialised form of bi-directional intracellular transport. This process is termed axonal 
transport and is responsible for maintaining the integrity of the axon and its nerve 
terminal. Fast anterograde transport is a collective term for the two fastest rate 
components, with the faster carrying membranous organelles at approximately 400 
mm/day and the slower carrying mitochondria at approximately 50 mm/day (Lewen et 
al. 1996). Organelles are transported down the axon utilising axonal microtubules as 
‘tracks’. Movement in the anterograde direction is mediated by the molecular motor, 
kinesin while the force necessary to move retrograde organelles is generated by dynein 
(Fig. 1.2). The slow component of axonal transport is responsible for the anterograde 
movement of the cytoskeleton and enzymes of intermediary metabolism (Ochs, 1972). 
Retrograde axonal transport carries axonal constituents from the periphery to the cell 
body at approximately half the rate of fast anterograde transport (Ochs, 1972). Thus, 
anterograde axonal transport is responsible for the movement of neurotransmitters, 
proteins and mitochondria from the cell body to the nerve terminals whereas retrograde 
axonal transport carries lysosomes, trophic factors, and tracer molecules from the nerve 
terminal to the cell body. Without normal axonal transport processes occurring within 
the axon, the integrity of the axon is compromised. Intact axonal transport systems are 
vital to the survival of all neurons.
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Figure 1.2 Illustration of movement of membrane-associated material in 
fast axonal transport
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1.4.5 Axonal ion channels
Myelinated axons have a unique architecture allowing them to transmit action potentials 
reliably and in an energy efficient manner (Waxman and Ritchie, 1993; Salzer, 1997). 
There is a highly segregated distribution of ion channels and transporters on the axon 
membrane that are designed to cany ionic currents required for action potential 
generation and propagation. Intemodal K+ channels are thought to contribute largely to 
the maintenance of a hyperpolarised resting membrane potential of about -80mV (Stys 
et al. 1997; Bostock and Grafe, 1985; Chiu and Ritchie, 1984; Chiu and Ritchie, 1982). 
The Na+ -K+-ATPase is the main active ion transporter designed to maintain adequate
transmembrane gradients of Na+ and K+, pumping Na+ out of the cell and K+ into the 
cell.
Voltage gated sodium ion channels are responsible for initiation and conduction 
of the neuronal action potential and, therefore play a fundamental role in the normal 
function of the nervous system. In cell bodies and axon initial segments, sodium ion 
channels determine the threshold for action potential generation and effect the duration 
and frequency of repetitive neuronal firing. There is a very high density of voltage- 
gated, rapidly activating and rapidly inactivating, sodium channels at the nodes of 
Ranvier (approx. 1,000-2,000 channels/pm2) (Waxman, 1995). A non-inactivating 
sodium conductance has also been demonstrated in the optic nerve (See section 1.5.3) 
(Stys et al. 1992a). Whether this non-inactivating sodium conductance represents a 
homogeneous population of sodium channels, a fraction of which fails to inactivate 
completely, or represents a distinct subpopulation of sodium channels, or even a 
uniform population which switches between gating modes, remains unclear. In 
synapses, repetitive sodium influx through voltage-gated sodium channels initiate 
glutamate release by propagating a depolarising stimulus to the sites of vesicular release. 
Presynaptic voltage-activated calcium channels at the release sites are opened in 
response to this depolarisation. The resultant elevation of cytoplasmic calcium levels in 
the nerve terminal initiates the process of exocytosis of glutamate.
The Na+-Ca2+ transporter couples transmembrane fluxes of Na+ to opposite 
fluxes of Ca . Under normal conditions the energy stored in the electrochemical Na
• •  9 4 - *74-gradient is used to export Ca from the cytoplasm, thus contributing to cellular Ca 
homeostasis (Steffensen and Stys, 1996). A number of other transport mechanisms also 
contribute to overall ionic homeostasis (Section 1.5.3). Together with electrically tight 
paranodal myelin seals, axonal ion channels generate transmembrane currents that are
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conducted from node to node in a saltatory fashion, thus allowing very rapid and 
efficient signal transduction.
1.5 MECHANISMS OF NERVE INJURY
1.5.1 Introduction
The CNS is divided into regions containing grey matter (cell bodies, dendrites and 
synapses) and white matter (nerve fibres and associated glia). Although historically 
there has been more interest in grey matter injury, both white and grey matter are 
dependent on an adequate blood supply, and any interruption of the CNS vasculature 
can compromise function in both types of tissue. Following the interruption of blood 
supply, while there are a number of common steps to both grey and white matter injury, 
there are also many events that are unique to white matter injury. Disruption of ion 
transporters, the cytoskeleton or glia, including the overlying myelin sheath, may result 
in impairment or complete failure of impulse transmission.
1.5.2 Glutamate-receptor-mediated neuronal cell body damage
Certain amino acids play important transmitter and modulatory roles in the brain, 
controlling functions such as learning, memory, and emotions. Glutamate and aspartate 
act as fast excitatory signal transmitters. Work by Lucas and Newhouse in 1957 showed 
that retinal neurons were damaged following prolonged exposure to glutamate. Since 
then it has become widely accepted that high extracellular concentrations of glutamate 
are neurotoxic (Rothman and Olney, 1986). Glutamate has been hypothesised to have a 
pivotal role in the pathogenesis of neuronal cell death due to acute focal or global 
ischaemia of the CNS (Muir and Lees, 1995). A 40-fold increase in extracellular
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glutamate in the striatum after middle cerebral artery occlusion in the rat has been 
demonstrated (Butcher et al. 1990).
Glutamate receptors can be differentiated into two main classes, i.e., ionotropic 
and metabotropic receptors. The ionotropic receptors contain integral, cation-specific 
ion channels, whereas the metabotropic receptors are coupled to G proteins and 
modulate the production of intracellular messengers (Fig. 1.3). The utilisation of 
recombinant DNA techniques has greatly advanced the understanding of the structure, 
properties and expression of the glutamate receptors. The metabotropic glutamate 
receptors are currently classified into three different groups according to their sequence 
identity, transduction mechanisms and agonist pharmacology (for review see Conn and 
Pin, 1997). Group I metabotropic receptors are coupled to the stimulation of 
phosphoinositide hydrolysis whereas group II and III are negatively coupled to cAMP 
formation. Several studies have suggested that agonists of group II and III metabotropic 
receptors can be neuroprotective whereas agonists of group I are without effect or may 
potentiate excitotoxicity. Interestingly, a recent study using a highly selective group II 
metabotropic glutamate receptor agonist resulted in no significant reduction in infarct 
volume in a rat model of focal cerebral ischaemia (Lam et al. 1998).
Ionotropic receptors are ligand gated ion channels, and they include N-methyl-D- 
aspartate (NMDA) and a-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid 
(AMPA)/kainate receptors. NMD A receptors are composed of homo- or heteromeric 
complexes of NMDAR-1 subunit and at least one of four NMDAR-2 subunits 
(NMDAR-2A, -2B, -2C, -2D) (Nakanishi, 1992). The NMDA receptor ion complex 
appears to be confined to the central nervous system, with a particularly high density in 
the hippocampus and the cerebral cortex. This complex possesses a number of 
modulatory sites in addition to that at which glutamate binds (Fig. 1.4). Under normal
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circumstances, NMDA receptor-mediated calcium fluxes couple receptor activation to 
intracellular responses such as protein phosphorylation, enzyme activation, and changes 
in gene expression. However, when cerebral blood flow is significantly reduced, nerve 
cells and glia are deprived of oxygen and nutrients such that their ability to generate 
high-energy phosphates to fuel the membrane-bound pumps is depressed. As a result, K+ 
leaks out and glutamate is not pumped into presynaptic nerve cells and glia, thus 
accumulating in the synaptic cleft. Electrical depolarisation of the presynaptic neuronal 
membrane causes calcium entry through voltage-gated calcium channels. Increased 
intracellular calcium leads to exocytotic release of glutamate into the extracellular 
milieu, further increasing its concentration in the synaptic cleft leading to an overload 
phenomenon and excitotoxicity (Olney, 1978). Glutamate binds to the NMDA, 
AMPA/kainate and metabotropic receptors on the postsynaptic membrane. 
Depolarisation also activates postsynaptic NMDA receptors by removing the 
magnesium plug in their ion channels. The pattern of glucose hypermetabolism in the 
peri-ischaemic zone corresponds both topographically and temporally with the uptake of 
both 3H-MK-801 and 123I-MK-801 after MCA occlusion (Wallace et al. 1992). 3H-MK- 
801 is a specific ligand for the agonist gated NMDA ion channel, therefore the in vivo 
binding is indicative of glutamate-induced ion channel activation. Activation of the 
ionotropic receptors allows for the entry of calcium and sodium through NMDA ion 
channels and sodium through AMPA/kainate ion channels in the postsynaptic 
membrane into neurons. In addition, metabotropic receptor stimulation leads to the 
generation of inositol-1,4,5-triphosphate (IP3) and diacylglycerol (DAG), which 
liberates calcium from internal stores (e.g., mitochondria and endoplasmic reticulum). 
Neuronal calcium concentration increases and activates a number of intracellular 
enzymes (e.g., kinases, calpains, xanthine oxidase, phospholipase A2, nitric oxide
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synthetase) which damage the nerve cell (Holt, 1997). Additionally, the stimulation of 
the enzyme nitric oxide synthetase leads to the accumulation of large amounts of nitric 
oxide. This in turn, can generate oxygen-derived free radicals that can damage cells and 
have effects on the redox site at the NMDA receptor to promote further calcium entry. 
Since the excitotoxic cascade has been developed, many other cascades, as alluded to 
above, have also been proposed to be involved in the pathophysiological response to 
cerebral ischaemia. Although these are not considered within this thesis, the challenge in 
the first instance being excitotoxicity, reviews and papers include, Viossat et al. 1993; 
Sharkey et al., in press; Hallenbeck, 1996; Arvin et al. 1996. Glutamate mediated 
neuronal damage is summarised in Fig. 1.3.
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Figure 1.3 Glutamate mediated neuronal damage
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Electrical depolarisation of the presynaptic neuronal membrane causes calcium entry 
through voltage-gated calcium channels. Increased intracellular calcium leads to 
exocytotic release of glutamate into the extracellular milieu. The binding of glutamate 
activates NMDA, AMPA/kainate and metabotropic receptors on the postsynaptic 
membrane. Depolarisation also activates postsynaptic NMDA receptors by removing the 
magnesium plug in their ion channels. Activation of ionotropic receptors allows for 
entry of calcium and sodium through NMDA ion channels and sodium through 
AMPA/kainate channels in the postsynaptic membrane into neurons. Metabotropic 
stimulation results in liberation of calcium from internal stores. Neuronal calcium 
increases and activates a number of intracellular enzymes (Holt, 1997).
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Figure 1.4 The NMDA receptor-ion channel complex
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Binding of glutamate to the glutamate binding site and electrical depolarisation activate 
the NMDA receptor-ion channel complex. This promotes the extrusion of the 
magnesium plug from the ion channel and allows for the entry of sodium and calcium 
and the exit of potassium. The NMDA ion channel can be blocked at a variety of 
different sites including the glycine, glutamate, polyamine and zinc sites. MK-801 binds 
in a non-competitive manner within the ion channel pore at a site distinct from the 
magnesium binding site. (Modified from Holt, 1997).
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1.5.3 White matter injury
Despite a large body of work dealing with the pathophysiology of grey matter, much less 
is known about that of anoxic/ischaemic injury to CNS myelinated axons. In vitro 
studies using an isolated optic nerve preparation have helped to elucidate the 
fundamental mechanisms involved in anoxic/ischaemic injury in white matter tracts. 
This is an ideal preparation to study the mechanisms involved in white matter injury 
since, unlike whole-animal studies, the preparation is devoid of synaptic connections, is 
composed exclusively of myelinated axons, oligodendrocytes and astrocytes and it is 
amenable to pharmacologic manipulations (Waxman et al. 1991). Function of excised 
rat optic nerves are studied in an interface chamber with suction electrodes which record 
the compound action potential (CAP) following supramaximal orthodromic stimulation. 
The area under the CAP provides an estimate of the number of fibres that are capable of 
conducting action potentials, a measure of the overall functional integrity of the optic 
nerve bundle.
Optic nerve function rapidly fails when it is exposed to anoxia (Stys et al. 1995). 
It is now well established that irreversible nerve injury is critically dependent on the 
molar concentration of extracellular calcium. Maintaining the tissue in calcium free 
solution throughout the anoxic period results in 100% CAP recovery, whereas 
increasing the perfusion of calcium during anoxia from zero to 4mM results in 
progressively less recovery. As the introduction of calcium free solution is progressively 
delayed with respect to onset of anoxia, a graded decrease in recovery of function is 
observed, suggesting that in white matter the deleterious effects of calcium accumulate 
slowly during anoxia (Stys et al. 1990). Supportive ultrastructural studies following 
anoxic injury indicate dissolution of the axonal cytoskeleton, swollen mitochondria and 
retraction of paranodal myelin (Waxman et al. 1992). In contrast, when calcium is
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removed from the bathing medium, the axons retain normal ultrastructural appearing 
microtubules and neurofilaments (Waxman et al. 1993).
Although the increase in intracellular calcium may arise partially from 
intracellular stores, most of the increase is due to influx across the axolemma. 
Identification of the precise routes of abnormal transmembrane ion flux is of paramount 
importance for the rational design of therapeutic intervention. A number of routes by 
which calcium crosses the axonal membrane during anoxia have been proposed; 
namely, (1) voltage-activated calcium channels such as NMDA receptors, (2) ligand- 
gated calcium channels, (3) leakage of calcium through channels imperfectly selective 
for another ionic species, such as sodium or potassium channels, (4) reverse operation of 
the sodium-calcium exchanger, a countertransporter that normally exports calcium 
across cell membranes, and (5) non-specific flux across the axolemma, possibly 
rendered leaky by early hypoxic injury (Stys et al. 1995).
Ketamine, a dissociative anaesthetic known to block NMDA receptors, was 
shown to protect the optic nerve following anoxia. However, NMDA agonists including 
glutamate (at concentrations which would cause severe injury to neurons), have no toxic 
effect on the optic nerve making it unlikely that ketamine’s protective effect was caused 
by NMDA receptor blockade (Ransom et al. 1990b). It is more likely that the high 
concentrations of ketamine resulted in blockade of the voltage-gated sodium channels. 
Initial observations indicated that calcium influx in white matter did not occur through 
conventional voltage- or ligand- gated calcium channels as it does in grey matter models 
of anoxia/ischaemia. However, it was observed that substantial improvement in CAP 
recovery occurred when voltage-gated sodium channels were blocked during anoxia 
with sodium channel blockers such as tetrodotoxin or saxitoxin (Stys et al. 1991b, 
1992b). Furthermore, increasing sodium channel permeability with veratridine during
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anoxia resulted in greater injury (Stys et al. 1992b) and removal of sodium prior to 
anoxia also protected the axons to some degree. These results indicate that influx of 
sodium ions through sodium channels is a necessary step in the anoxic cascade. The 
route for sustained entry of sodium into white matter during anoxia posed an interesting 
question since the classical voltage-gated sodium channels, which initiate the rapid 
upstroke of the axonal action potential, also contribute to its termination by fast and 
complete inactivation, implying that these channels should rapidly close during anoxic 
depolarisation. Further investigations suggested that it is a non-inactivating sodium 
channel responsible for the continued influx of sodium ions during anoxia (Stys et al.
1993). Like the classical sodium channel, this conductance rapidly activates with 
depolarisation but inactivates either very slowly or incompletely even with prolonged 
depolarisation. More recent evidence suggests that a small component of sodium also 
enters through a cesium sensitive mixed Na+ and K+ permeable inward rectifier (Stys et 
al. 1998).
As already intimated, calcium influx across the membrane occurs secondary to a 
rise in the intra-axonal sodium. The calcium influx occurs mainly, although not 
exclusively, due to the reverse operation of the sodium-calcium exchanger following the 
large sodium influx from the extracellular space (Stys et al. 1991a). The Na+-Ca+ 
exchanger membrane protein functions under normoxic conditions to maintain calcium 
homeostasis by extruding calcium from the cytoplasm in exchange for sodium influx, 
using the energy stored in the transmembrane sodium gradient. Blockers of the sodium- 
calcium exchanger (bepradil, benzamil, dichlorobenzamil), significantly protect the 
optic nerve from anoxic injury (Stys et al. 1991b; Stys et al. 1992b). A small proportion 
of Ca+ also enters directly through Na+ channels. The possibility that the damaging 
influx of calcium is via voltage-sensitive calcium channels was originally investigated
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using inorganic calcium blockers (Co2+, Mn2+ or La3+) and organic blockers (nifedipine 
and nimodipine). Although no statistical improvement in recovery of the CAP with 
either group of drugs was reported (Ransom et al. 1990a), subsequent work suggests that 
L-type, and to a lesser degree, N-type calcium channels are involved in the development 
of anoxic injury in CNS white matter (Fern et al. 1995a). Clearly, the contribution of 
voltage-gated calcium channels still requires some clarification (Stys, 1998).
In summary, a number of steps are involved in anoxic/ischaemic white matter 
injury (Fig. 1.5). An impairment of glucose and/or oxygen delivery causes ATP levels to 
decrease, resulting in the failure of several key ATP-dependant ion pumps such as the 
axolemmal Na+-K+-ATPase, thus causing accumulation of Na+ within and loss of K+ 
from the axoplasm, and endoplasmic reticulum Ca2+-ATPase failure allowing Ca2+ to 
escape from the internal stores. A rise in intracellular Na+ and depolarisation due to K+ 
loss promotes reverse operation of the Na+-Ca2+ exchanger admitting large quantities of 
Ca2+ into the fibre.
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Figure 1.5 Anoxia-induced calcium accumulation in myelinated CNS 
axons
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Hypothetical sequence of events leading to anoxia-induced calcium accumulation in 
myelinated CNS axons. Under conditions of anoxia/ischaemia, reserves of ATP are 
depleted rapidly, leading to failure of the Na,K-ATPase and subsequent collapse of ionic 
gradients. Sodium ions enter the axoplasmic space through persistently open sodium 
channels. This influx of sodium ions leads to a rise in intracellular sodium 
concentration, which may be exaggerated by restricted diffusion of ions under the nodal 
membrane. Both membrane depolarisation and an increase in intracellular sodium 
concentration cause reverse operation of the Na+-Ca+ exchanger, which admits 
damaging quantities of calcium into the cell. Voltage-gated calcium channels may 
provide a parallel route for calcium entry. (Modified from Stys, P.K., 1998).
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Recently, the anoxic cascade has been shown to be subject to modulation via an 
autoprotective mechanism that involves both GABA, acting on the GABAb receptors, 
and adenosine, acting via adenosine receptors (Fig 1.6) (Fern et al. 1995b). Maximal 
recovery from anoxia was obtained with GABA concentration of lpM, with less 
effective protection at higher concentrations perhaps indicative of receptor 
desensitisation. Adenosine produced a protective effect similar to that found with 
GABA (Fern et al. 1994). Furthermore, GABA and adenosine act synergistically 
through different receptors, to produce a protective action at the low concentrations 
found in anoxic white matter. It is thought that the two receptors are linked to a common 
effector mechanism via a G protein linked to the intracellular second messenger protein 
kinase C (PKC). The exact mechanism by which PKC translates into axonal protection 
is unclear. It has been suggested that activation of PKC results in down regulation of the 
Na+/Ca+ exchange thus reducing calcium influx during anoxia. Alternatively, PKC may 
result in down regulation of the Na+ channels which mediate the Na+ influx for driving 
the Na+/Ca+ exchanger in reverse mode during anoxia (Fern et al. 1996a). Nifedepine is 
a potent inhibitor of the release of adenosine and also blocks the actions of adenosine at 
the adenosine receptors. Therefore the observation that higher concentrations of 
nifedipine failed to protect white matter from anoxic injury is fully consistent with the 
earlier work of Stys (Stys et al. 1992b). The lack of effect of polyvalent cations has been 
reconciled with the fact that they irreversibly reduce the CAP when applied for 100 min 
and it is this apparent toxicity, rather than a lack of effect on calcium channel blockade, 
that accounts for this lack of effect on the development on anoxic injury. The potential 
for manipulating the autoprotective mechanisms provide exciting therapeutic potential
Figure 1.6 Anoxia induced GABA release
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Anoxia induces release of GABA and adenosine from sites endogenous to the nerve.
The resulting increase in the extracellular concentration of GABA and adenosine 
triggers the activation of adenosine and GABAb receptors, initiating an intracellular 
pathway involving a G-protein/PKC cascade. Optic nerve axons are made more resistant 
to anoxia as a result. The target of PKC phosphorylation is unknown, but could be the 
Na+/Ca+ exchanger, whose phosphorylation, and subsequent down regulation would 
limit Ca+ influx or the Na+ channel. (Modified from Fern et al. 1996a).
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1.5.4 Action of calcium
Cellular calcium overload is generally thought to represent a key and fundamental step 
in the pathogenesis of axonal damage following grey and white matter injury (Fig. 1.7) 
(For review see Orrenius et al. 1996). As described in section 1.5.3, irreversible anoxic
I
injury depends on energy failure and the presence of extracellular Ca . Electron probe 
X-ray microanalysis has confirmed the gradual and continuous accumulation of 
axoplasmic Ca2+, which increases from a baseline of 0.8 mM total Ca (free and bound) 
to 3.5 mM at the end of 60 min of anoxia (Stys, 1996). Recent work has begun to 
implicate proteolysis of cytoskeletal proteins as an important component in the 
neurodegeneration cascade following cerebral trauma, cerebral ischaemia and spinal 
cord injury (Kampfl et al. 1997) (see section 7.2.3). High intracellular concentrations of 
calcium may cause irreversible injury through mitochondrial injury and overactivation 
of various calcium dependent systems such as lipases, calpains and protein kinase C. 
Indeed, calcium alone is capable of disassembly of certain types of microtubules (for 
review see Maxwell et al. 1997a). Mitochondrial injury following ischaemia occurs due 
to degradation of mitochondrial phospholipids (Nakahara et al. 1991), collapse of 
mitochondrial membrane potential and subsequent failure of respiratory chain-linked 
oxidative phosphorylation and ATP synthesis (Orrenius et al. 1996; Sciamanna et al. 
1992).
In moderate to severe blunt head injury, the change in axolemmal permeability 
(Povlishock et al. 1997; Pettus and Povlishock, 1996; Pettus et al. 1994) could allow 
normally excluded ions, including calcium, to enter the intra-axonal compartment, and 
result in microtubular disruption and NF sidearm loss by calcium activated proteases 
(calpains) (Povlishock and Christman, 1995; Hall and Lee, 1995; Maxwell, 1995). 
Horse-radish peroxidase was used in the above studies to demonstrate altered
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axolemmal permeability, and it has been suggested that it is not an appropriate marker 
of damage to the axolemma at an ionic level (Maxwell et al. 1998). Recently, 
cytochemical evidence has demonstrated an increased content of intra-axonal calcium 
following optic nerve stretch injury with subsequent loss of an organised axonal 
cytoskeleton (Maxwell et al. 1995). A-similarly close relationship of calcium mediated 
damage following head injury exists between influx of calcium ions and ischaemic 
damage (Waxman et al. 1992,1993,1994).
Although the relative contributions of various calcium regulated processes to 
neuronal cytoskeleton damage are as yet unknown, the properties and localisation of the 
calcium-activated neutral proteases, calpains, in the CNS have supported their proposed 
roles in cytoskeletal proteolysis, neuronal cell damage, cell death, and impaired 
neurobehavioral function following experimental brain injuries in vivo (Kampfl et al. 
1997). Several lines of evidence suggest that overactivation of calpains may play a 
major role in cerebral ischaemia in vivo. Activation of calpains caused by an influx of 
calcium ions, is an attractive explanation for rapid disassembly of microtubules and 
further breakdown of their structural components following traumatic and ischaemic 
insults (for review see Kampfl et al. 1997). Calpains are calcium-activated, neutral, 
cysteine proteases. Two major isoforms of calpains exist, differing primarily in the 
concentration of calcium required for activation with one form requiring pM levels of 
calcium for activation, and the other form requiring mM levels (Bartus, 1997). Calpains 
are located throughout the neuron in somatodendritic regions and in axons (Hamakubo 
et al. 1986) and also may be a constituent of myelin (Li and Banik, 1995). Calpain 
substrates are numerous and diverse and include microtubules, microfilaments and 
neurofilament polypeptides, and in particular, the high molecular weight microtubule 
associated protein (MAP2), NFH, NFM and spectrin (see section 1.3) (Siman et al.
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1996). Because uncontrolled simultaneous proteolysis of these multiple substrates 
would be neurotoxic, unregulated calpain proteolysis potentially represents a final 
common neuropathogenic pathway and could have profound effects on neuronal cell 
body and axonal structure and function.
Pathobiological calpain activation is believed to occur when intracellular free 
calcium levels surpass a certain threshold. Indirect evidence that calpain is activated in 
neurons following experimental injury has been shown by the use of antibodies that 
react specifically to calpain mediated breakdown products of cytoskeletal proteins such 
as spectrin. Spectrin is believed to provide shape and structural integrity to the cell while 
contributing to regulation of motility and function of various transmembrane proteins. 
The role of calpains in axonal injury following ischaemia is still under investigation but 
increased immunoreactivity for calpain-degraded a-spectrin has been shown in animal 
models following cerebral ischaemia in vivo (Roberts-Lewis et al. 1994). Some reports 
provide evidence that calpain activation can contribute to axonal damage following TBI 
(Saatman et al. 1996a), although others disagree (Yaghmai and Povlishock, 1992; Pettus 
et al. 1994). While the reason for these discrepancies is not entirely clear it may be that 
calpain-mediated proteolysis in axons involves the most severe end of the injury 
spectrum (Povlishock et al. 1997).
Inhibition of calpain mediated proteolysis might be a potential therapeutic 
strategy for reducing injury induced cellular damage and neurobehavioural deficits 
following acute CNS injury. In recent years considerable interest has been directed to 
the potential value of calpain inhibitors as postischaemia treatment of stroke (Bartus,
1997). Protease inhibitors that block calpain activation have proven to be 
neuroprotective following cerebral ischaemia and traumatic brain injury providing 
support for the calpain hypothesis (Saatman et al. 1996b; Posmantur et al. 1997; Hong et
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al. 1994; Bartus et al. 1997). Although no specific reference to axonal salvation was 
suggested, the calpain inhibitor (AK295) administration has proven to significantly 
reduce infarct volume in an animal model of cerebral ischaemia (Bartus et al. 1994).
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Figure 1.7 Mechanisms of grey and white matter injury compared
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1.6 NEUROPROTECTION WITH GLUTAMATE ANTAGONISTS
1.6.1 Introduction
Since glutamate is implicated in the pathophysiology of brain damage, prevention of its 
release or blockade of its postsynaptic action to protect central mammalian neurons 
from hypoxic-ischaemic injury has been extensively examined. Many neuroprotective 
studies have been performed with a variety of NMDA and non-NMDA glutamate 
antagonists, and glutamate release inhibitors, the majority of which have shown 
neuroprotective efficacy in animal models (Gill et al. 1991; Park et al. 1988a; Park et al. 
1988b; Ozyurt et al. 1988). Although many different glutamate antagonists have been 
produced by the pharmaceutical industry, the investigations described in this thesis 
concentrate on two; namely, MK-801 and BW19C89. A brief description of the mode of 
action of these two drugs is discussed below.
1.6.2 Blockade of postsynaptic action of glutamate
NMDA-mediated elevation of intracellular free calcium appears to be pivotal in the 
initiation of irreversible cell death. The NMDA ion channel can be blocked at a variety 
of different sites. The effects of NMDA receptor antagonists in experimental models of 
focal ischaemia effect a marked reduction in the amount of irreversible ischaemic 
damage irrespective of the species, the model of cerebral ischaemia, when the animals 
are sacrificed after the ischaemic episode, whether ischaemia is permanent or temporary 
and followed by reperfusion, and irrespective of the particular site within the NMDA 
receptor at which the drug acts (McCulloch, 1992). Dizoclipine/MK-801 (Merck Sharp 
and Dohme) binds in a non-competitive manner at a binding site within the ion channel 
pore (Fig. 1.4) and is a use dependent, open channel blocker which binds more
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effectively when NMDA receptors are activated by elevated levels of extracellular 
glutamate. In 1987 MK-801 was shown to prevent NMDA-induced cell death in the 
chicken retina (Olney et al. 1987). Since then, the non-competitive antagonist, MK-801 
(Kemp et al. 1987; Wong et al. 1986) has been demonstrated to significantly reduce the 
volume of ischaemic damage in the cerebral hemisphere when administered pre or post 
occlusion of the middle cerebral artery in cat and rat models (Gill et al. 1991; Park et al. 
1988a; Park et al. 1988b; Ozyurt et al. 1988) (Fig. 1.8).
The NMDA receptor-ion channel complex appears to be confined to the central 
nervous system, with a particularly high density in the hippocampus and cerebral cortex. 
Although there is a plethora of evidence to support the neuroprotective effects of 
NMDA receptor antagonists, there is little evidence to support the protective effect of 
such drugs on white matter following ischaemia. Negligible NMDA receptors have been 
demonstrated in myelinated axonal tracts (Jones and Baughman, 1991) and NMDA 
agonists do not damage the rat optic nerve in vitro (Ransom et al. 1990a). Clearly, the 
pathophysiological mechanisms involved in grey matter injury described above, and the 
consequent rationale for the use of NMDA antagonists in grey matter protection, cannot 
be so readily applied to white matter.
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1.6.3 Prevention of glutamate release
A fresh approach to ameliorating ischaemic brain infarction has been investigated 
through blocking the presynaptic release of glutamate (Leach et al. 1993). Presynaptic 
blockade of glutamate release is advantageous in that it prevents the activation of both 
the NMDA and non-NMDA receptor sites. The contribution of sodium ion channels to 
the mechanisms leading to anoxic white matter injury have been well characterised by 
Waxman and co-workers in the optic nerve (see section 1.5.3).
BW619C89 is an inhibitor of neuronal sodium ion channels and blocks 
ischaemia induced presynaptic glutamate release. It is ‘use dependent’, meaning that it 
blocks glutamate release with greater efficacy under conditions of persistent or 
repetitive depolarisation, as would be encountered under pathological circumstances, 
than under normal physiological circumstances (Goldin et al. 1995). It has been shown 
to decrease the release of glutamate in vitro, decrease the release of ischaemia induced 
glutamate in vivo, and decrease infarction following permanent and temporary MCA 
occlusion in rats (Kawaguchi and Graham, 1997; Leach et al. 1993; Smith et al. 1993). 
Unlike NMDA antagonists it does not produce the cytopathological and behavioural 
side effects that are produced by MK-801 (Graham et al. 1994). In addition, the 
reduction in brain damage by BW619C89 correlates with significant long-term 
functional improvement in rats (Smith et al. 1997). BW619C89 also inhibits glutamate 
release in the caudate nucleus, even though they do not prevent infarction in this region. 
Given the demonstrated benefit of sodium channel blockade in the anoxic rat optic 
nerve, it is interesting to posit that sodium channel blockers, such as BW619C89 
administered in vivo will be effective axonal protectors following ischaemic injury. It is 
also of interest to note that BW619C89, as well as inhibiting sodium channels, has 
recently been demonstrated to inhibit human N-type voltage-gated Ca channels
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(McNaughton et al. 1997). These Ca channels have also been indicated to be involved 
in the development of anoxic injury in CNS white matter (Fern et al. 1995a) (section 
1.5.3). The assessment of axonal protection following administration of BW619C89 
will be of interest, particularly as it acts at two channel sites, both of which are integral 
to the pathogenesis of axonal injury following ischaemia.
1.7 ASSESSMENT OF WHITE MATTER INJURY IN VIVO
1.7.1 Introduction
With increasing awareness of the importance of white matter injury following both 
traumatic and ischaemic insults, attention has turned to methods by which white matter 
injury can be assessed. The levels of resolution of methods used to investigate white 
matter injury are diverse, ranging from the investigation of structural components of the 
axonal cytoskeleton using immunocytochemistry, to the assessment of white matter tract 
abnormalities using magnetic resonance imaging (MRI). There does not appear to be a 
‘gold standard’ by which white matter structure and function can be assessed; by 
concentrating solely on one aspect of white matter function, such as measurement of an 
action potential, only a partial view is obtained. Perhaps a combination of techniques 
will always be required to fully assess axonal structure and function. In the following 
section, a few of the techniques that are currently used to advance our knowledge of 
white matter injury are discussed.
1.7.2 Immunohistochemistry
Unlike grey matter, where standard histological techniques such as haematoxylin and 
eosin staining allow a neuropathologist to delineate neuronal death, more complex
protocols are required for the assessment of axonal injury. For many years a standard 
histological silver impregnation technique was used which allowed the visualisation of 
axonal retraction balls following head injury. The availability of a whole spectrum of 
antibodies targeted towards axonally transported proteins, components of microtubules, 
microtubule associated proteins and neurofilament proteins, has revolutionised 
investigations of axonal structure and function following both traumatic and ischaemic 
insults. Results obtained using immunocytochemical markers of axonal injury indicated 
that the frequency of axonal injury had previously been vastly underestimated using 
conventional silver techniques (Gentleman et al. 1995).
Amyloid precursor protein (APP) and synaptosomal associated protein of 25kDa 
(SNAP25) are two examples of proteins which move by anterograde axoplasmic 
transport and accumulate in detectable levels following cytoskeletal disruption due to 
inhibition of axoplasmic flow (Sherriff et al. 1994a; Koo et al. 1990). The discovery that 
antibodies against these proteins could be used to study axonal injury following 
ischaemia was serendipitous. Original interest in APP was in relation to Alzheimer’s 
disease since the main component of the amyloid plaques, a pathologic hallmark of 
Alzheimer’s disease, is pA4, a 39-43 amino acid peptide cleaved from APP (Coria et al. 
1992; Glenner and Wong, 1984). The localisation of APP in rat brain has recently been 
studied with a cytoplasmic domain-specific antibody and found to be present, in varying 
degrees, in most neurons (Card et al. 1988; Ouimet et al. 1994). This suggests that this 
protein plays a role common to all neurons, perhaps with a more specific role in the 
functions of certain classes of neurones. APP may function in cell-cell adhesion or 
contact, stabilisation of synaptic contacts, neuritic outgrowth, serine protease inhibition, 
growth regulation, or it may be a receptor for an unidentified ligand involved in some 
signal transduction process (Ouimet et al. 1994). It has been speculated that interference
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of axonal transport is an integral step in the subsequent tangle and dystrophic neurite 
formation and in p-amyloid protein deposition in Alzheimer’s disease. Blockade of 
axoplasmic flow could cause an accumulation of APP resulting in amyloidogenesis. 
Several studies of APP in relation to Alzheimer’s research has given insight into the use 
of APP as a marker of axonal damage in other conditions including ischaemic damage.
Similarly, original interest in SNAP25 had not been as a marker of axonal injury 
but its role in the synaptic function of specific neuronal systems (Oyler et al. 1989; 
Oyler et al. 1992). In development, the expression of SNAP25 mRNA and protein 
corresponds with the onset of synaptogenesis and recent evidence has shown that in 
addition to being involved in neurotransmitter release, it is involved with the fusion 
between synaptic vesicles and the presynaptic membrane, and many other membrane 
fusion processes within axons (Due and Catsicas, 1995; Sollner et al. 1993). The fact 
that SNAP25 is incidentally transported by fast anterograde transport along axons lends 
it as another possible candidate as a marker of axonal injury (to be discussed in more 
detail in subsequent chapters).
Despite there being a plethora of axonally transported proteins, and the 
availability of antibodies targeted towards them, quantification of axonal injury has 
posed a perplexing problem. The awareness of the need to quantify axonal injury has 
been highlighted by the absence, or at best a scant presence, of suitable methods 
described in the literature. In man, grading of diffuse axonal injury has been useful for 
diagnostic purposes but does not provide the detailed information about the anatomical 
distribution of axonal injury. In grade 1 diffuse axonal injury there is only microscopic 
evidence of axonal injury, in grade 2 there is also a focal lesion in the corpus callosum 
and in grade 3 there is an additional focal lesion in the dorsolateral quadrant of the 
brainstem (Adams et al. 1989). Similarly, many scientific papers assess the presence of
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APP only by semi-quantitative means such as allocating a score based on the amount of 
APP as small, moderate and extensive (Graham et al. 1995), negative, sparse, moderate, 
dense (Roberts et al. 1991) or present and absent (Gentleman et al. 1993) (Fig. 1.9). 
More recently a sector scoring method has been described where the presence of axonal 
injury from head injury, is defined by APP positive immunoreactive axonal swellings 
recorded on a series of line diagrams of standard whole brain divided into 116 sectors to 
provide an Axonal Injury Sector Score ranging from 0-116. The advantage of this 
technique is that by identifying those sectors in which there is evidence of axonal 
damage, an overview of the pattern of axonal injury in a particular brain is seen readily 
and by counting the number of sectors in which axonal injury is present, an axonal 
injury sector score is also obtained (Blumbergs et al. 1995). The disadvantage of this 
method is that a positive score is given irrespective of whether there is mild or extensive 
APP immunoreactivity so at best, this method gives only an indirect measure of the 
amount of axonal injury in a given brain. Nevertheless, in general, the higher scores 
correlate with the Glasgow Coma Scale allocated to patients. A modified sector scoring 
method has also been used in an experimental setting to investigate axonal injury in 
sheep following head impact (Lewis et al. 1996). Again, there is a good correlation 
between the sector score and index of physiological response to injury. Although the 
sector scoring method gives some information about topographical distribution of 
increased immunoreactivity, it still is only semi-quantitative assessment of APP 
immunoreactivity.
In order to evaluate the success of putative therapies on axonal injury, a more 
quantitative approach may be required. Quantitative analysis of immunocytochemical 
staining of pAPP in the entorhinal cortex has been developed using a computerised cell 
counting programme. This was found to be both accurate and efficient compared to
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manual cell counting (McKenzie et al. 1995). Sections were examined microscopically 
and images captured using a video camera, a sensitivity threshold selected such that 
APP positive cells were distinguished from background staining on the basis of the 
contrast in colour, and the cell number then automatically counted. A similar method 
using modem image analysis techniques has also been reported to quantify prion protein 
deposition in Creutzfeldt-Jacob disease (Sutherland et al. 1996). The deposits are 
recognised by the computer in terms of image intensity and a value for the overall 
amount of prion protein deposition can then be produced. In the latter example, the area 
of prion deposits were calculated, rather than the number of positive cells as described 
for the PAPP quantification. The quantification of axonal injury using APP as a marker 
forms a substantial part of the work described in more detail in subsequent chapters of 
this thesis.
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Figure 1.9
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Figures A, B, C and D illustrate semi-quantitative grading system used to quantify 
APP immunoreactivity following head injury in man. (Courtesy o f D. I. Graham)
1.7.3 Evoked potentials
Evoked potentials are electrical waves that can be recorded from the brain after 
stimulation of the sense organs. The contribution of fibre tract ischaemia to functional 
impairment of the cortex has been deduced indirectly from abolition of evoked 
potentials in normally perfused cortical areas (Graf et al. 1990a). Graf and colleagues 
performed some very elegant experiments recording regional cerebral blood flow, 
somatosensory evoked potentials, and auditory evoked potentials in the thalamic relay 
nuclei and in the somatosensory and auditory cortices during and after 1 h of transient 
MCA occlusion (Graf et al. 1990b). Regional cerebral blood flow was also measured in 
the thalamocortical tracts. Regional cerebral blood flow was severely reduced during 
MCA occlusion in the left primary auditory cortex and in white matter pathways. In 
contrast, regional cerebral blood flow did not change significantly in the somatosensory 
cortex or in either thalamic nucleus. However, evoked potentials were abolished in both 
cortical areas. Cortical somatosensory evoked potentials disappeared later than auditory 
evoked potentials suggesting that ischaemic tolerance is higher in the white matter tracts 
than in the grey matter. In addition, following recirculation, there was a rapid and almost 
complete recovery of somatosensory evoked potentials, but little recovery of the 
auditory evoked potentials. Again, this suggests that the white matter tracts have a better 
recovery than grey matter once blood flow is restored. Since cortical somatosensory 
blood flow was unchanged following MCA occlusion, the loss of somatosensory evoked 
potentials following MCA occlusion must have been due to ischaemia of the white 
matter tracts and not due to ischaemia of the grey matter. Much information can be 
gleaned about the function of white matter tracts following ischaemic insults using 
electrophysiological techniques. The knowledge of functional circuitry combined with
41
the technique of evoked potentials exemplifies the type of research that could allow the 
evaluation of putative therapies on axonal function following ischaemic insults.
1.7.4 M RI
The advent of computed tomography (CT) and magnetic resonance imaging (MRI) has 
resulted in a dramatic change in the evaluation of patients with suspected intracranial 
abnormalities. MRI is more sensitive than CT particularly for white matter (Baird and 
Warach, 1998) and has become the method of choice for the clinical evaluation of the 
brain in normal and pathological conditions (Makris et al. 1997). MRI depends on the 
physical phenomenon of spinning subatomic particles of nuclei called nucleons. When 
in a magnetic field, the spinning nucleons are either in parallel or antiparallel to the 
direction of the field, and nuclei with an even number of nucleons do not exhibit 
significant magnetic properties since the nucleons tend to cancel one another out. 
Unpaired atomic nuclei act like small spinning bar magnets when placed in a strong 
magnetic field. The most commonly utilised nucleus is hydrogen due to its relatively 
strong MRI signal and its natural abundance in biological tissue. Tissues placed in a 
strong magnetic field result in a tendency for these protons to orientate in a direction 
along the magnetic field. When a radiofrequency wave is introduced, it adds energy to 
the protons. It is introduced at an energy level or frequency specific for both the 
magnetic field strength and the particular proton. The introduction of the radiofrequency 
pulse causes protons to move out of alignment with the magnetic field direction. When 
the radiofrequency excitation is stopped, the proton is free to return to the orientation of 
the magnetic field direction. This return to the original direction occurs over time. The 
process of a proton returning to the orientation of the magnetic field is called relaxation. 
During relaxation, the proton gives off the radiofrequency energy on signal acquired
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during radiofrequency pulsation. This signal can be detected by a sensitive antenna or 
coil, is then amplified and processed by a computer. The specific area of tissue emitting 
a signal can be identified through a system known as magnetic field gradients. Image 
intensity varies with proton relaxation properties and depends on their chemical 
composition and binding. Because MRI depends on the detection of weak 
radiofrequency signals emitted by protons that are situated in a strong magnetic field, 
the image is dependent on the difference in detected signals in varying tissue types. 
Unlike most other imaging modalities, MRI allows a variety of manipulations to obtain 
a diagnostic image and vary the contrast on the images. In particular, the independent 
tissue variables that provide contrast on diagnostic examinations include the proton 
density, the Ti and T2, and flow. The Ti relaxation time is the time required for the 
nucleons to return to their original alignment within the strong static magnetic field. The 
T2 component is a measurement of the decreasing transverse activity. The type of tissue 
contrast obtained depends on the type of imaging sequence. In general T1 weighted 
sequence is used to obtain anatomic detail. The Ti-weighted image places an emphasis 
on fat tissue; the fat in images appears white. A T2-weighted image has the emphasis on 
increased tissue water or liquid structures, and these structures appear white. In general, 
an area of increased intensity (white) on an MRI image is designated as having a short 
Ti (Ti weighted imaging). If it is dark it has a long Ti (Ti weighted imaging). An area 
of increased signal intensity on a T2 weighted image is referred to as having a long T2; 
and if the signal is decreased on T2 weighted imaging it is referred to as having a short 
T2 (Orrison, 1989).
The contrast between white and grey matter is largely due to the myelination of 
the white matter tracts. Myelin is composed of a bilayer of lipids, cholesterol, and large 
proteins. There are differences in the relaxation time between white matter and grey
matter. In white matter, the myelin lipids themselves contain few mobile protons visible 
to routine MRI, but they are hydrophobic, and therefore, as myelination progresses, 
there is a loss of brain water and a decrease in T2 signal. Cholesterol tends to have a 
short Ti, and the increased protein also decreases the Ti of water. This results in white 
matter having a reduced intensity on T2-weighted images and increased intensity on Ti- 
weighted images compared with unmyelinated fibres or grey matter. MRI is very 
sensitive to white matter abnormalities but not specific. Following a critical reduction in 
blood flow to a particular region, normally myelinated white matter is destroyed.
Advances in MRI include diffusion imaging, which gains an understanding of 
microscopic water shifts as the different types of oedema develop, and perfusion 
imaging, which can assess microvasculature perfusion at a high resolution. The overall 
principle of diffusion measurement is that the spatial location of each water molecule is 
tagged such that any movement of a water molecule over the time of observation results 
in a signal loss or darkening of the images. Thus on diffusion weighted images, regions 
of relatively fast rates of diffusion (e.g., cerebrospinal fluid) will appear darker than 
regions of normal brain, which appear darker than regions of hyperacute ischaemic 
injury, which have slower than normal diffusion (for review see Baird and Warach, 
1998). Diffusivity is anisotropic in orientated tissue such as fibre tracts and the latest 
techniques in diffusion -weighted MRI have resulted in the definition of white matter 
lesions following stroke (Warach et al. 1995) and the capability to map (in terms of 
orientation, location and size) the ‘stem’ (compact portion) of the principal association, 
projection, and commissural white matter pathways of the human brain in vivo. In 
addition, following stroke, differences in the relative size of major association pathways 
have been illustrated in the living human (Makris et al. 1997). In the clinical domain,
this method will have a potential impact on the understanding of the diseases that 
involve white matter such as stroke.
The different techniques of MR perfusion imaging typically deal with blood 
volume, transit times, and blood flow as relative measures, although absolute 
quantification may also be possible. Two types of MR perfusion imaging have found 
applicability to clinical conditions and scientific studies- (1) susceptibility-based 
techniques that use either paramagnetic contrast agents, most commonly those 
containing gadolinium (contrast agent block tracking), or endogenous changes in 
deoxyhaemoglobin, which is an intrinsic paramagnetic molecule (blood oxygen level 
dependant [BOLD]); and (2) arterial spin labelling techniques (Baird and Warach,
1998). In the first method, gadolinium is injected intravenously and the scan may be 
performed every 1-2 seconds for 1-2 minutes. The amount of signal loss is proportional 
to the concentration of the contrast agent and is directly proportional to the blood 
volume of healthy brain tissue. BOLD imaging detects changes in the concentration of 
deoxyhaemoglobin that may occur under conditions of altered blood flow. When a 
region of neural tissue becomes active, its oxygen consumption increases. Blood flow to 
the region also increases, but so much that it overfulfills tissue oxygen requirements, so 
that deoxyhaemoglobin concentration actually falls resulting in an increased BOLD 
signal intensity (Prichard and Cummings, 1997). In ischaemia there is a decrease in the 
BOLD signal intensity reflecting decreased tissue oxygenation. The major limitations to 
the routine clinical and experimental use of perfusion MRI are the availability, 
practicality and the time intensive nature of the processing of perfusion data. The great 
attraction of diffusion weighted imaging and perfusion imaging in the investigation of 
ischaemic stroke pathophysiology is that diffusion weighted imaging provides an early 
marker of cellular injury in developing ischaemic lesions and serial, high resolution
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studies can be performed to provide temporal information. Other techniques such as 
magnetic resonance spectroscopy allows the measurement of specific brain metabolites, 
e.g. lactate which appears in ischaemic tissue, allow even greater insight into the 
pathophysiology of ischaemic brain conditions. These techniques can be successfully 
applied to animal models of stroke and may provide insights of major relevance to 
human stroke about the pathophysiology and mechanisms of ischaemic lesion evolution.
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1.8 AIMS OF THESIS
A large body of work exists dealing with the pathophysiology of grey matter. In 
contrast, much less is known about the fundamental mechanisms of anoxic/ischaemic 
injury to CNS myelinated axons, despite the fact that white matter has been shown to be 
very vulnerable to this type of injury (Pantoni et al. 1996; Follis et al. 1993). These 
observations emphasise that differences in the pathophysiology of grey and white matter 
anoxic injury are likely to necessitate multiple strategies for optimal CNS protection.
Myelinated axons are essential for the normal functioning of the brain. Since 
myelinated axons, like grey matter, are dependent on a continuous supply of energy, it is 
likely that strokes compromise axonal function as well as that of the neuronal cell 
bodies. Although many drugs have been targeted towards cell body protection, it has not 
yet been established whether this approach also protects axons. In order to establish this, 
the tools required include a suitable marker of axonal injury, a method by which the 
marker can be quantified and an animal model in which to test the hypothesis. The aims 
of the work described in this thesis were fourfold:
• To define markers of axonal injury appropriate for use in the assessment of axonal 
pathology consequent to focal cerebral ischaemia
• To develop quantitative techniques for the assessment of axonal injury
• To apply a suitable marker of axonal injury and a method of quantification of axonal 
injury in the rat following focal cerebral ischaemia
• To explore the utility of techniques of quantification of axonal injury in species 
where there is a larger volume of white matter compared to that in the rat brain.
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CHAPTER 2 
MATERIALS AND METHODS
The following chapter describes the materials and methods frequently used in the work 
relating to this thesis. The first section describes the general methods used in animal 
experimentation and this is followed by the description of light and electron 
immunocytochemistry used to assess axonal injury. The sources of commonly used 
materials are listed in Appendix 1 and the composition of routinely used stock solutions 
and buffers in Appendix 2. Additional materials and chemicals not listed are specified 
elsewhere in the text. The specific details for individual studies are described in 
subsequent chapters.
2.1 FOCAL CEREBRAL ISCHAEMIA IN THE RAT
2.1.1 Source and Strain
The studies employed adult, male Fischer 344 rats weighing approximately 300g. The 
Fischer rats were supplied by Harlan Olac Ltd., Bicester, Oxon, U.K.. On arrival the rats 
were allowed to acclimatise for five days before any surgical procedures were 
performed. The rats were maintained under controlled lighting and thermal environment 
and were allowed free access to food and water. The Fischer 344 rat was used 
throughout the studies described in this thesis. This decision was based on evidence 
suggesting that the Fischer 334 strain is the normotensive strain of choice for MCA 
occlusion studies. The influence of rat strain on the quantification of cerebral infarction 
was investigated by Duverger and MacKenzie who found that following MCA occlusion 
the lesion in the Fischer rat was sizeable and similar to that observed in the Sprague-
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Dawley rat, yet the co-efficient of variation was considerably less significant than the 
latter (Duverger and MacKenzie, 1988). This was supported by a later study 
investigating the strain-dependent drug effects following MCA occlusion in the rat. 
Quantitative differences in infarction volume between strains existed, not only when 
there was no drug intervention, but also following the administration of three different 
drug classes (including MK-801). However, the largest effects with all three drug 
classes was attained in the Fischer 344 rats, and this strain showed the biggest volume of 
infarction with the least variance among the normotensive strains of rats (Sauter and 
Rudin, 1995) (Fig. 2.1). The above described attributes of the Fischer rats were 
considered to offer advantages in the study of the pathophysiology and therapy of focal 
cerebral ischaemia.
2.1.2 Anaesthesia
Anaesthesia was induced by placing the rats in a perspex chamber into which 70% 
nitrous oxide, 30% oxygen and 5% halothane was flowing. For acute experiments, a 
tracheostomy was performed. A femoral artery and vein were cannulated using 
polyethylene catheters (Portex:external diameter 0.96 mm; internal diameter 0.58 mm) 
to allow the continuous monitoring of mean arterial blood pressure (P23 ID Gould 
Stratham, Model 2202), the repeated sampling of blood and the administration of fluids 
when appropriate. Animals were maintained normocapnic, normoxic and normothermic 
throughout the experimental period by adjusting the volumes of gases delivered to the 
animal. Rectal temperature was measured and the rats were maintained normothermic 
(37 + 0.5°C) by heating lamp.
The protocol for survival animals is as described above except that, instead of 
performing a tracheostomy, rats were intubated per os using a 45 mm, 16 gauge catheter.
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In addition, arterial and venous lines were exteriorised at the dorsal surface at the neck 
to allow continuous monitoring of blood pressure and drug/fluid administration once the 
animals had recovered from anaesthesia. Following middle cerebral artery occlusion, 
anaesthesia was discontinued and the animals allowed to regain consciousness under 
strict observation. Saline was injected subcutaneously (2.5 ml) to minimise dehydration 
post-operatively. The animals were housed individually and had access to softened food 
and water.
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Figure 2.1
Fronto-parietal motor cortex
Genu corpus callosum
Caudate nucleus
Primary olfactory cortex
Wistar/Kyoto
100% 
> 50% 
< 50%
Sprague Dawley Fischer 344
SHR Stroke Prone-SHR
Incidence and topography of the infarction at the level of the caudate nucleus 
in five rat strains. Adapted from Duverger and MacKenzie, 1988.
2.1.3 Middle cerebral artery occlusion
The middle cerebral artery (MCA) occlusion model are used extensively in stroke 
research and have been suggested to be of particular importance to the drug discovery 
process because of their clinical relevance. This is because the most common sites for 
obstruction in man are points of bifurcation of blood vessels, especially in the territory 
of the MCA. Experimental stroke models generally involve MCA occlusion either by 
electrocoagulation (Tamura et al. 1981) or by blockade with a luminal filament thread 
(Zea Longa et al. 1989) (for review of focal models of stroke see McAuley, 1995). All 
studies within this thesis involved MCA occlusion by electrocoagulation (Fig. 2.2).
The left MCA was exposed using a subtemporal approach (Tamura et al. 1981), 
leaving the zygomatic arch intact (Shigeno et al. 1985). The animals were placed in 
lateral recumbency and a 1 cm vertical skin incision made between the left orbit and the 
external auditory canal. The underlying fascia was removed and the exposed temporalis 
muscle bluntly dissected and retracted to expose the inferior part of the temporal fossa. 
A small craniectomy was made using a dental drill at the junction between the medial 
wall and the roof of the temporal fossa, approximately 1 mm dorsal to the foramen 
ovale. The dura was opened using a 30 gauge dental needle and then removed using a 
fine hook to reveal the MCA. The main trunk of the artery was exposed proximal to the 
olfactory tract to where it crosses the inferior cerebral vein. The exposed artery was 
occluded by micropolar coagulation from its origin to the point where it crosses the 
inferior cerebral vein and then severed to prevent recanalisation. The craniectomy was
covered by Gelfilm® (Upjohn). The muscle and skin were sutured using 2/0 braided 
silk.
The survival periods and protocol for drug administration for each study are 
described in the following chapters.
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Figure 2.2
Dorsal view o f rat brain showing middle cerebral artery
Inferior cerebral vein
Middle cerebral artery
Lenticulostriate branch
Rhinal branch
Schematic diagram o f middle cerebral artery. Occlusion was performed 
between sites A and B. (Modified from M. A. McAuley, 1995.)
2.1.4 Transcardiac perfusion and subsequent tissue processing
At the end of the procedure the halothane anaesthesia was deepened and the animal 
placed supine. A thoracotomy was performed and a cannula inserted into the ascending 
aorta via the left ventricle, the right atrium was incised, and 200 ml of heparinised saline 
infused at the animals mean arterial blood pressure, followed by 200 ml of fixative. 
Different fixatives were used in the studies described in this thesis, the choice being 
dependent on the subsequent work to be performed on the tissue. Tissue processing 
varied for each fixative used and is described below.
Formaldehyde (4%) fixation
The fixative used was 40% formaldehyde, glacial acetic acid, absolute methanol in the 
ratio 1:1:8, v/v. Following transcardiac perfusion, the animal was decapitated and the 
head stored in fixative for at least 24 hours at 4°C before being removed and transferred 
to a 70% solution of methanol. After detaching the hindbrain, the forebrain was cut into 
four equally spaced coronal blocks, embedded in paraffin wax, and sectioned (nominally 
10 pm thick) at multiple levels.
Paraformaldehyde (4%) fixation
The fixative composed of 4% paraformaldehyde in 50 mM phosphate buffered saline 
was used for immunocytochemical studies at the light microscope level. Following 
transcardiac perfusion, the animal was decapitated and the brain removed, post-fixed for 
48 h and cryoprotected in 30% sucrose in phosphate buffered saline at 4°C. Following 
this the brain was frozen in isopentane at -42°C for two minutes. Coronal sections of 30
pm were cut in a cryostat and stored in cryprotectant solution (30% glycerol/ 30% 
ethylene glycol in sodium phosphate buffer) at -20°C.
Gluteraldehyde (0.5%) and paraformaldehyde (4%) processing
Brain material to be used for electron microscope studies was fixed using a mixture of 
gluteraldehyde and paraformaldehyde since this combination gives a better preservation 
of tissue than using either aldehyde alone. Formaldehyde penetrates tissues much more 
rapidly than gluteraldehyde and it is thought that the formaldehyde temporarily stabilises 
structures which are subsequently fixed more permanently by the gluteraldehyde 
(Kamovsky, 1965). The fixative was buffered with phosphate rather than cacodylate 
since the latter contains arsenic which is toxic. Since fixation is more rapid and effective 
the higher the temperature of the perfusate, the perfusion fluids (saline and fixative) 
were transfused at 37°C. Careful consideration was given to the duration of the prewash 
with saline since the organs and vasculature would be deprived of oxygen during this 
wash. Saline was therefore perfused for a period until blood was removed from the 
circulation and was followed immediately by the fixative for at least 10 minutes at a 
pressure equal to or greater than the systolic blood pressure. The brain was removed and 
left in the fixative overnight at 4°C. The fixed brain was cut using a vibrating 
microtome into 50pm sections and collected into cell wells containing phosphate buffer. 
Adjacent sections were collected for light microscopy and electron microscopy.
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2.2 FOCAL CEREBRAL ISCHAEMIA IN THE CAT
2.2.1 Source
The studies employed adult, male and female cats weighing 3-4 kg. On arrival the cats 
were allowed to acclimatise for five days before any surgical procedures were 
performed. The cats were housed outdoors and fed twice daily.
2.2.2 Anaesthesia
The cats were anaesthetised initially with Saffan (Alphaxalone/Alphadolone) (9mg/kg 
i.v.), intubated, and connected to a positive pressure ventilator delivering nitrous oxide 
and oxygen in an open circuit. Polyethylene catheters were inserted into both femoral 
veins and one femoral artery for the administration of drugs and the continuous 
monitoring of arterial blood pressure, and blood gases and glucose. Anaesthesia was 
maintained throughout the course of the investigation with chloralose (60 mg/kg i.v.), 
supplemented as necessary to prevent the return of the comeal reflex. Throughout the 
experimental period, the animals were maintained normotensive (mean arterial blood 
pressure (MABP) greater than 80 mm Hg); normocapnic (PaCC>2 close to 32 mm Hg) by 
adjusting the stroke volume of the respirator. Metabolic acidosis was corrected by 
administration of sodium bicarbonate (8.4%). Samples of arterial blood were taken 
frequently for the determination of the respiratory status using a direct reading electrode 
system and for the measurement of plasma glucose levels (automated assay based on the 
glucose oxidase reaction). The cats were maintained normothermic (rectal temperature 
37°C) by means of a heating blanket with feedback control via a rectal thermometer.
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2.2.3 Middle cerebral artery occlusion
The left MCA was occluded via a transorbital approach. The head of the cat was placed 
in a stereotactic frame. With microsurgical techniques, the left orbit was exenterated and 
the optic foramen and optic fissure were enlarged with a dental drill to expose the dura 
mater overlying the MCA close to its origin. Under the operating microscope the dura 
was incised and the MCA exposed. The trunk of the MCA and all visible branches of 
the lenticulostriate arteries were coagulated with a bipolar diathermy and divided with 
microscissors.
Six hours after the occlusion of the middle cerebral artery, the cat was killed by 
transcardiac perfusion fixation with FAM (see 2.1.4). Briefly, the cat was placed in a 
supine position and heparinised. A thoracotomy was performed and a cannula was 
introduced into the ascending aorta via the left ventricle. Physiological saline was 
infused at a pressure equivalent to mean arterial pressure until blood was removed from 
the body. This was followed immediately by 1.5 1 of FAM fixative at the same pressure. 
After perfusion, the cats were decapitated and the head stored in fixative at 4° C for at 
least 12 h; the brain was then removed and left in FAM for a further 24 h before transfer 
to 70% methanol. After marking the left-hand side of the forebrain with Indian ink, the 
hindbrain was detached by a cut through the midbrain and the cerebral hemispheres 
were cut into five equally spaced coronal blocks. These blocks were embedded in 
paraffin wax and 6 sections 10 pm thick were cut at 200 pm intervals throughout the 
specimens.
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2.3 LIGHT MICROSCOPE IMMUNOHISTOCHEMISTRY
2.3.1 FAM fixed material
Sections were mounted on 3-aminopropyltriethoxy-saline (APES) or poly-L-lysine 
coated slides and dried at 37°C overnight. In order to remove the wax, the sections were 
placed in xylene. The sections were dehydrated by placing them in absolute alcohol for 
two minutes and rinsed in methanol. They were left in methanol and hydrogen peroxide 
solution (0.5%) for 30 minutes. Tissue pretreatments, if required, took place at this stage 
(see 2.3.4). The sections were then rinsed in tap water and finally phosphate buffered 
saline (PBS) for 2 minutes. Bovine serum albumin (5%) and normal horse serum (10%) 
in PBS, was applied for 1 hour to block non-specific binding sites. The excess blocker 
was wiped off and optimally diluted primary antibody, which had been made up in the 
bovine serum albumin and normal horse serum in PBS, was applied and was left 
overnight at 4°C. As controls, the primary antibody was eliminated. No positive staining 
was seen in any of the control sections (Fig. 2.3). The sections were washed in PBS for 
3 x 1 0  minutes. Diluted biotinylated antibody solution was applied for 1 h and sections 
washed again in PBS for 3 x 10 minutes. The avidin/biotinylated horseradish peroxidase 
solution (Vectastain Elite ABC Kit or Vectastain Standard ABC kit, Vector Labs) which 
had been prepared 30 minutes prior to use, was applied for 1 h. The washing procedure 
with PBS was repeated and then the sections allowed to develop in 3,3’- 
diaminobenzidine solution (Sigma) for 8-10 minutes. Finally, the sections were rinsed 
with water, dehydrated, cleared and mounted in DPX mountant.
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Figure 2.3 Negative control
v
A typical example o f a negative control section used in iinmunohistochemistry using 
DAB as the chromagen. Negative controls in which the primary antibody was omitted, 
were carried out for each immunohistochemistry run. Non-specific immunoreactivity 
was not detected in these tissue sections.
2.3.2 PAM fixed sections
Free-floating sections were rinsed in PBS, incubated for 30 min in 0.2% Triton X-100 
followed by 20 min in 3% H2O2 and then for 1 h in 10% normal horse serum and 2%
bovine serum albumin in PBS to block non-specific binding sites. Incubations with 
primary antibodies diluted in blocking buffer were overnight at 4°C. As controls, the 
primary antibody was eliminated. No positive staining was seen in any of the control 
sections. Primary antibody binding was detected using a biotinylated secondary antibody 
(rat adsorbed horse anti-mouse IgG (H+L), 1:100, Vector Labs) diluted in blocking 
buffer and an avidin-biotin complex kit (Standard and Elite Vectastain, Vector Labs) 
with 3,3'-diaminobenzidine (DAB Substrate Kit, Sigma) as the chromagen. Finally, the 
sections were washed in tap water before being dehydrated, cleared and mounted in 
DPX mountant.
2.3.3 Tissue pretreatments
A large proportion of the material used for immunohistochemistry in this thesis was 
FAM fixed and paraffin embedded. Fixation is known to cause partial or complete 
masking of the 13-amyloid precursor protein epitopes (13APP). The demonstration of the 
I3APP antigen could be significantly improved by treatment with the proteolytic enzyme, 
trypsin. Antigen demonstration is improved due to the enzyme breaking the protein 
cross links formed by the FAM fixation and thereby exposing the hidden antigenic sites 
(Jackson and Blythe, 1993). Optimal immunolabelling occurred when the sections were 
pretreated with trypsin (0.1%) with calcium chloride (0.1%) at 37 °C for 15 minutes.
The microwave oven was also used to enhance antigenicity as this method has 
previously been demonstrated to improve 13APP immunoreactivity (greater contrast with 
low background staining) following axonal injury (Sherriff et al. 1994b). Sections were
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brought to the boil in citrate buffer (pH 6) in the microwave oven for 5 minutes, 
checked to ensure that they were still covered with buffer, reboiled for a further 5 
minutes and then allowed to cool for 20 minutes before continuing with the 
immunohistochemistiy protocol. Although the exact reason for the success of the 
microwave is uncertain, it is suggested that the procedure breaks some of the weak 
intramolecular cross-linkages that are formed during fixation.
2.3.4 Antibody concentrations
Dilution curves were carried out to determine the optimum dilution for each antibody 
i.e. that which produced the best signal to background ratio. Tables 2.1, 2.2 and 2.3 
show the optimum concentration of antibodies and pretreatments for material fixed by 
both FAM and PAM.
Table 2.1 Concentration curves for immunocytochemistry on FAM 
fixed rat material
Concentration
ofAPP
ABC kit 
Standard/Elite
Microwave Trypsin Quality of 
immunostaining
1:60 Elite No Yes + + +
1:120 Elite No Yes + + +
1:300 Standard No Yes +
1:300 Elite No Yes +
1:3,000 Elite Yes No + +
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Table 2.2 Concentration curves for immunocytochemistry on PAM 
fixed rat material
Antibody ! Concentration i ABC kit 
Standard/Elite
Quality of 
immunostaining
SNAP25 1:60,000 Standard + +
1:120,000 Standard + + +
1:240,000 Standard +
MAP5 1:250 Standard +
1:500 Standard + +
1:1,000 Standard + + +
NF68kD 1:10 1 Standard + + +
1:50 Standard +
1:100 Standard +
1:200 Standard +
1:400 Standard +
1:800 Standard +
1:10 Elite + + +
1:100 Elite + + +
1:1,000 Elite + +
APP 1:10 Standard + + +
1:20 Standard + + +
1:300 Standard +
1:600 Standard +
1:300 Elite +
p-tubulin 1:5,000 Standard + +
1:10,000 Standard + + +
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Table 2.3 Cat tissue concentration curves for amyloid precursor protein
Antibody Trypsin 
concentration i
Microwave ABC kit Quality of 
j Standard/Elite j staining
1:500 No Yes Elite + + + +
1:1000 No ; Yes Elite j +  +
1:3000 No j Yes ! Elite | +
1:50 No No Elite 1 + +
1:100 No No Elite j +
1:300 No No Elite +
1:500 No j No | Elite j +
1:50 Yes No Elite + +
1:100 Yes No Elite j +
1:300 Yes No Elite +
1:500 Yes No Elite j +
1:50 No Yes Standard + + + +
1:100 No Yes Standard + + +
1:300 No Yes Standard +
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2.4 HISTOLOGICAL PROCEDURES
Sections were stained with haematoxylin & eosin and a method that combines luxol fast 
blue and cresyl violet (Appendix 3). This combination allows the identification of early 
ischaemic brain damage where the cell body and nucleus are shrunken and become 
triangular in shape and the cytoplasm stains intensely with eosin and bright blue to dark 
mauve with the Luxol fast blue/cresyl violet technique (Graham, 1977).
2.5 MEASUREMENT OF VOLUME OF INFARCTION
2.5.1 Determination in the rat
The sections stained by haematoxylin and eosin and Luxol fast blue and cresyl violet 
were examined by conventional light microscopy by an investigator ‘blinded’ to the 
immunocytochemistry results. Areas of infarction (Brierley and Graham, 1984) were 
delineated on paraffin sections at the eight preselected stereotactically determined 
coronal levels and transcribed onto scale diagrams (x 4 actual size) of forebrain drawn 
from the atlas of Konig and Klippel (Osborne et al. 1987; Konig and Klippel, 1963)
(Fig. 2.4 and Fig. 2.5). An approximation to total volume of ischaemic damage was 
achieved by integration of area with the distance between each level.
2.5.2 Determination in the cat
The sections were stained by haematoxylin and eosin and cresyl violet and Luxol fast 
blue. Those sections that corresponded most closely to 16 stereotactically predetermined 
coronal planes of cat brain from the atlas of Reinoso-Suarez, (1961) were examined by 
conventional light microscopy without prior knowledge of the animal’s history. Any 
abnormalities were charted on the diagrams drawn to scale and formed the basis of
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quantitative assessment of ischaemic brain damage in manner analogous to that 
previously described for the rat (Osborne et aL 1987) (Fig. 2.6). The area of ischaemic 
necrosis in the cerebral hemisphere, cerebral cortex and caudate nucleus was determined 
from the diagrams at each of the 16 coronal planes. The volumes of ischaemic necrosis 
were calculated from the areas of damage at the different coronal planes and their 
anterior-posterior co-ordinates.
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Figure 2.4
5
2
3
8
The eight coronal levels in the rat brain selected from the atlas of Konig and 
Klippel for quantification of infarction following MCA occlusion. Co-ordinates 
for the levels one to eight are 10.5 mm, 8.92 mm, 7.19 mm, 6.06 mm, 5.15 mm, 
3.75 mm, 2.18 mm and 1.02 mm respectively.
Figure 2.5
Representative sections from coronal level 2 (anterior co-ordinate 8.92 mm) from a 
single animal to show transcription o f area o f  infarction onto a line diagram, as assessed 
by viewing adjacent sections with haematoxylin and eosin, and luxol fast blue. Scale 
bar is approximately 1.1 mm.
Figure 2.6
Sixteen coronal levels in the cat brain selected from the atlas of Reinoso-Suarez 
for quantification of infarction following MCA occlusion.
C R A N IA L
C A U D A L
2.6 ELECTRON MICROSCOPE IMMUNOHISTOCHEMISTRY
2.6.1 Correlated light and electron microscopy
Following sectioning of the tissue (see 2.1.4), the 50jim brain slices were placed in 50% 
ethanol for 30 minutes. Endogenous peroxidase activity was inhibited by placing the 
sections into a solution of 10% methanol and 3% hydrogen peroxide in PBS for a period 
of about 5 minutes. Sections were washed with PBS several times until bubbles ceased 
to rise. The immunocytochemistry was performed as described (see 2.3.1). On 
completion of the immunostaining the sections that were for light microscopy were 
picked up on slides, dehydrated, cleared and mounted with cover slips. The remaining 
sections were processed so that they could be visualised by electron microscopy.
Sections were washed with 0.1 M phosphate buffer (pH 7.4) in glass vials and 
then 1-2 ml of 1% osmium tetroxide solution was applied using a glass pipette and the 
vials covered. This was performed in a fume hood. The sections were post-fixed for 
approximately 20-25 minutes before pipetting off the osmium which was placed in 
waste osmium bottles. The brain sections were washed at least three times for 15 
minutes each in phosphate buffer. Prior to resin embedding, water was removed by 
sequentially placing the tissue into 70%, 95%, and 2 x 100% ethanol solutions for 10 
minutes each. Once all the water was removed the tissue was gradually transferred to 
pure resin (Appendix 2) by passing it through a 3:1 ethanol:resin, 1:1 ethanol:resin, 1:3 
ethanol:resin mixture for 30 minutes each. Finally the sections were placed into two 
changes of pure resin with at least one change overnight. The sections were then 
embedded between two acetate sheets. A weight was placed on top so that the sections 
were flat, and left at 60°C overnight to allow the resin to polymerise. Sections that had 
been stained for light microscopy were examined and the areas of interest were then
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identified in the adjacent sections that had been processed for electron microscopy 
(correlated light and electron microscopy) (Fig. 2.7).
The top acetate sheet was peeled away and, having identified the region of 
interest using the light microscope, guidecuts were made in the resin with a pointed 
scalpel blade. The resin was softened by placing the section on a hot plate and the area 
of interest (which was still adherent to the bottom acetate sheet) cut and removed with 
fine forceps. The piece of tissue was placed into a truncated embedding capsule which 
was then filled with resin and labelled. The resin was polymerised at 60°C for 48 h. 
Once the resin had hardened the capsule was removed using a razor blade.
Capsule
Resin
Acetate
Tissue
Thick sections (2pm) were cut using a pyramitome and, in some instances, stained with 
1% toluidine blue in borax. These were viewed by light microscopy and the region of 
interest isolated by further trimming with the pyramitome. Fine sections were cut using 
an Ultratome II and placed on copper grids. The thickness of the sections was monitored 
by their interference colours, in this case in the silver-gold band. The sections were 
stained with uranyl acetate and lead citrate (Appendix 2). Electron microscopy was 
performed using Jem lOOcxII. The effects of tissue preparation for transmission electron
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microscopy may introduce artefacts (Maxwell et al. 1997); this may be especially 
pertinent for ischaemic tissue in which the main blood vessel supplying the region has 
been occluded thus compromising fixation.
2.6.2 Antibody concentrations
Dilution curves were carried out to determine the optimum dilution for each antibody 
(Table 2.4).
Table 2.4 Concentration curves for immunocytochemistry on material 
for electron microscopy
Antibody Concentration ABC kit 
Standard/Elite
Quality of 
immunostaining
NF68kD 1:100 Elite + +
1:1000 Elite + + +
APP 1:10 Elite + + +
1:100 Elite +  4-
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Figure 2.7 Correlated light and electron microscopy
Sections that were stained for light microscopy were examined. A) Light microscope 
appearance o f  immunostaining for NK68kD in the MCA territory in the caudate nucleus 
following 4 h MCA occlusion (50pm). Once the areas o f interest had been identified by 
light microscopy, adjacent sections were processed for electron microscopy. B) A thick 
section (2pm ) showing NF68kD immunostaining in the caudate nucleus.
Scale bar = 20pm
CHAPTER 3
MARKERS OF AXONAL INJURY
3.1 INTRODUCTION
White matter injury may be a major determinant of clinical outcome. The study of 
traumatic brain injury in both man and in a non-human primate model of experimental 
injury, suggests a direct link between the extent of diffuse axonal injury and the ensuing 
patient morbidity (Gennarelli et al. 1982; Adams et al. 1989). Axonal injury following 
cerebral ischaemia has attracted less attention than damage in grey matter. However, 
there is now increasing evidence that damage to axons does occur following an 
ischaemic insult (Pantoni et al. 1996; Dewar and Dawson, 1997; Yam et al. 1997). In 
order to define the responses of axons to injury a variety of markers have been 
investigated. Amyloid precursor protein (APP) (Sherriff et al. 1994a; Gentleman et al. 
1993; Gentleman et al. 1995), neurofilament subunits (Ng et al. 1994; Christman et al. 
1994; Grady et al. 1993) and ubiquitin (Gultekin and Smith, 1994) have been used to 
investigate axonal injury after head injury and these immunocytochemical labels suggest 
that axonal injury is more widespread than originally indicated by traditional silver 
stains (Gentleman et al. 1995). Furthermore, local neurofilament changes following 
blunt head injury in human postmortem and experimental studies have been described 
using antibodies targeted against the 68kD subunit (NFL subunit as described in Chapter 
1). Alterations in the staining of these antibodies are sensitive in detecting early changes 
in the axon which correlate with the genesis of impaired axoplasmic transport (Yaghmai 
and Povlishock, 1992; Grady et al. 1993; Erb and Povlishock, 1988; Povlishock et al. 
1983).
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Prior to writing this thesis, little work had been done to investigate the axonal 
changes following focal cerebral ischaemia in the rat. Therefore, a study was undertaken 
to determine the time course of changes induced by focal cerebral ischaemia in axonal 
transport and proteins associated with the microtubular and neurofilament components 
of the cytoskeleton. Alterations in immunoreactivity of antibodies directed at an 
axonally transported protein, microtubule associated and neurofilament proteins were 
investigated at different time points following permanent MCA occlusion in rats. 
SNAP25 which plays a role in synaptic exocytosis and like APP, undergoes fast 
anterograde transport (Sollner et al. 1993; Oyler et al. 1989); the NF68kD subunit of 
neurofilament protein, which has been extensively studied in diffuse axonal injury after 
traumatic brain injury (Yaghmai and Povlishock, 1992; Grady et al. 1993; Erb and 
Povlishock, 1988; Povlishock et al. 1983), and MAP5 which is a component of the 
microtubular system (Ochs, 1972) and has been shown to be sensitive to cerebral 
ischaemia (Dewar and Dawson, 1997), were all examined. In addition to the light 
microscope studies, electron microscopic studies were performed at one time point to 
further investigate the immunolabelling in the axon using antibodies specific for APP 
and NF68kD following MCA occlusion.
3.2 LIGHT MICROSCOPIC STUDIES
3.2.1 Animal preparation
Investigations were performed in 24 adult male Fischer rats (263-360 g). Anaesthesia, 
cannulation of blood vessels, MCA occlusion was performed as described in section
2.1.2 and 2.1.3. Following MCA occlusion, anaesthesia was maintained for periods of 
30 minutes (n = 4), 1 h (n = 4), 2 h (n = 4) or 4 h (n = 4). Sham-operated animals (n = 2
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at each time point) underwent the same experimental procedure except that the MCA 
was not occluded. The animals were killed by transcardiac perfusion with saline 
followed 4% paraformaldehyde (section 2.1.4). and subsequent processing as previously 
described (section 2.1.4). Immunostaining was performed on free-floating sections 
(section 2.3.2). The following mouse monoclonal antibodies were used: MAP5 (Sigma, 
clone A A 6,1:1000), NF68kD (Sigma, clone NR4 1:1000), SNAP25 (Stemberger, clone 
SMI 81, 1:120,000), pAPP (Boehringer Mannheim, clone 22C11,1 :20) and MAP2 
(Sigma, clone HM-2, 1: 750).
3.2.2 Analysis of material
Equivalent coronal sections from each animal were viewed by conventional light 
microscopy and the pattern and intensity of the immunostaining of antibodies targeted to 
SNAP25, MAP5 and NF68kD in the subcortical white matter and myelinated fibre 
tracts, were assessed. A semi-quantitative rating was given for alterations in 
immunoreactivity at each time point for each antibody, viz., 0 for no change in 
immunoreactivity from sham operated animals, + for a mild alteration in pattern or 
intensity of immunoreactivity, + + for a moderate and + + + for a marked alteration in 
pattern or intensity of immunoreactivity.
3.2.3 Results
The results are summarised in Table 3.1
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Table 3.1 Immunoreactivity of SNAP25, NF68kD and MAP5 at
different time points following MCA occlusion in the rat
SHAM 30 min l h 2 h 4 h
SNAP25 - - + + + + + +
NF68kD - - - + + + + +
MAP5 - + + + + + + +
The relative changes of SNAP25, NF68kD and MAP5 immunoreactivity following 30 
min, 1, 2 and 4 h of MCA occlusion. Immunostaining in sham operated animals, 
Altered immunoreactivity from mild to marked: + to + + +.
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MAP2 immunostaining
MAP2 has been shown to be a sensitive marker of ischaemic damage at short survival 
times following MCA occlusion (Dawson and Hallenbeck, 1996; Yanagihara et al.
1990; Kitagawa et al. 1989). Since traditional histologic stains such as haematoxylin and 
eosin do not permit definitive conclusions to be drawn concerning neuronal viability at 
short survival times, the anatomical extent of ischaemic damage in this study was 
detected using MAP2 immunostaining. Figure 3.1 shows equivalent sections stained for 
MAP2, H&E and LFB. In sham operated controls ipsilateral to the MCA and in the 
contralateral hemispheres of MCA occluded animals, there was no reduction in MAP2 
immunostaining. However, at 30 min, 1, 2 and 4 h after MCA occlusion, MAP2 
immunostaining was decreased in the caudate nucleus ipsilateral to the occluded MCA 
in all animals (Fig. 3.2). The reduction of immunostaining was most marked at 4 h. In 
addition, areas of decreased immunoreactivity were detected in the cerebral cortex 
ipsilateral to the MCA, although the reduction was patchy in its distribution. Figure 3.3 
shows the relationship between ischaemic damage, as assessed by MAP2 
immunostaining, and the topography of axonal changes seen with SNAP25, NF68kD 
and MAP5 immunostaining.
SNAP25 immunostaining
In sham operated controls ipsilateral to the exposed MCA and in the contralateral 
hemispheres of MCA occluded animals, axons in subcortical white matter and white 
matter tracts permeating the striatum were lightly stained with SNAP25 (Fig. 3.4 and 
Fig. 3.5).
Following 4 h of MCA occlusion there was a marked increase in SNAP25 
immunoreactivity which was bulbous in appearance in axons in subcortical white matter
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and in the myelinated tracts permeating the striatum in the ipsilateral hemisphere at the 
border of ischaemic damage (Fig. 3.4 and 3.5). At 2 h following MCA occlusion, the 
immunoreactivity was less marked than that at 4 h. Following 1 h of MCA occlusion, 
there was only a slight increase in SNAP25 immunoreactivity. This was less noticeable 
at 30 min following MCA occlusion. Axonal immunostaining with APP was similar in 
both time course and distribution (not shown). However, superior immunostaining was 
obtained with SNAP25 despite the concentration of antibody being 1:120,000 compared 
to that used for APP of 1:20. APP pattern of APP immunostaining was more easily 
assessed in FAM fixed material and is described in greater detail in Chapter 4. The 
pattern of SNAP25 immunoreactivity was similar in all animals at a given time point.
NF68kD immunostaining
In sham operated controls and in the contralateral hemisphere of MCA-occluded 
animals, NF68kD immunostaining had a smooth regular appearance in the subcortical 
white matter and in the myelinated fibre tracts within the caudate nucleus (Fig. 3.6 and 
Fig. 3.7).
Following 4 h of MCA occlusion the pattern of NF68kD staining had a rough, 
disorganised and tortuous appearance in the ipsilateral hemisphere within MCA 
territory. This was particularly prominent in the axons permeating the caudate compared 
to the subcortical white matter (Fig. 3.7). Changes in the pattern of immunostaining 
were confined to the ipsilateral MCA territory. Changes in immunoreactivity within 
axons were also evident following 2 h of MCA occlusion, although it was less marked 
at this time point. At 1 h post occlusion, there were only subtle changes evident in axons 
in subcortical white matter and those permeating the caudate nucleus, and the pattern of 
immunostaining was more regular and smooth in appearance, resembling that of sham
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operated animals. No changes in NF68kD immunostaining were evident following 30 
min of MCA occlusion.
MAP5 immunostaining
In sham-operated controls and in the contralateral hemisphere of MCA-occluded 
animals, MAP5 antibody only lightly stained axons in subcortical white matter and 
white matter tracts permeating the caudate (Fig. 3.8). The pattern seen was smooth, 
regular and organised.
In similarity to the immunostaining obtained with NF68kD, the changes seen 
with MAP5 immunostaining were progressive over time following MCA occlusion. 
These changes were particularly marked at 4 h following MCA occlusion when there 
was a bulb-like immunoreactivity in the axons permeating the caudate nucleus and in 
the subcortical white matter. (Fig. 3.8). At 2 h post occlusion, there was both increased 
immunoreactivity and a rougher, globular, punctate pattern of staining compared to 
sham operated animals. At 1 h post occlusion, there was a slight increase in 
immunoreactivity and subtle changes in the orientation of the pattern of staining in 
axons within MCA territory. Following 30 min of MCA occlusion there was a subtle 
increase in MAP5 immunoreactivity but not orientation of the staining in the axons 
permeating the caudate nucleus. The changes described were present in all the animals 
in each group within the ischaemic white matter.
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Figure 3.1
MAP2 H&E LFB
Equivalent coronal section stained for MAP2, H&E and LFB following 4h 
MCA occlusion. Scale bar is approximately 2.5 mm.
Figure 3.2
Sham 30 min 1 h
2 h 4 h
Photomicrgraphs showing the pattern o f MAP2 immunoreactivity following a sham, 
30 min, lh, 2h and 4h MCA occlusion in the rat. Scale bar is approximately 2.5 mm.
Figure 3.3
MAPSMAP2
SNAP25 NF68kD
Representative section stained for MAP2 following 4 h MCA occlusion. Shaded areas 
represent regions o f altered immunoreactivity for each antibody, namely, MAP5 (top 
right), SNAP25 (bottom left) and NF68kD (bottom right) in relation to the topography 
o f decreased MAP2 immunoreactivity (top left).
Figure 3.4
SHAM 1 h
2 h 4 h
Immunostaining o f SNAP25 in myelinated fibre tracts in the caudate nucleus in a 
sham operated rat and at 1, 2 and 4 h after middle cerebral artery (MCA) occlusion. 
The changes in immunoreactivity were progressive from 1 h to 4 h following MCA 
occlusion. By 4 h following occlusion the increase in immunoreactivity was most 
dramatic and was bulbous in appearance (scale bar = 5 pm).
Figure 3.5
'
*.v v, t A-./ '
Sham
4 h
Immunostaining o f  SNAP25 in myelinated fibre tracts in the subcortical white matter 
in a sham operated animal and at 4 h after MCA occlusion. In the sham operated animal 
the white matter was lightly stained with SNAP25 immunoreactivity. However, 
following 4 h o f occlusion increased SNAP25 immunoreactivity could be seen which 
was bulbous in appearance (arrows). Magnification x 750.
Figure 3.6
Sham
Immunostaining o f NF68kD in myelinated fibre tracts in the subcortical white matter 
in a sham operated rat and 4 h after MCA occlusion. Progressive changes in the 
pattern o f staining were observed. This was most obvious at 4 h post occlusion but 
was more subtle than that observed in the myelinated fibre tracts permeating the 
striatum (x 750 magnification.)
Figure 3.7
Sham
Immunostaining o f NF68kD in myelinated fibre tracts in the caudate nucleus in a 
shamoperated rat and at 1 ,2 , and 4 h after MCA occlusion. The changes in 
immunoreactivity were progressive from 1 h to 4 h following MCA occlusion. By 
4 h, the pattern o f NF68kD staining had a rough, disorganised and tortuous 
appearance in the ipsilateral hemisphere within the MCA territory. Changes in 
axons at 1 and 2 h were also present although less marked (x 750 magnification).
Figure 3.8
Sham
Immunostaining o f MAP5 in myelinated fibre tracts in the caudate nucleus in a sham 
operated rat and at 4 h after MCA occlusion. As with NF68kD staining, progressive 
changes with immunostaining were observed following MCA occlusion. These 
changes were most dramatic at 4 h when there was a disorganised pattern and bulb like 
immunoreactivity (arrows) (x 750 magnification).
3.3 ELECTRON MICROSCOPE STUDIES
3.3.1 Animal Preparation
Investigations were performed in 3 adult male Fischer rats. Anaesthesia, cannulation of 
blood vessels and MCA occlusion was performed as described in section 2.1.2 and 
2.1.3. Following MCA occlusion, anaesthesia was maintained for 4 h. The animals were 
killed by transcardiac perfusion with saline followed by gluteraldehyde (0.5%) and 
paraformaldehyde (4%) (section 2.1.4). and subsequent processing as previously 
described. Immunostaining was performed on free-floating sections (section 2.3.2). The 
following mouse monoclonal antibodies were used: NF68kD (Sigma, clone NR4 
1:1000) and PAPP (Boehringer Mannheim, clone 22C11, 1:10). The material was then 
processed for correlated light and electron microscopy (see section 2.6.1). Equivalent 
coronal sections were viewed from each animal using the electron microscope. Since the 
fixation was optimised for immunocytochemistry, resulting in poorer tissue fixation, 
analysis of the material was qualitative rather than quantitative. Areas of interest 
included the corpus callosum and caudate in both the ipsilateral and contralateral 
hemispheres.
3.3.2 Results 
NF68kD
Within the caudate nucleus in the contralateral hemisphere immunoreactivity to 
NF68kD was evident mainly in the larger myelinated fibres (Fig. 3.9). In the 
contralateral hemisphere following 4h MCA occlusion, the immunostaining was smooth 
and regular in the caudate nucleus. However, following 4h of MCA occlusion the 
pattern of NF68kD in the ipsilateral hemisphere within the MCA territory was more
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disorganised and disrupted compared to the contralateral hemisphere. At higher 
magnifications, there appeared to be increased spacing in NF68kD immunostaining in 
the ipsilateral hemisphere compared to the contralateral hemisphere (Fig. 3.10). This is 
consistent with light microscopic findings (Fig. 3.7).
APP
Within the caudate nucleus and subcortical white matter in the contralateral hemisphere 
there was no evidence of increased immunoreactivity at 4h following MCA occlusion. 
However, following 4h of MCA occlusion in the ipsilateral hemisphere, increased APP 
immunoreactivity was present within some of the myelinated tracts in both the 
subcortical white matter and caudate nucleus adjacent to the core of infarction, denoting 
the sites of injury and impaired axoplasmic transport (Fig. 3.11). Within the corpus 
callosum there were axons that appeared to be in stages of axotomy (Fig. 3.12). This is 
supported by further findings of axonal bulb formation with the accumulation of large 
amounts of APP seen longitudinal section (Fig. 3.13 A), and accumulation of many 
mitochondria (also transported by fast axonal transport) and APP in a transverse fibre 
tract in the caudate nucleus (Fig. 3.13B).
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Figure 3.9
Contralateral
  - # ' ! > '
Ipsilateral
Immunostaining o f NF68kD in myelinated fibre tracts in the caudate nucleus in the 
contralateral hemisphere and ipsilateral hemisphere following 4 hours o f MCA 
occlusion in the rat. The NF68kD immunoreactivity was more obvious in the larger 
myelinated fibre tracts in both the ipsilateral and contralateral hemispheres. The pattern 
o f NF68kD staining within the infarcted territory in the ipsilateral hemisphere was 
dispersed and more disorganised compared to the contralateral hemisphere. Original 
magnification x 4,000.
Figure 3.10
Contralateral Ipsilateral
Immunostaining o f NF68kD in contralateral (A and C) and ipsilateral (B and D) 
caudate nucleus following 4 h MCA occlusion. Original magnification x l4,000 (A 
and B) and x 40,000 (C and D). In the contralateral sections the immunostaining o f 
NF68kD within the myelinated axons is dense. However, in the ipsilateral sections, 
the NF68kD immunostaining is more dispersed.
Figure 3.11
T,A /? ;
A) Transverse section o f fibre tracts in the caudate nucleus from a rat 4 h after 
MCA occlusion. Increased APP accumulation is evident within some o f the 
fibres (arrows). Original magnification x 4,000. B) Longitudinal section o f an 
axon showing accumulation o f APP. Original magnification x 14,000. The APP 
accumulation in A and B is indicative o f axonal transport dysfunction.
Figure 3.12
Longitudinal section from the corpus callosum following 4h MCA occlusion 
in the rat. There is evidence o f impending axotomy. Original magnification 
x 20,000.
Figure 3.13
A) A longitudinal thin section o f an axon in the corpus callosum in the ipsilateral 
hemisphere adjacent to area o f infarction in a rat following 4h o f MCA occlusion. The 
APP immunolabelling has accumulated in an axonal bulb. This finding is consistent with 
axotomy. Original magnification x 20,000. B) A transverse section o f  a fibre tract in the 
caudate nucleus from a rat 4h after MCA occlusion. There is accumulation of organelles 
and a marked increase in APP immunoreactivity. Original magnification x 27,000.
3.4 DISCUSSION
The studies described in this chapter are the first to assess the time course of changes to 
NF’s, proteins that undergo fast axonal transport and a structural component of the 
microtubular system following 30 minutes of focal cerebral ischaemia in the rat. In 
addition, immunocytochemistry has been visualised at the electron microscope level 
revealing novel changes in NF structure and extends observations previously noted of 
axonal bulb formation following both trauma and ischaemia.
Neurofilaments, and their three dimensional relationships to other NF’s, MT’s, 
and the microtrabecular matrix including the cytoskeleton of the axolemma and actin 
filaments, govern the integrity and calibre of the axon (section 1.4.1) (for review see 
Hirano and Llena, 1995). The finding in this study of NF68kD immunoreactivity in the 
larger myelinated axons is consistent with reports of highest NF expression in neurons 
with large-calibre myelinated axons (Cleveland et al. 1991). Following traumatic brain 
injury and experiments using the anoxic optic nerve model, disruption of the axonal 
cytoskeleton has been suggested by local NF changes, most frequently involving the 
large calibre axons (Waxman et al. 1992; Yaghmai and Povlishock, 1992). As a result of 
moderate or severe traumatic brain injury induced by fluid percussion, antibodies 
targeting the NF68kD subunit revealed intense immunoreactivity associated with the 
progression of axonal change, and the NF’s were tightly packed and aligned in a random 
fashion in relation to the long axis of the cylinder (Povlishock et al. 1997). This 
contrasts with the changes seen in a small proportion of axons following optic nerve 
stretch-injury in the guinea-pig (Jafari et al. 1998), and those observed following focal 
ischaemia described above, where the NF’s seemed more sparse or ‘dispersed’, and 
unlike in traumatic brain injury, were not localised centrally within the axon. The
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reasons underlying the difference in NF disruption following these different types of 
insults are uncertain. One could posit that there may be different mechanisms involved 
in initial axonal damage following traumatic and ischaemic brain injuiy or that the 
axons are being viewed at different stages of the injury cascade. There certainly appears 
to be a time course in damage to the NF as evidenced by light microscopy (Fig. 3.7).
The cause of cytoskeletal changes following ischaemia and trauma is thought to 
be related to excessive calcium influx and altered calcium homeostasis (section 1.5.4). 
Influx of calcium has been suggested following stretch injury of the guinea-pig optic 
nerve (Maxwell, 1996; Maxwell et al. 1995) and a central role for calcium in anoxic 
injury to the rat optic nerve has been demonstrated using electrophysiological 
techniques (Stys et al. 1990). More recent quantitative data suggestive of increased 
intracellular calcium content following anoxic injury, supports the hypothesis that influx 
of calcium is a pivotal event in the pathogenesis of axonal damage (Brown et al. 1998). 
The exact route(s) of intracellular calcium influx is still under investigation. An 
alteration in axolemmal permeability is well established following traumatic brain injury 
as demonstrated by a change in extracellularly confined horse-radish peroxidase 
(Povlishock and Pettus, 1996; Pettus and Povlishock, 1996; Pettus et al. 1994).
However, because of its relative size, horse-radish peroxidase is possibly not an 
appropriate marker of damage to the axolemma at an ionic level (Maxwell et al. 1998). 
Physiological studies in the anoxic rat optic nerve, and recent studies using freeze- 
fracture and cytochemical techniques in the adult guinea-pig optic nerve subjected to 
stretch-injury, have provided evidence for changes in membrane structure (Maxwell et 
al. 1998) and the activity of membrane pumps (Stys et al. 1995; Maxwell et al. 1998). 
Perhaps altered membrane pump activity and cytoskeletal changes are the sequelae of 
mitochondrial failure. In this regard, controlled cortical impact injury (Xiong et al.
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1997) and ischaemia (Orrenius et al. 1996; Sciamanna et al. 1992; Nakahara et al. 1991) 
in rats induces sustained perturbation of cellular Ca homeostasis with ultimate 
mitochondrial Ca2+ overload and inhibition of mitochondrial chain-linked functions.
Loss of normal ionic gradients may provide a mechanism for influx of calcium 
which could then result in subsequent cytoskeletal disruption by the action of calpain 
mediated proteolysis (Hall and Lee, 1995), activation of kinases (Maxwell et al. 1997) 
or activation of calcium-independent proteases (Goldstein et al. 1987). Because there is 
evidence of ‘increased’ NF subunit following traumatic brain injury, it has been 
suggested that the axonal degeneration is not calpain mediated (Povlishock et al. 1997; 
Yaghmai and Povlishock, 1992), although this is still under debate. However, the 
finding of decreased NF68kD immunoreactivity and increased NF spacing following 
focal cerebral ischaemia is consistent with the calpain hypothesis (section 1.5.4). It is 
also interesting to note from the light microscope findings that the changes in NF68kD 
immunostaining are progressive from 1 h to 4 h following MCA occlusion, a finding 
consistent with calcium-mediated damage (Povlishock, 1992).
Ultimately, the repertoire of axonal change to various injuries is limited. It is 
likely, that despite the possibility of different initiating mechanisms of cytoskeletal 
disruption following traumatic and ischaemic injury, both insults result in impaired 
axoplasmic transport due to perturbation of the cytoskeleton. In this regard, NF 
misalignment (Fig. 3.10) (Yaghmai and Povlishock, 1992) and other cytoskeletal 
changes, as evidenced by light microscopic studies using antibodies targeted towards 
MAP5 (Fig. 3.8) and the demonstration of MT loss following optic nerve stretch 
(Maxwell and Graham, 1997) and anoxia (Waxman et al. 1992), would support this 
view. Although MT’s were not assessed directly following ischaemia the alteration in 
the MAP5 immunostaining would be highly suggestive of disrupted MT’s. Perhaps
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more convincing of MT disruption is the increased immunoreactivity of proteins 
normally transported along the MT’s. Local swelling and expansion of the axonal 
cylinder was apparent due to accumulation of organelles and proteins, the latter being 
detected with antibodies to APP by electron microscopy (Fig. 3.13) and SNAP25 by 
light microscopy (Fig. 3.4 and 3.5). The changes in MAP5 immunoreactivity was an 
early event, preceding that of increased SNAP25 immunoreactivity. Finally, there was 
evidence of lobulation of the focal axonal swelling and eventual disconnection, so- 
called ‘secondary axotomy’ (Fig. 3.12).
Each antibody makes its own contribution to the understanding of the events 
occurring following ischaemic injury. In this study, antibodies have been used that target 
relatively stationary cytoskeletal elements and those that undergo rapid axonal transport. 
The findings and implications of the light and electron microscope studies described in 
this chapter are discussed further in Chapter 7.
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CHAPTER 4
QUANTITATIVE ANALYSIS OF AXONAL INJURY
IN THE RAT
4.1 INTRODUCTION
To allow future assessments of protection of white matter by therapeutic interventions, a 
method by which axonal injury can be visualised and quantified is required. One such 
candidate marker of axonal injury is amyloid precursor protein (APP). This is a 
transmembrane glycoprotein from which P-amyloid protein, the main component of 
amyloid plaques in Alzheimer’s disease, is derived (Coria et al. 1992; Glenner and 
Wong, 1984). APP is ubiquitously expressed in the nervous system from early 
embryogenesis throughout adulthood (Allinquant et al. 1994). It is associated with the 
cytoskeleton (Refolo et al. 1991) and undergoes fast anterograde axonal transport in the 
peripheral nervous system (Koo et al. 1990). The interruption of axonal transport, 
whether it be due to traumatic (Otsuka et al. 1991), ischaemic (Kalaria et al. 1993; 
Stephenson et al. 1992) or chemical insults (Nakamura et al. 1992; Kawarabayashi et al. 
1991), or colchicine injection (Shigematsu and McGeer, 1992), has been shown to result 
in the accumulation of APP. These observations are of considerable interest as they 
provide compelling evidence that APP accumulates after disruption of axonal transport 
and, since axonal transport is an integral component of axonal function, APP may be a 
good marker of axonal injury.
The following study was undertaken to investigate APP as a suitable marker of 
white matter injury in response to MCA occlusion in the rat. Only once this has been
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established, can APP be used as a marker to assess the effect of therapeutic intervention 
on the salvage of axons. The aims of the study were threefold: (1) to determine whether 
increased APP immunoreactivity is a consistent observation after focal ischaemia, (2) to 
determine the topography of increased APP immunoreactivity in relation to the 
boundary of ischaemic lesions following MCA occlusion and (3) to determine whether 
there is a quantitative relationship between increased APP immunoreactivity and 
volume of the focal ischaemic lesion.
4.2 METHOD
4.2.1 Anaesthesia and MCA occlusion
Anaesthesia was induced in 14 rats and MCA occlusion performed as previously 
described (section 2.1.3). MCA occlusion was performed by Dr. Tei Takasago. 
Following MCA occlusion, anaesthesia was discontinued and, under strict observation, 
the animals allowed to regain consciousness. Twenty-four hours after MCA occlusion, 
the rats were re-anaesthetised and maintained with 3% halothane by face mask. The 
animals were killed by transcardiac perfusion with 200ml of heparinised saline followed 
by 200 ml of FAM (section 2.1.4).
Physiological parameters were monitored over the 24h period. There were 
minimal interanimal variability in measured physiological parameters which may 
influence the extent of infarction (Table 4.1). Blood pressure was lower in the operative 
period than in the post-operative period reflecting the halothane anaesthesia. Pa0 2  was 
higher at this time, reflecting the higher level of oxygen in the inspired gas mixture than 
air.
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Table 4.1 Physiological variables prior to and following middle cerebral 
artery occlusion
MABP
(mmHg)
pH PaC02
(mmHg)
Pa02
(mmHg)
Glucose
(mM)
Rectal 
Temp (°C)
pre-
MCAO* 87.6 + 3.9 7.42 + 0.01 38.7 + 0.7 159 + 6 8.0 + 0.3 37.2 + 0.0
MCAO* 90.6 + 3.3 7.39 + 0.01 42.3 + 0.9 147 + 6 7.7 + 0.3 37.0 + 0.1
1 h 116.1+3.1 7.41 + 0.00 40.2 + 0.9 76 + 2 6.4 + 0.3 37.5 + 0.1
24 h 120.2+1.8 7.49 + 0.01 34.7 + 0.6 97 + 2 6.1 +0.3 38.1+0.1
MABP: Mean arterial blood pressure, Rectal Temp: Rectal temperature. Data are 
presented as mean + SEM. n=14. * Animals were anaesthetised for surgical occlusion of 
the MCA. At 1 h and 24 h the animals were conscious.
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4.2.2 Mapping areas of infarction
After detaching the hindbrain, the forebrain was cut into four equally spaced coronal 
blocks, embedded in paraffin wax, and sectioned (nominally 10 pm thick) at multiple 
levels. The sections were stained by haematoxylin and eosin and a method that 
combines Luxol fast blue and cresyl violet, and were examined by conventional light 
microscopy (section 2.4). Areas of infarction were delineated on paraffin sections at 
eight preselected stereotactically determined coronal levels (Fig. 2.4), previously shown 
to be the minimum number of levels at which the assessment can be made without loss 
of accuracy (Osborne et al. 1987), and transcribed onto anatomical scale diagrams (x 4 
actual size) of forebrain drawn from the atlas of Konig and Klippel (Fig. 2.5). The areas 
of ischaemic damage in the cerebral hemisphere, were determined from the diagrams, at 
each of the eight coronal planes using a computer based image analysis system (MCID). 
Following calibration, the area of infarction was measured at each coronal level. An 
approximation to total volume of ischaemic damage for each animal was achieved by 
integration of area with the distance between each level (Table 4.2).
In order to obtain a diagram showing total area of ischaemia for the 14 animals, 
for each rat, the areas of ischaemia shown on the 8 anatomical diagrams were transposed 
to a manually drawn diagram. This was carried out on a light box to allow accurate 
placement of the ischaemic areas in relation to the anatomical diagrams. Fiducial marker 
points at the four comers of the template were also copied to each diagram to allow for 
co-registration of all the completed diagrams. The diagrams were then digitally scanned 
using a UMAX Powerlook flatbed scanner and imported into the NIH program on the 
Apple computer. The diagrams were aligned to an identical orientation using the 
Alignment software and guided by the fiducial markers. The image for each diagram 
was converted to a binary form with the area of ischaemia being allocated the value of 1.
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The set of 14 aligned images were added using the Image Math facility on NIH Image.
In this way an area of consistent ischaemia, seen at the same position in all rats, had a 
value of 14 and areas with less consistent ischaemia had lower values on the 1-14 scale. 
The final combined image was overlaid onto a scanned image of the 8 section template 
to show the anatomical positions of the combined ischaemic areas. The final image was 
displayed using a 15 colour look-up table image (Fig. 4.1).
4.2.3 Immunocytochemistry
Sections adjacent to those used for mapping areas of infarction were prepared for 
immunocytochemistry so that the topography of increased APP immunoreactivity could 
be compared to that of infarction. Immunocytochemistry was performed as previously 
described (see 2.3.1). In this case the APP antibody (clone 22C11, Boehringer 
Mannheim) was at a concentration of 1:500. As there were over 100 sections, they were 
immunostained in batches on different days.
4.2.4 Topography of increased APP immunoreactivity
Since diaminobenzidine was used as a chromagen in the immunocytochemistry, the 
increase in APP immunoreactivity within the white matter was brown. Equivalent 
coronal sections from each animal, at defined coronal planes (Osborne et al. 1987), were 
placed on a light box and the image captured via an 8 bit standard CCD video camera 
and transferred to a MCID-M4 image analyser. The complete coronal section could then 
be viewed on a monitor at xlO magnification, digitised and image printed using an HP 
laser printer. The images produced showed the increased APP immunoreactivity. The 
sections were also viewed using a conventional light microscope (Leitz DMRB) at x 50 
magnification to check that all the increased APP immunoreactivity was visible on the
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printed images. This procedure was repeated for each animal at each coronal level. 
Therefore, an accurate determination of the overall topography of increased APP 
immunoreactivity for the 14 animals could be established by tracing and superimposing 
the increased APP immunoreactivity at each coronal level for the 14 animals onto a 
single line diagram which was drawn on an acetate sheet (Fig. 4.2). The superimposition 
of increased APP immunoreactivity for the 14 animals was repeated at each of the 8 
coronal levels (Fig. 4.1).
4.2.5 Quantitative analysis of APP immunoreactivity
In order to investigate a quantitative assessment of the relationship between increased 
APP immunoreactivity and infarction, a method was developed using the MCID to 
measure the area of increased APP immunoreactivity. Although different approaches for 
densitometric analysis were explored, the methods were flawed and considered 
unsuitable for further use within this thesis. The methods, results and discussion relating 
to the densitometric analysis of APP can be found in full in Appendix 4.
A semi-quantitative method of APP analysis, which had several advantages over 
the densitometric method (appendix4), was developed in order to assess the relationship 
of APP immunoreactivity and volume of ischaemia. Each coronal section was analysed 
for APP by light microscopy and a semi-quantitative rating given viz. 0 for no APP, 1 
for some APP , 2 for a moderate amount of APP and 3 for large amounts of APP (Table
4.3 and Fig. 4.3). The total APP immunoreactivity score for each animal, out of a 
maximum of 24, was the sum of the scores for the eight coronal levels (Table 4.2). To 
determine the reproducibility of this semi-quantitative scoring system, the APP score 
was determined for five animals on two separate occasions (Fig 4.4).
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Table 4.3 APP score for each coronal level
Coronal level 1 2 3 4 5 6 7 8
Anatomical
Landmark
Olfactory
tract
Nucleus
accumbens
Septal
nuclei
Globus
pallidus
Anterior
hypothalamus
Lateral
habenula
Medial
geniculate
Aqueduct
Co-ordinate
(mm)
10.50 8.92 7.19 6.06 5.15 3.75 2.18 1.02
Animal No.
1 + + - - - - - -
2 - + + + + - + + - -
3 + + + + - - + + - -
4 - + + + + + + + - - -
5 ns ns + + + + + + + + - - -
6 + + + + + + + + + - - - -
7 + + + + + + + + + + - -
8 + + + + + + + + + + - -
9 + + + + + + + + + + + - -
10 + + + + + + + + + + + - -
11 + + + + + + + + + + + + + + - - -
12 + + + + + + + + + + + + + + + + - -
13 + + + + + + + + + + + + + + + + - -
14 + + + + + + + + + + + + + + + + + - -
Semi-quantitative scale showing allocated APP score at each coronal level for the 14 
animals. no APP; +, some APP; + +, moderate amount of APP; + + +, lots of APP. In 
subsequent analysis, a score of 0 for 1 for +, 2 for + + and 3 for + + +, was given. Rat 
brain co-ordinates taken from the Atlas of Konig and Klippel. ns, no appropriate section 
available.
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Figure 4.2
oox
Photomicrograph showing increased APP immunoreactivity in subcortical white 
matter and along myelinated fibre tracts permeating the striatum (Bar = 400pm). 
Below is a representative example o f a line diagram showing increased APP 
immunoreactivity transcribed from the section shown in the photomicrograph.
Figure 4.3
Representative line diagrams from three animals showing areas of neuronal necrosis 
(A, B and C) and the location of increased APP immunoreactivity. The APP score for 
these animals was 3, 2 and 1 respectively.
4.3 RESULTS
4.3.1 APP immunocytochemistry after middle cerebral artery occlusion
In the non-ischaemic contralateral hemisphere, in all animals, APP immunoreactivity 
was faint. In contrast, in the ipsilateral ischaemic hemisphere, all animals had 
anatomically circumscribed zones of increased APP immunoreactivity in the subcortical 
white matter and in the myelinated fibre tracts permeating the striatum. The increased 
axonal immunoreactivity was ‘bulbous’ in appearance (Fig. 4.5), reminiscent of axonal 
swellings which occur following traumatic brain injury and which have been suggested 
as an early indicator of axotomy (Povlishock, 1992) (discussed further in section 7.2). 
Increased APP immunoreactivity was present in both the medial caudate and dorsal 
subcortical white matter and was confined to a zone immediately adjacent to the 
boundary of ischaemia. This could be readily seen when zones of ischaemic damage and 
points of APP immunoreactivity were visualised either at a single level within an animal 
(Fig. 4.3) or in the composite diagram for the 14 animals (Fig. 4.1). Increased APP 
immunoreactivity was detected in cell bodies in the ischaemic side as has been reported 
in previous studies (Stephenson et al. 1992). Increased APP immunoreactivity was not 
detected in the subcortical white matter or in myelinated fibre tracts in the lateral 
caudate deep within the areas of ischaemia (Fig. 4.6).
4.3.2 Reproducibility of semi-quantitative analysis
To determine the reproducibility of the semi-quantitative scoring system, the APP score 
was determined for five animals on two separate occasions (Fig 4.4). On 57.5% of 
occasions the score allocated was the same, and on 95% of occasions the score allocated 
was the same or just one point different. The non parametric Spearman correlation, r =
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0.75. The reproducibility at the individual coronal levels was reasonable and the errors 
random. Since the total APP score for each rat was the summation of the APP scores for 
each of the eight coronal levels, the reproducibility was enhanced.
4.3.3 Relationship between ischaemia and APP accumulation
Zones of ischaemic damage (Brierley and Graham, 1984), were restricted to those areas 
of the brain normally supplied by the middle cerebral artery (Yamori et al. 1976). There 
was ischaemia in all the animals at level 2 (anterior co-ordinate of 8.92 mm). Levels 1 
and 3 (anterior co-ordinates of 10.50 and 7.19 mm respectively (Konig and Klippel, 
1963)) were affected in the majority of animals and fewer animals had evidence of 
ischaemia in the more caudal coronal sections (anterior co-ordinates of 2.18 and 1.02 
mm). Ischaemia was not seen in the contralateral hemisphere in any case. The volume of 
ischaemia in the cerebral hemisphere was 136+10 mm (mean + standard error, n =
' i
14). The volume of cortical necrosis was 105 + 9 mm and the volume of striatal 
necrosis was 24+1 mm . There was an association between the volume of ischaemic 
damage and the amount of increased APP immunoreactivity as assessed by semi- 
quantitative analysis (Fig. 4.7), the increase in APP immunoreactivity being greatest in 
rats with the largest volumes of neuronal necrosis. A similar association could be 
discerned between the area of ischaemic damage and the extent of increased APP 
immunoreactivity at individual coronal planes (Fig. 4.8).
I l l
Figure 4.4 Reproducibility of semi-quantitative APP analysis
75-i
25-
+2
Semi-quantitative analysis
Forty rat sections were analysed on two separate occasions to assess scoring 
reproducibility. An APP score of 0,1, 2 or 3 was given on each occasion as previously 
described. The value allocated on the second occasion was deducted from that on the 
first occasion to give a final result ranging from -1 to +2. Therefore, where a section was 
given the same score on both occasions the value allocated was 0.
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Figure 4.5
Increased APP immunoreactivity in the caudate nucleus following 24 h 
MCA occlusion in the rat. The immunoreactivity was ‘bulbous' in 
appearance (arrows). Bar = 50 pm.
Figure 4.6 Location of increased APP immunoreactivity
(a) Line diagram o f coronal level 3 showing the location o f the following 
photomicrographs, (b) Increase in APP immunoreactivity in corpus callosum 
immediately adjacent to the ischaemic lesion, (c) no increase in APP 
immunoreactivity evident in the non-ischaemic corpus callosum and (d) no 
increase in APP immunoreactivity evident in the densely ischaemic corpus 
callosum. (Bar = 50 pm for b, c and d).
Figure 4.7
Relationship of APP accumulation to volume of infarction
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The volume of ischaemic damage was compared to total accumulation of APP for 
each animal. The total APP accumulation was the score sum for the eight coronal 
levels. Total APP accumulation score increased with increasing volume of 
infarction. Each point represents data from a single animal
Figure 4.8
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Mean APP accumulation score and mean area of the ischaemic lesion for the 14 animals 
at each coronal level were calculated. Mean APP accumulation score was highest in the 
coronal levels with the largest area of ischaemic damage (anterior co-ordinates 7.19 and 
8.92 mm), data are presented as mean ±  SEM (n=14).
4.4 DISCUSSION
This study demonstrated that increased APP immunoreactivity is a consistent outcome 
in white matter after focal cerebral ischaemia. APP undergoes fast anterograde axonal 
transport (Koo et al. 1990) and the interruption of this transport is likely to reflect APP 
accumulation (Shigematsu and McGeer, 1992). In order to use APP as a quantitative 
marker of axonal injury, and to assess the potential beneficial effects of therapeutic 
intervention, a reliable method of quantifying the increased APP immunoreactivity is 
required. Although, it is generally accepted that quantification of immunocytochemistry 
is complex, a semi-quantitative method of APP quantification was developed. This is 
the first study where an attempt has been made to map and quantify the accumulation of 
APP and relate this to the region and extent of ischaemic damage.
Semi-quantitative analysis was relatively straight forward and quick to perform. 
All eight coronal levels could be scored in one day, an important requisite for consistent 
scoring using this method. The sensitivity of this method was limited and methods by 
which it could be improved are discussed and utilised in subsequent chapters of this 
thesis (Chapter 6 and 7). Nevertheless, the amount of APP accumulation was shown to 
be rt'tvWv lesion size. Because of the ease with which semi-quantitative analysis 
could be performed, and the fact that it has shown that APP accumulation is determined 
by lesion size, this method was chosen for the quantification of APP following 
therapeutic intervention in the rat (Chapter 5).
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CHAPTER 5
QUANTITATIVE ANALYSIS OF APP FOLLOWING 
DRUG INTERVENTION IN THE RAT
5.1 INTRODUCTION
Extracellular glutamate level elevation is one of the major events contributing to the 
spread of secondary damage following CNS injury of grey matter (for review see Holt, 
1997). Consequently a variety of drugs have been developed by the pharmaceutical 
industry to reduce the extent of glutamate-mediated pathologies either by inhibiting the 
release of glutamate or by inhibiting the activation of postsynaptic receptors by 
glutamate. Voltage-activated sodium channels in axons and nerve terminals affect 
glutamate release by propagating a depolarising stimulus to sites of vesicular release .
^  I
Presynaptic voltage-activated Ca channels at the release sites are opened in response to
^  I
this depolarisation. The elevation of cytoplasmic Ca levels in the nerve terminal 
initiates the process of exocytosis of glutamate (Goldin et al. 1995). Neuronal sodium 
channel antagonists include the compound BW619C89; this compound apparently also 
has calcium channel blocking properties (McNaughton et al. 1997) (see section 1.6.3). 
Presynaptic blockade of glutamate release is advantageous in that it prevents the 
activation of both the NMDA and non-NMDA receptor sites.
In order for glutamate to exert its biological effect it must bind to specific sites 
on the target tissues. Glutamate receptors are reviewed in section 1.5.2. The NMDA 
receptor is recognised to be involved in the mediation of glutamate toxicity.
Accordingly, research aimed at reducing secondary damage after injury has been
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directed toward pharmacological blocking of NMDA receptors. Many of the studies on 
neuroprotection have involved the use of the non-competitive NMDA antagonist, MK- 
801 (Wong et al. 1986) (see section 1.6.2). In injuries involving grey matter, the 
mechanism of protection by MK-801 involves blockage of the NMDA receptors which 
are permeable not only to monovalent cations but also to calcium, and which are known 
to be opened during ischaemia due to excessive release (and impaired uptake) of 
glutamate.
A number of studies using BW619C89 and MK-801 have shown them to be 
neuroprotective following focal cerebral ischaemia in the rat (Gill et al. 1991; Park et al. 
1988b; Graham et al. 1994; Kawaguchi and Graham, 1997; Leach et al. 1993).
However, in all of these studies, ‘ neuroprotection ’ was assessed by a reduction in infarct 
volume; the effect on axons being largely ignored. In Chapter 4, APP was shown to be a 
suitable marker of axonal injury and a method has been developed for its quantification. 
The studies described in this chapter use APP as the marker of axonal injuiy to assess 
whether either BW619C89 or MK-801 protect axons following focal cerebral ischaemia 
in the rat.
5.2 METHOD
5.2.1 MK-801 treated animals
The investigation was carried out in 26 adult male Fischer rats. Anaesthesia and MCA 
occlusion was performed as previously described (2.1.2 and 2.1.3). The animals were 
divided into two groups: MCA occlusion vehicle group (n = 13) and MCA occlusion 
drug treatment group (n = 13). In the drug treatment group, 0.12 mg/kg of MK-801 was 
given as an i.v. bolus immediately after completion of MCA occlusion and 1.8
|Lig/kg/min as an infusion, a regime previously shown to maintain a steady state plasma 
level of MK-801 throughout the ischaemic period and shown to give a highly significant 
reduction in volume of ischaemic brain damage in the cerebral cortex and hemisphere 
(Gill et al. 1991). The control group received a 1 ml/kg i.v. bolus of saline followed by 
an infusion of saline at a rate of 0.0079 ml/min. For both groups, initial dosing was 
started immediately following MCA occlusion, the bolus dose being administered over a 
30 s period and the infusion continued for the duration of the experiment which was 4 h.
5.2.2 BW619C89 treated animals
The investigation was carried out in 21 adult male Fischer rats. Anaesthesia and MCA 
occlusion was performed as previously described (2.1.2 and 2.1.3) by Dr. Ramanjit Gill. 
The animals were divided into two groups: MCA occlusion vehicle group (n = 10) and 
MCA occlusion drug treatment group (n = 11). In the drug treatment group, lOmg/kg of 
BW619C89 was given as an i.v. bolus over a period of 10 minutes, 5 minutes after 
completion of MCA occlusion. The drug was kindly supplied by Hoffinan-La Roche 
Ltd. The control group received a 1 ml/kg i.v. bolus of saline over 10 minutes, 5 minutes 
after MCA occlusion. Following MCA occlusion the animals, anaesthesia was 
discontinued and the animals allowed to regain consciousness. The animals were killed 
24 h following MCA occlusion.
5.2.3 Tissue processing and APP analysis
The animals were killed by transcardiac perfusion, the fixative being FAM (see 2.1.4). 
The brain was cut into 10pm sections at the eight preselected coronal levels and 
histology performed using haematoxylin and eosin and Luxol fast blue and cresyl violet 
(see section 2.4). Sections adjacent to those used for mapping areas of infarction were
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prepared for immunocytochemistry (see 2.3.1) so that the topography of increased APP 
immunoreactivity could be compared to that of infarction.
The method of semi-quantitative analysis of APP accumulation as described in 
Chapter 4, was applied. Equivalent coronal sections from each animal, at defined 
coronal planes (Konig and Klippel, 1963) were viewed by conventional light 
microscopy and the distribution of increased APP immunoreactivity mapped onto line 
diagrams by an observer ‘blind’ to the topography of the ischaemic lesion in grey 
matter. To determine the topography of APP accumulation for the animals, the line 
diagrams on which the increased APP immunoreactivity was mapped, at predetermined 
co-ordinates, were superimposed for the two groups.
In order to assess the APP immunoreactivity further, each coronal section was 
analysed for APP by light microscopy and a semi-quantitative rating given viz. 0 for no 
APP, 1 for some APP, 2 for a moderate amount of APP and 3 for large amounts of APP. 
The total APP immunoreactivity score for each animal, out of a maximum of 24, was 
the sum of the scores for the eight coronal levels. The distribution and quantity of APP 
accumulation in relation to volume of infarction for the drug treated (MK-801 and 
BW619C89) and vehicle treated animals were compared.
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5.3 RESULTS OF MK-801 STUDY
5.3.1 Physiology
There was minimal interanimal variability in measured physiological parameters which 
may influence the extent of infarction (Table 5.1). After MK-801 administration the rats 
showed a fall in blood pressure as has been previously reported (Park et al. 1988b).
Since this might be expected to increase brain damage, blood pressure was normalised 
to 80 mmHg by decreasing halothane administration.
5.3.2 APP immunocytochemistry after MCA occlusion
In the non-ischaemic contralateral hemisphere, in all animals, APP immunoreactivity 
was faint. In contrast, in the ipsilateral hemisphere, in both the drug and vehicle groups, 
all animals had anatomically circumscribed zones of increased APP immunoreactivity in 
the subcortical white matter and in the myelinated fibre tracts permeating the striatum.
In both groups, the increased APP immunoreactivity was confined to a zone 
immediately adjacent to the boundary of ischaemia. This can be readily visualised in the 
composite diagrams for each of the two groups (Fig 5.1).
5.3.3 Effect of MK-801 on ischaemic damage
Ischaemic damage was observed only within the territory of the occluded MCA, that is, 
in the dorsolateral cortex and in the caudate nucleus. The standard deviation of lesion 
size for the two groups was small; 25% for the vehicle group and 31% for the MK-801 
treated group. The histological appearance of the ischaemic brain tissue in rats treated 
with MK-801 was similar to that in the untreated group. The administration of MK-801 
reduced the volume of ischaemic damage in the cerebral hemisphere by 15.0%
compared to untreated rats and by 15.1% in the cerebral cortex compared to untreated 
rats following MCA occlusion (see Table 5.2 and Table 5.3 and Fig. 5.2A). The areas of 
ischaemic damage in the hemisphere in the animals treated with MK-801 were smaller 
than those in the untreated control group at each stereotactic coronal plane examined 
(Fig. 5.3A).
5.3.4 Effect of MK-801 on APP accumulation
In the MK-801 treated rats, with increasing volume of ischaemic damage there was a 
general increase in APP accumulation as assessed by semi-quantitative analysis (Fig.
5.4). The primary hypothesis being tested was that if MK-801 protects axons, the APP 
score should be reduced. However, '
th e  mean total APP score for the vehicle treated group was 11.3 
+ 0.7 and the mean total APP score tor the MK-801 treated group was 10.6 ± 0.9 (Table
5.4). In addition to looking at the total APP score, the relationship of the APP score and 
area of ischaemia at different coronal planes (Fig. 5.3B) and subgroup analysis was 
performed to assess if there were any trends in the data. Subgroup analysis was 
performed whereby the drug treated group was separated into those with infarction 
greater than 100mm and those with infarction less than 100mm and APP score 
compared to vehicle treated animals. Even in the latter group, in which there was an 
overall reduction in volume of infarction of 30% compared to the vehicle group, there 
was not a statistically significant reduction in mean APP accumulation score in this 
subset compared to the vehicle group (ANOVA, F = 1.183, P = 0.32) (Fig. 5.5). The 
data provided no evidence to suggest that MK-801 reduces the APP score.
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Figure 5.1
VEHICLE MK-801
To gain an overall impression of distribution of increased APP immunoreactivity for 
the vehicle and drug treated animals, the increased APP immunoreactivity for the 
two groups was mapped onto line diagrams which were subsequently superimposed 
(represented as dots on ipsilateral hemisphere).
Figure 5.1 cont.
VEHICLE MK-801
Table 5.2 Ischaemic damage following MCA occlusion: vehicle group
Hem isphere Level 1 ; Level 2 Level 3 Level 4 Level 5 Level 6 j Level 7 | Level 8 j Total (mm3)
1 6.3 ; 12.3 15 16 13.8 7.1 5.5 ; 1 j 103.9
2 7.5 I 13.7 21.6 16.3 11.6 11.1 2.6 ; 4.4 121.6
3 5 j 12.7 19.6 24 22.7 7 3 5.5 0 j 126.4
4 4.2 j 17.1 20.2 19.9 17.9 3.7 1.5 ! 0.7 j 113.4
5 4.8 j 11.3 11.9 9.7 8.7 3.9 2.8 j 1.2 j 74.7
6 3.5 I 11.2 12.2 15.8 7.9 35 2.1 ! 1 ; 76.5
7 4.4 | 18.7 19.4 23 22.9 10 7.6 j 1 i 142.3
8 2.9 15 20.8 18.3 16.4 8.9 7.1 I 4 3  I 125.6
9 4.8 j 16.2 14.9 14.8 13 1 6 0 I 0 I 88.6
10 3.1 j 13.2 14.8 12.1 9.5 1.5 0 j 0 j 73.6
11 4.9 j 16.9 20.4 20.4 14.4 11.2 1.5 i 2.2 124.2
12 6 j 15.4 18.9 23.4 18.7 12 7.6 j 3.2 j 140.2
13 1.9 i 7 9 13.1 14.9 6.5 4.4 1.4 | 1.7 j 68.3
Mean 4.6 j 14.0 17.1 17.6 14.2 6.6 3.5 16  ; 106.1
Std Dev 1.5 j 3.0 3.5 4.4 5.4 3.8 2.8 j 1.5 ; 26.7
SEM 0.4 | 0.8 1.0 1.2 1.5 10 0.8 0.4 7.4
Cortex
1 6.3 ; 8.6 11.5 11.8 9.5 7/l 5.5 j 1 I 83.4
2 7.5 j 8.6 14.9 9.8 8.7 9.4 2.6 j 4.4 91.3
3 5 8.2 11.8 16.1 17.3 73 5.5 j 0 j 93.4
4 4.2 j 11.3 12.4 10.6 11.7 27 1.5 j 0.7 j 74.6
5 4.8 7.5 6.2 5.4 4.4 3.9 2.5 j 1.2 ! 50.7
6 3.5 j 6.9 6.2 9.6 3.5 2 7 2.1 j 1 j 48.1
7 4.4 j 13.2 13.2 15.5 16.5 10 7.6 j 1 j 109.5
8 2.9 j 10.3 13 12.3 11.9 7A 7.1 I 4.3 93.2
9 4.8 j 10.6 7.7 8.3 8.1 0.5 0 j 0 I 55
10 3.1 7.8 8 6.2 4.9 1 5  I 0 I 0 ; 43.7
11 4.9 j 11.3 13.1 12.5 10.1 9.1 1.5 ; 2.2 ! 88.3
12 6 j 10.1 11.5 14.8 12.8 10.4 7.6 j 3.2 | 103
13 1.9 I 3.5 6.8 7.4 2.7 3.6 1.4 ; 1 7  ! 38.7
Mean 4.6 ; 9.1 10.5 10.8 9.4 5.8 j 3.5 I 1 6  I 74.8
Std Dev 1.5 | 2.5 3.1 3.5 4.7 3.5 2.8 ; 1.5 j 24.4
SEM 0.4 j 0.7 0.8 1.0 1.3 1.0 0.8 0.4 6.8
C audate
1 I 2.2 2.4 2.6 1.6 0 j 10.6
2 3.3 5 4.7 1.7 0.9 18.8
3 ! 37 6.4 6.2 3.7 0 24.5
4 I 3.1 5.2 6.7 4.1 0.8 23.6
5 I 2.1 3.8 3.3 2.8 0 14.7
6 j 2.3 5 5.2 4.2 0.8 20.9
7 j 3.6 4.8 5.7 4.1 0 21.9
8 j 3.2 6.2 4.4 2.7 0.6 21
9 I 42 6.2 5.8 4.1 0.8 25.4
10 I 4.5 6.2 5.2 4.2 0 24.7
11 ! 42 5.7 6.7 3.4 0.6 24.8
12 j 4.2 6.2 7 4.1 0.8 26.5
13 j 4.4 5.9 6.8 3.9 0.7 26
Mean 3.5 5.3 5.4 3.4 0.5 21.8
Std Dev j 0.9 1.2 1.4 0.9 0.4 4.7
SEM ; 0.3 0.4 0.4 0.3 0.1 1.5
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Table 5.2 Ischaemic damage following MCA occlusion: MK-801 group
H em isphere Level 1 i Level 2 Level 3 Level 4 | Level 5 I Level 6 j Level 7 ; Level 8 j Total (mm3)
1 6.2 ! 18.2 20.3 23.3 j 23.2 I 11.4 ! 3.9 { 1.6 j 144.4
2 5.1 j 14.6 12.9 6 5.2 ; 0.8 1.5 I 0 | 66.2
3 4.6 j 13.5 15.7 16.4 ! 5 ! 1.9 j 1.8 I 0.4 j 80.6
4 0 10 16.2 17.6 ; 3.6 j 3.9 j 3.4 ; 0 ; 72.2
5 4.1 j 14.1 11.2 11.5 j 12.3 | 8 3.3 j 1.3 j 90.3
6 1.3 ! 14.3 7.1 3.9 j 1.3 1 2  i 0.8 ; 0 j 44.3
7 3.3 j 13.3 10.6 7.3 j 3.2 | 2.7 [ 0.6 j 0 j 58.4
8 0 j 9.7 13.8 16.9 ; 10.7 j 2.9 j 8.2 j 2.6 j 84.3
9 4.4 j 15.7 16 18.9 j 19 I 8.9 j 0 ; 0 110.4
10 2.4 j 18.2 17.9 21.2 ; 19.4 I 107  i 4.2 ! 4 6  I 131.3
11 6.6 j 11.6 19.9 16.2 I 8.6 j 2.9 j 0.6 ! 0 ! 89.9
12 4.5 j 12.7 16.2 12 13.7 I 5 7  I 0.4 j 0 j 88.6
13 4.7 16 17.1 16.5 ; 18.7 j 4.8 j 3.4 j 1.8 j 111.3
Mean 3.6 j 14.0 15.0 14.4 j 11.1 j 5.1 j 2.5 I 0.9 I 90.2
Std Dev 2.1 j 2.7 3.8 5.9 j 7.3 j 3.6 j 2.3 14 28.3
SEM 0.6 0.7 1.0 1.6 2.0 ! 1 0  I 0.6 \ 0.4 7.8
Cortex
1 6.2 j 13.8 13.2 16.3 j 17.7 ; 10.7 j 3.9 j 1.6 j 112.4
2 5.1 j 10.2 8.3 4.6 i 2.7 ! 0.8 j 1.5 j 0 j 48.1
3 4.6 9.6 9.5 9.8 j 1.9 ! 1 9  I 1.8 j 0.4 j 55
4 0 j 6.1 8.7 10.4 j 1.1 ; 3.9 j 3.4 I 0 j 44.7
5 4.1 j 10.9 8.8 9.5 j 7.3 ; 5.9 j 3.3 i 1 3  i 70.8
6 1.3 8.7 7.1 3.9 1.3 j 1.2 j 0.8 I 0  ; 35
7 3.3 8.9 6 2.2 1.2 1.8 | 0.6 0 j 35.7
8 0 ; 4.8 7.3 9.6 j 7.2 i 1 7  ! 8.2 ! 2 6  i 53.8
9 4.4 j 10.3 9.7 13 12.2 j 5.5 j 0 I o j 73.5
10 2.4 j 12.1 11.5 14.7 i 14.1 j 10.7 j 4.2 j 4.6 99.4
11 6.6 j 8.1 11.2 8.7 5.5 ! 2 3  i 0.6 j 0 j 59.5
12 4.5 ; 8.1 9 6.1 9.8 j 4.5 0.4 0 j 58.4
13 4.7 j 10.1 9.8 10.5 : 13.3 j 4.8 3.4 I 1.8 j 78.7
Mean 3.6 9.4 9.2 9.2 7.3 ! 4 3  ! 2.5 i 0 9  i 63.5
Std Dev 2.1 2.4 1.9 4.2 5.7 j 3.3 j 2.3 1 4 23.2
SEM 0.6 j 0.7 0.5 1.2 1.6 j 0.9 j 0.6 j 0.4 j 6.4
C audate
1 j 2.6 5.2 5.4 j 3.1 I 0.7 j 20.5
2 3.1 3.7 0.8 2.1 j 0 j 12.2
3 2.7 5.2 6 2.7 ! 0 I 20.1
4 3.5 5.4 4.8 2.6 ! 0 ! 20
5 1.9 1.3 0.9 I 4.1 I 0.9 ; 10.7
6 3.7 0 0 0 j 0 j 4.6
7 3.4 3.3 4 2 ! 0.9 j 16.1
8 3.9 4.8 5.1 2.4 I o.9 ; 20.6
9 41 5 5 j 4 I 0.7 22.7
10 3.7 4.6 4 3 2.9 0 19
11 ; 2.5 7 6.3 j 2.5 j 0.6 23
12 3.6 6.1 5.3 j 3 ! 0 7  I 22.7
13 4.6 6.1 4 7  i 3.9 |  0 j 23.8
Mean 3.3 4.4 4.0 j 2.7 j 0.4 18.2
Std Dev 0.7 1.9 2.0 | 1.0 I 0.4 j 5.5
SEM 0.2 0.5 0.6 j 0.3 I 0.1 j 1.5
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Table 5.3 Influence of MK-801 upon the volume of ischaemic damage 
and APP score after MCA occlusion
Volume of infarction (mm )
Vehicle MK-801
Cerebral hemisphere 106.1 ±7.4 90.2 ± 7.8
Cerebral cortex 74.8 ± 6.8 63.5 ±6.4
Caudate nucleus 21.8 ± 1.5 18.2 ±1.5
APP score 11.3 ±0.7 10.6 ±0.9
Data are presented as means ± SEM. Vehicle (n = 13); MK-801 (n = 13).
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Table 5.4 APP score for each coronal level in vehicle and MK-801
treated animals
Coronal
level
1 2 3 I 4 5 6 7 8 Total
Vehicle
1 0 0 1 1 2 2 0 0 6
2 2 2 1 1 1 1 1 0 9
3 0 3 3 j 3 2 2 1 0 14
4 1 1 2 2 2 1 1 0 10
5 1 2 2 1 2 1 2 0 11
6 0 1 2 2 1 2 1 0 9
7 3 2 2 I 2 2 1 0 0 12
8 1 2 3 1 2 2 1 0 12
9 1 1 2 1 2 2 0 0 9
10 2 3 3 1 2 2 0 0 13
11 1 2 3 ! 3 2 2 1 1 15
12 1 2 3 2 2 2 2 0 14
13 1 2 2 3 2 2 1 0 13
Average 1.2 1.8 2.2 j 1.8 1.8 1.7 0.8 0.1 11.3
Std dev 0.8 0.8 0.7 I 0.8 0.4 0.5 0.7 0.3 2.6
SEM 0.2 0.2 0.2 j 0.2 0.1 0.1 0.2 0.1 0.7
Drug
1 2 3 2 1 1 1 0 0 10
2 3 3 1 1 1 1 0 0 10
3 2 3 2 1 1 0 1 0 10
4 0 3 2 1 2 1 1 0 10
5 2 1 1 2 2 2 0 0 10
6 0 2 1 0 0 0 0 0 3
7 2 2 2 1 2 1 0 0 10
8 1 2 3 3 2 2 1 14
9 1 2 1 2 2 1 0 0 9
10 1 3 3 2 2 2 2 0 15
11 1 1 3 2 2 1 0 0 10
12 1 2 2 2 2 2 1 0 12
13 2 2 3 3 1 1 2 1 15
Average 1.4 2.2 2.0 1.6 1.5 1.2 0.6 0.2 10.6
Std dev 0.9 0.7 0.8 0.9 0.7 0.7 0.8 0.4 3.1
SEM 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.1 0.9
Semi-quantitative score allocated for amount of APP at each coronal level for the 26 
animals. 0, no APP; 1, some APP; 2, moderate amount of APP; 3, lots of APP.
Figure 5.2 Effect of MK-801 on total volume of ischaemic damage and 
total APP score following MCA occlusion
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Volume of ischaemic brain damage in the cerebral hemisphere, cerebral cortex 
and caudate nucleus in vehicle treated control rats and in rats treated with MK- 
801. Each point represents data from a single animal. The mean value for the 
group is indicated by a solid horizontal line.
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represents data from a single animal. The mean value for the group is indicated 
by a solid horizontal line.
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Figure 5.3 Effect of MK-801 on area of ischaemic damage and mean APP
score at eight defined coronal levels following MCA occlusion
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The effect of MK-801 upon the area of ischaemic damage in the cerebral 
hemisphere at 8 defined coronal planes. Data are presented as mean + SEM. 
Vehicle (n = 13); MK-801 (n = 13).
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Figure 5.4 Relationship of volume of ischaemic damage and APP 
accumulation score: effect of MK-801
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The volume of ischaemic damage was compared to total accumulation of APP 
for each animal in A) Vehicle treated animals and B) MK-801 treated animals. 
The total APP accumulation was the score sum for the 8 coronal levels. Total 
APP accumulation score increased with increasing volume of infarction. Each 
point represents data from a single animal.
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Figure 5.5 APP accumulation score in MK-801 treated animals: 
subgroup analysis
Vehicle MK-801 MK-801
Infarction Infarction
>100mm3 <100mm3
The mean APP score for the vehicle treated group and for the MK-801 treated animals 
was compared. The drug treated group was further broken down into those animals that 
had hemispheric infarction greater than 100mm3 and those with less than 100mm3. The 
drug treated animals with the smallest volumes of infarction did not have a significant 
decrease in mean APP accumulation score. Data are presented as mean + SEM. Vehicle 
(n = 13); MK-801 with infarction > 100mm3 (n = 4) and MK-801 with hemispheric 
infarction < 100mm3 (n = 9).
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5.4 RESULTS OF BW619C89 STUDY
5.4.1 APP immunocytochemistry after MCA occlusion
The APP immunoreactivity in the drug treated and vehicle animals had a similar 
distribution to that described for the MK-801 study (section 5.3.2). In both groups, the 
increased APP immunoreactivity was confined to a zone immediately adjacent to the 
boundary of ischaemia. In general, the APP immunoreactivity in both the vehicle and 
drug treated groups was not as intense as that seen in the rat material from the MK-801 
study. The topography of APP accumulation for the two groups of animals is illustrated 
in Fig. 5.6. The distribution of APP in the two groups is similar.
5.4.2 Effect of BW619C89 on ischaemic damage
The administration of BW619C89 reduced the volume of ischaemic damage in the 
cerebral hemisphere by 16.1% compared to untreated rats and by 20.6% in the cerebral 
cortex compared to untreated rats following MCA occlusion (Table 5.5 and Table 5.6 
and Fig. 5.7A). The volume of ischaemic damage in the caudate nucleus was minimally 
effected by treatment with BW619C89. In the cerebral hemisphere and cortex, 
BW619C89 reduced the area of ischaemic damage in every coronal plane studied (Fig. 
5.8A).
5.4.3 Effect of BW619C89 on APP accumulation
In the non-ischaemic contralateral hemisphere, in all animals, APP immunoreactivity 
was faint. In contrast, in the ipsilateral ischaemic hemisphere, all animals had 
anatomically circumscribed zones of increased APP immunoreactivity in the subcortical 
white matter and in the myelinated fibre tracts permeating the striatum. However,
despite there being a reduction in the volume of infarction in the BW619C89 treated 
animals, BW619C89 failed to significantly reduce the APP score (Table 5.7 and Fig. 
5.7B). The mean total APP score for the vehicle treated group was 12.2+1.3 and the 
mean total APP score for the BW619C89 treated group was 11.3 + 1.2 (Table 5.6).
The relationship of APP score and volume of infarction for the two groups of 
animals is illustrated in Fig. 5.9. In the vehicle animals there was not a clear linear 
relationship between APP accumulation score and volume of ischaemic damage as has 
been previously reported (Yam et al. 1997). BW619C89 showed no evidence of 
reducing the APP score. In addition to looking at the total APP score, the mean APP 
score was assessed at each of the eight coronal levels for the drug treated and vehicle 
groups. Again, there was no evidence of a reduction of APP score in the drug treated 
group. Subgroup analysis was performed whereby the drug treated group was separated 
into those with infarction greater than 100mm and those with infarction less than 
100mm3 and APP score compared to vehicle treated animals. Even in the latter group, in 
which there was an overall reduction in volume of infarction of 32% compared to the 
vehicle group, there was not a statistically significant reduction in mean APP 
accumulation score in this subset compared to the vehicle group (Fig. 5.10). The data 
provided no evidence to suggest that BW619C89 reduces the APP score.
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Figure 5.6
VEHICLE BW619C89
To gain an overall impression of distribution of increased APP immunoreactivity for 
the vehicle and drug treated animals, the increased APP immunoreactivity for the 
two groups was mapped onto line diagrams which were subsequently superimposed 
(represented as dots on ipsilateral hemisphere).
Figure 5.6 cont,
VEHICLE BW619C89
Table 5.5 Ischaemic damage following MCA occlusion: vehicle group
Hemisphere level 1 level 2 level 3 level 4 1 level 5 j level 6 ! level 7 level 8 Total (mm3)
1 4.2 14.8 19.4 22.2 I 21.5 I 15.9 j 3.4 j 0.7 135.8
2 4.6 16.6 19.2 19.5 j 18.5 I 8.9 j 1.8 1 120.7
3 5 16.7 17.7 20.4 I 21 ! 11.8 i 2.2 ! 2.2 129.6'
4 5.2 18.8 23.8 16.7 ; 15.8 I 7 1.5 ! 0 121.5
5 6.2 17.8 16.8 18.6 j 18.2 i 6.2 | 1.2 I 0 114.5
6 8.1 19.1 21.3 19.7 ! 21.3 i 9.8 i 8.6 I 3.8 151.5
7 4.6 11 16.5 14 j 10.7 ! 3.9 I 0.9 i o 82.9
8 6.8 18.2 23.1 22.3 j 18.5 j 15.2 j 7.2 I 5.2 158
9 7.1 15.5 15.5 17.8 I 18.4 ! 3.9 j 2.3 ! 0 107.8
10 9.1 16.6 17.7 17.4 j 20.3 ! 5.2 j 2.6 I 1.1 121.6
Average 6.1 16.5 19.1 18.9 j 18.4 I 8.8 i 3.2 j 1.4 123.8
Std Dev 1.7 2.4 2.8 2.5 j 3.2 I 4.4 I 2.6 I 1.8 22.7
SEM 0.5 0.8 0.9 0.8 I 1.0 I 1.4 I 0.8 j 0.6 7.2
Cortex
1 4.2 10.4 12.3 14.1 I 15.5 I 13.9 I 3.4 j 0.7 100.3
2 4.6 10.8 12.4 11.4 | 12.9 I 7.7 j 1.8 1 84.8
3 5 8.8 10.5 12.3 ! 15.1 ! 10.9 j 2.2 I 2.2 89.9
4 5.2 9.9 12.7 10.4 j 11.2 i 6 i 1.5 i o 77.7
5 6.2 9 9.9 11.2 j 13 i 5 j 1.2 o 74.8
6 8.1 12.9 12.1 12.5 ! 15.6 I 9 j 8.6 I 3.8 112.9
7 4.6 7.1 9.1 7.4 i 6.7 : 3.2 i 0.9 0 53.4
8 6.8 11.8 14.2 14.7 I 12.9 j 13.9 i 7.2 5.2 118.6
9 7.1 9.7 9.2 10 : 13.2 i 3.3 j 2.3 0 74.3
10 9.1 8.5 8.9 9.7 j 14.4 I 4.4 j 2.6 1.1 79.8
Average 6.1 9.9 11.1 11.4 i 13.1 ! 7.7 j 3.2 1.4 86.7
Std Dev 1.7 1.7 1.8 2.2 j 2.6 I 4.1 i 2.6 1.8 19.5
SEM 0.5 0.5 0.6 0.7 j 0.8 I 1.3 i 0.8 0.6 6.2
Caudate
1 3.4 5.8 6.9 j 3.7 I 1 20.8
2 4.2 5.5 7 3.6 j 0.8 j 21.1
3 6.7 6.3 6.8 j 3.8 I 0.7 I 24.3
4 7.8 9.9 5.4 I 3.5 I 0.7 j 27.3
5 7.6 6.2 6.6 j 4.1 ; 0.8 i 25.3
6 4.3 8 6.2 j 3.7 I 0.7 I 22.9
7 3.3 6.8 6.6 I 3.8 I 0.7 I 21.2
8 4.3 7.6 6.1 j 3.7 I 0.9 j 22.6
9 4.7 5.6 6.8 ! 4 I 0.6 I 21.7
10 7.5 8.4 6.7 j 4 j 0.8 j 27.4
Average 5.4 7.0 6.5 j 3.8 ! 0.8 I 23.46
Std Dev 1.8 1.4 0.5 j 0.2 i 0.1 i 4.0
SEM 0.6 0.5 0.2 j 0.1 ! 0.0 ! 1.3
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Table 5.5 cont... Ischaemic damage following MCA occlusion: 
BW619C89 group
Hemisphere level 1 level 2 level 3 level 4 level 5 level 6 j level 7 i level 8 Total (mm3)
1 3.1 11.1 18.3 16.4 6.1 1.4 I 0.5 I 0 76.2
2 5.5 17.3 16.5 15.6 11.7 2.1 I 0 j 0 93.9
3 2.7 14.7 17.7 20.5 16.7 11.7 I 2.5 ! 0.8 116
4 2.6 10.6 14.5 16.7 16.3 2.9 i 0 I o 82.5
5 4.1 17.6 21.6 19.8 20.5 14.1 i 2.6 ! 0 135.1
6 2.9 13.3 12.3 14.6 13.4 7.9 i 1 i 0 87.8
7 6 21.1 21.6 20 19.9 12.6 j 8.9 j 4.6 156
8 4.5 12.6 18.1 17.3 17.5 10.4 j 1.9 I 2.3 113.1
9 5.5 13.7 18.1 19.9 18.7 9.4 ; 3.2 i 0 117.7
10 3 11 16 15.9 10.8 2.4 j 2.4 I 1.9 84
11 0.6 13.5 14.2 14.9 13.2 3.5 i 1.2 j 0 80.7
Average 3.7 14.2 17.2 17.4 15.0 7.1 j 2.2 j 0.9 103.9
Std Dev 1.6 3.3 2.9 2.2 4.4 4.8 j 2.5 j 1.5 25.7
SEM 0.5 1.0 0.9 0.7 1.3 1.4 I 0.7 I 0.5 7.8
Cortex
1 3.1 6.5 6.7 8.8 1.8 0.5 ; 0.5 : 0 37.8
2 5.5 8.5 8.6 8.1 7.4 1.3 ! 0 j 0 54.1
3 2.7 9.4 10.3 12.5 11.8 10.5 ! 2.5 ! 0.8 81.2
4 2.6 7.9 8.4 8.9 10.9 1.8 j 0 I o 53.8
5 4.1 11 13.2 11.7 15.2 13 ! 2.6 0 96.2
6 2.9 6.9 4.9 7.6 8.7 6.7 j 1 j 0 52.3
7 6 12.2 11.5 12.6 14.7 11.1 } 8.9 ! 4.6 111.1
8 4.5 8.8 11.3 10 12.4 9.2 j 1.9 I 2.3 81.9
9 5.5 8.9 10.2 11.8 12.7 8.3 i 3.2 i o 81.7
10 3 7 9.4 8.8 7.2 2.4 ; 2.4 ! 1.9 56.7
11 0.6 8.5 8 7.8 8.6 2.8 I 1.2 ! 0 50
Average 3.7 8.7 9.3 9.9 10.1 6.1 j 2.2 j 0.9 68.8
Std Dev 1.6 1.7 2.3 1.9 3.9 4.5 I 2.5 ! 1.5 22.8
SEM 0.5 0.5 0.7 0.6 1.2 1.4 I 0.7 I 0.5 6.9
Caudate
1 4.1 11 6.8 3.7 0.8 ; 26.4
2 7.2 7.2 7 3.7 0.7 i 25.8
3 3.9 5.4 6.6 3.4 0.7 j 20
4 2 5 6.6 3.6 0.7 j 17.9
5 4.7 7.3 6.8 3.3 0.7 j 22.8
6 5.4 6.9 6.6 3.9 0.7 ; 23.5
7 7 9.1 6 3.6 0.8 ! 26.5
8 3.3 6 6.5 3.9 0.8 j 20.5
9 3.7 7 6.7 4 0.7 i 22.1
10 3.6 5.8 6.5 3.4 0 19.3
11 4.3 5.8 6.8 3.8 0.6 j 21.3
Average 4.5 7.0 6.6 3.7 0.7 ! 22.4
Std Dev 1.6 1.8 0.3 0.2 0.2 j 2.9
SEM 0.5 0.5 0.1 0.1 0.1 j 0.9
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Table 5.6 Influence of BW619C89 upon the volume of ischaemic 
damage and APP score after MCA occlusion
Volume of ischaemic damage (mm )
Vehicle BW619C89
Cerebral hemisphere 123.8 ±7.2 103.9 ±7.8
Cerebral cortex 86.7 ±6.2 68.8 ±6.9
Caudate nucleus 23.5 ±1.3 22.4 ± 0.9
APP score 12.2 ±1.3 11.3 ±1.2
Data are presented as means ± SEM. Vehicle group (n = 10); BW619C89 treated group 
(n = 11).
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Table 5.7 APP score for each coronal level in vehicle and BW6119C89
treated animals
Coronal
level
1 2 3 4 5 6 i 7 8 Total
Vehicle
1 2 1 2 2 1 2 i o 2 12
2 0 2 2 2 2 2 i o 0 10
3 2 1 1 1 0 0 1 0 6
4 1 2 2 1 1 1 I 0 0 8
5 1 3 3 3 3 I 2 j 0 0 15
6 1 1 1 1 1 1 ; 2 1 9
7 2 3 2 2 3 j 2 i o 1 15
8 3 3 3 3 2 ! 3 1 1 19
9 3 3 2 3 2 i 1 j 0 0 14
10 1 2 3 2 2 i 2 1 1 14
Average 1.6 2.1 2.1 2 1.7 j 1.6 I 0.5 0.6 12.2
Std dev 1.0 0.9 0.7 0.8 0.9 0.8 ! 0.7 0.7 3.9
SEM 0.3 0.3 0.2 0.3 0.3 I 0.3 I 0.2 0.2 1.3
BW619C89
1 1 1 2 3 1 1 1 0 10
2 3 1 1 2 1 1 I 0 0 9
3 2 1 1 0 o  i 0 I 0 0 4
4 1 1 2 2 1 2 j o 0 9
5 1 2 2 2 2 j 2 I 0 0 11
6 1 2 2 2 2 j 1 ! 0 0 10
7 ; 2 1 1 3 2 i 1 j 2 1 13
8 2 2 3 2 2 ! 1 ! 0 0 12
9 1 2 2 2 2 j 2 I o 0 11
10 2 3 2 3 3 3 1 1 18
11 1 3 3 3 3 I 3 1 0 17
Average 1.5 1.7 1.9 2.2 1.7 j 1.5 I 0.5 0.2 11.3
Std dev 0.7 0.8 0.7 0.9 0.9 i 0.9 I 0.7 0.4 3.8
SEM 0.2 0.2 0.2 0.3 0.3 ! 0.3 j 0.2 0.1 1.2
Semi-quantitative score allocated for amount of APP at each coronal level for the 26 
animals. 0, no APP; 1, some APP; 2, moderate amount of APP; 3, lots of APP.
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Figure 5.7 Effect of BW619C89 on total volume of ischaemic damage 
and total APP score following MCA occlusion
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Volume of ischaemic brain damage in the cerebral hemisphere, cerebral 
cortex and caudate nucleus in vehicle treated control rats and in rats treated 
with BW619C89. Each point represents data from a single animal. The 
mean value for the group is indicated by a solid horizontal line.
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Total APP accumulation score in the cerebral hemisphere in vehicle treated 
control rats and in rats treated with MK-801 after MCA occlusion. Each point 
represents data from a single animal. The mean value for the group is indicated 
by a solid horizontal line.
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Figure 5.8 Effect of BW619C89 on area of ischaemic damage and mean
APP score at eight defined coronal levels following MCA occlusion
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The effect of BW619C89, administered following MCA occlusion, upon the area of 
ischaemic damage in the cerebral hemisphere at 8 defined coronal planes. Data are 
presented as mean + SEM. Vehicle (n = 10); BW619C89 (n = 11).
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The effect of BW619C89 upon the mean APP score in the cerebral hemisphere 
at 8 defined coronal planes. Data are presented as mean + SEM.
Vehicle (n = 10); BW619C89 (n = 11).
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Figure 5.9 Volume of ischaemic damage and APP accumulation score: 
BW619C89
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The volume of ischaemic damage in the cerebral hemisphere was compared to 
total accumulation of APP for each animal in A) vehicle treated control animals 
and B) BW619C89 treated animals. The total APP accumulation was the score 
sum for the eight coronal levels. Each point represents data from a single animal
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Figure 5.10 APP accumulation score in BW619C89 treated animals:
subgroup analysis
Vehicle BW619C89 BW619C89
Infarction Infarction
>100m m 3 <100m m 3
The mean APP score for the vehicle treated group and for the BW619C89 treated 
animals was compared. The drug treated group was further broken down into those 
animals that had hemispheric infarction greater than 100mm3 and those with less than 
100mm . The drug treated animals with the smallest volumes of infarction did not have 
a significant decrease in mean APP accumulation score. Data are presented as mean + 
SEM. Vehicle (n = 10); BW619C89 with infarction > 100mm3 (n = 5) and BW619C89 
with hemispheric infarction < 100mm3 (n = 6).
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5.5 DISCUSSION
The demonstration of axonal injury requires special staining techniques. APP has 
previously been shown to be a good marker of axonal injury and in Chapter 4, a method 
of semi-quantitative analysis of APP was described. This technique was utilised to 
determine whether MK-801 or BW619C89 attenuates the axonal alteration previously 
described following MCA occlusion.
In the MK-801 study the reduction in cerebral infarction in the drug treated 
group was not as large as has been previously reported. Unilateral, permanent occlusion 
of the MCA in rats has gained increasing acceptance in recent years as a model of 
ischaemic stroke and has been widely used to assess the efficacy and potency of various 
drugs. Several groups have found neuroprotection with MK-801 (Gill et al. 1991; Park 
et al. 1988b), but others have failed to do so (Dimagl et al. 1990). Although there may 
be experimental differences between laboratories, the discrepant findings of non­
competitive NMDA antagonists may relate to variability in the extent of cerebral 
infarction after MCA occlusion in different strains of rat (Duverger and MacKenzie, 
1988) or from slight differences in individual surgical techniques. In this regard, even in 
untreated control rats, the extent and variability of infarct size depends on the rat strain 
(Duverger and MacKenzie, 1988). Furthermore, the extent of total infarct volume 
reduction elicited by three drugs, including MK-801 is significantly varied among rat 
strains (Sauter and Rudin, 1995). A plausible reason for the strain-dependant infarct size 
in untreated control rats has been traced to the vascular anatomy, as the varying arterial 
branching, number of anastomoses and collaterals in different rat strains seems to 
correlate with the final size of infarction (Coyle and Heistad, 1991) and this is supported 
by cerebral blood flow studies (Carswell et al., in press). Previous studies investigating
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the effect of MK-801 upon the amount of ischaemic brain damage following MCA 
occlusion have tended to use Sprague Dawley rats. However, due to the smaller and 
more variable lesions of this rat species, Fischer 344 rats were used in the present study. 
The possibility that Fischer rats have less salvageable tissue following MCA occlusion 
i.e. more core than penumbra, thus resulting in only a small amount of tissue salvage 
following MK-801 treatment, cannot be discounted. It must also be considered whether 
the dose of MK-801 was adequate. The dose selected for this study has previously 
shown to give a highly significant reduction in volume of ischaemic brain damage in the 
cerebral cortex and hemisphere (Gill et al. 1991). Despite this, it is not possible to say 
with certainty that a steady state plasma level of MK-801, previously shown to be 
neuroprotective, was achieved since plasma samples were not collected for 
measurement of MK-801.
MK-801 failed to significantly reduce the APP score. Since the reduction in 
infarct volume was less than might have been expected, the MK-801 treated animals 
were divided into two groups for further subgroup analysis of APP accumulation; those 
with volumes of infarction greater than 100mm and those with less than 100mm . Even
n m
in the group of animals with volumes of infarction less than 100mm , significantly 
lower than that of the vehicle group, there was only a marginal reduction in APP 
accumulation score. This would suggest that the NMD A antagonist, MK-801, fails to 
protect axons following focal cerebral ischaemia in the rat. Perhaps this is not a 
surprising finding. Since NMDA receptors are thought to be active mainly in the grey 
matter (Jones and Baughman, 1991), is it likely to exert its protective effect on axons 
following cerebral ischaemia?
In contrast, the contribution of sodium and calcium ion channels to the 
mechanisms leading to anoxic white matter injury have been well characterised by
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Waxman and co-workers in the optic nerve (see section 1.5.3). BW619C89, which acts 
at such sites, resulted in a significant reduction in neuronal necrosis. Despite this, the 
drug did not appear to cause significant protection of axons as assessed by the difference 
in APP accumulation score between the drug treated and vehicle group. However, some 
difficulties in allocating an APP score to the sections were encountered. The reasons for 
this were twofold. Firstly, the sections had marked oedema, and although this is a 
consistent feature of the MCA occlusion stroke model (Sydserff et al. 1996), it was quite 
pronounced in this particular rat material. The oedema may be an explanation for the 
relatively small amount of APP immunoreactivity present, even in the vehicle treated 
animals, compared to other sections analysed throughout this thesis. The oedema may 
also have been attributed to the fact that the rats in this study survived for 24 hours 
rather than 4 hours as in the MK-801 study. This survival time was selected because the 
relationship of volume of infarction to APP score at 4 hours in the MK-801 study (for 
both the vehicle and drug treated animals), was poor compared to that seen following 24 
hours as described in Chapter 4 (Fig. 4.7). Despite this survival time, there was not a 
clear relationship between volume of ischaemia and APP accumulation, thus further 
compounding the difficulties in assessing the putative protection of axons in the 
BW619C89 treated group. Perhaps this latter problem could also have been attributed to 
the oedema. The possibility that BW619C89 protects axons following MCA occlusion 
in the rat cannot be discounted. However, from this study no firm conclusions can be 
drawn.
Although a method of semi-quantitative analysis of APP accumulation had been 
developed, there were some difficulties in the practical application of the method for the 
assessment of axonal injury and protection following drug intervention. Although not all 
of the problems encountered in the studies described were directly related to the method
of quantification, some were. One concern was that the semi-quantitative analysis was 
not sensitive enough to measure small changes in axonal injury following therapy. This 
may in part be due to the small variance in lesion size between the two groups making 
separation of APP scores between vehicle and drug treated animals more difficult. 
Furthermore, the lesion sizes within groups was within a narrow range making it more 
difficult to assess the association of APP score with infarction size (Fig. 5.4 and Fig. 
5.9).
Perhaps a more refined method for quantification of APP may be required which 
is more robust and, at the same time, more sensitive to small changes in APP 
accumulation. Methods by which the sensitivity could be increased may be achieved by 
assessing a greater number of coronal levels rather than just the eight that were used in 
these studies. Alternatively, the experiment could be undertaken in a species in which 
there is more white matter relative to that of grey matter such that protection of axons 
can be more easily visualised. To look at the association of APP score with infarction, a 
wide range of infarction values would also be desirable. To this effect, experiments in 
the following chapter describe analysis of axonal injury in the cat using modified 
methods of quantification to overcome the limitations encountered in these rat studies.
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CHAPTER 6
QUANTITATIVE ANALYSIS OF APP FOLLOWING 
DRUG INTERVENTION IN THE CAT
6.1 INTRODUCTION
APP was demonstrated to be a viable marker of axonal injury in the rat (Chapter 4). 
However, when used to assess the effects of drug intervention, it proved difficult to see 
either a shift in the topography of increased APP immunoreactivity in relation to the 
boundary of infarction, or a significant change in the APP score. Indeed, this may 
simply be because the neuroprotective drugs, MK-801 and BW619C89, are not saving 
white matter following an ischaemic injury. In the rat brain the volume of white matter 
is relatively small compared to the volume of grey matter, therefore the possibility that 
neuroprotective drugs such as MK-801, are saving white matter but this protection is 
unable to be detected in the rat brain, must be considered. The cat brain is more 
comparable to that in man in that it is gyrencephalic and the volume of white matter is 
relatively large. Unlike in the rat, the boundary between viable and necrotic neurones 
after focal ischaemia in the cat can be shifted several centimetres across the cortical 
surface (Fig. 6.1). Since there is also a larger amount of underlying white matter within 
the salvaged zone compared to that in the rat, this theoretically should allow easier 
evaluation of white matter protection. Furthermore, by assessing a larger number of 
coronal levels, and by refining the method of APP quantification, limitations 
encountered in the rat tissue could potentially be overcome. It is feasible that with such 
refinements there would be increased sensitivity of APP as marker of axonal injury
following MCA occlusion. Conceivably, a shift in the boundary and a change in the 
quantity of APP accumulation could be more readily appreciated following 
neuroprotection in the cat than the rat.
The experiment undertaken in the cat had three inter-related purposes. Firstly, it 
was necessary to establish whether increased APP immunoreactivity was a consistent 
outcome following focal cerebral ischaemia; secondly, to establish if there is a 
relationship between the quantity of APP immunoreactivity and volume of infarction. 
And finally, once the first two questions have been established, to use APP as a marker 
of axonal injury to ascertain whether the classic NMDA antagonist, MK-801, protects 
white matter as well as grey matter following focal cerebral ischaemia in the cat.
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Figure 6.1 Tissue salvage following NMDA receptor blockade in the cat and rat
RAT
10mm
MARGINAL EVENT MAJOR TISSUE SALVAGE
Neuronal protection with NMDA receptor blockade after MCA occlusion has 
been investigated in both rats and cats. Following MK-801 administration, the 
stippled area is the salvaged zone derived from median animals and the solid 
area is never salvaged (Modified from Ozyurt et al, 1988). Because of the 
physical size, mechanisms in the salvaged cortex and underlying white matter 
can be more readily evaluated in the cat than the rat.
6.2 METHOD
6.2.1 Anaesthesia, MCA occlusion and tissue processing
Anaesthesia was induced in 16 cats (section 2.2.2) and MCA occlusion performed as 
previously described (section 2.2.3). MCA occlusion was performed by Mr. Laurence 
Dunn, Consultant Neurosurgeon, Southern General Hospital. The cats were randomly 
divided into a vehicle treated control group (n=10) and a drug treated group (n=6). The 
vehicle treated control group of cats received a one ml intravenous injection of saline 15 
minutes prior to MCA occlsion and then an intravenous saline infusion at a rate of 
0.15ml/min for the duration of the experiment. The drug treated group received a bolus 
of MK-801 (0.5 mg/kg) which was administered by intravenous injection 15 minutes 
before MCA occlusion and then infused at 0.14 mg/kg/hour after completion of the 
bolus injection (0.15ml/min). Although there has been no implicit investigation of 
neuroprotection with this dose, the bolus and infusion concentrations were selected to 
achieve a steady state target plasma concentration of 300nM. This dosing regime was 
based on previous experiments which have provided the information on the plasma half 
life of MK-801 (see below) , knowledge of loading dose requirements (Mayer et al. 
1975) and previous experiments stating plasma concentrations of MK-801 that have 
resulted in neuroprotection (Gill et al. 1991). The half life of plasma MK-801 was 
calculated from assays taken in 9 separate experiments where intravenous MK-801 had 
been administered at a concentration of 5mg/kg (Table 6.1 and Fig. 6.2) (Ozyurt et al. 
1988). MK-801 was prepared as described below.
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Drug preparation
Bolus: Weigh (cat weight divided by 2) mg of MK-801
Dissolve in 5 ml saline 
Inject over 2 mins 
Infusion: Weigh (1.94 x cat weight) mg
Dissolve in 125 ml saline 
Infuse at 0.15 ml/min 
Basis of calculation:
T1/2 cat of 2.5 hours (Ozyurt et al. 1988)
Loading dose = 1.4 x Tm x maintenance dose (Mayer et al. 1975)
Following MCA occlusion, anaesthesia was maintained for 6 h and physiological 
parameters were monitored as previously described (section 2.2.2) (Table 6.2). The 
animals were killed by transcardiac perfusion with FAM and brain processed (section 
2.2.3). The sections were stained by haematoxylin and eosin and a method combining 
cresyl violet and Luxol fast blue and areas of infarction transcribed onto scale diagrams 
at 16 predetermined coronal planes (Fig. 2.6) and volume of ischaemic damage 
subsequently calculated (section 2.5.2).
Sections adjacent to those used for mapping areas of infarction were prepared for 
immunocytochemistry so that the topography of increased APP immunoreactivity could 
be compared to that of infarction (section 2.3.1). The tissue sections were microwaved 
to enhance antigenicity (section 2.3.3) and APP antibody used at a concentration of 
1:300.
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Table 6.1 Plasma MK-801 concentration analysis
MK-801 cat studies: dosing at 5mg/kg. Samples were assayed from 9 separate 
experiments (Ozyurt et al. 1988).
Time after MK-801 administration (hours)
Experiment
no.
1 2 3 4 5 6
Plasma MK-801 concentration (pm) '
1 2.2 1.5 1.0 0.9 0.8 0.5
2 2.6 2.0 1.6 1.3 1.2 0.9
3 2.1 1.2 1.0 0.9 0.8 0.6
4 2.1 1.4 1.2 0.9 2.6 0.8
5 2.5 2.1 1.6 1.8 1.3 1.1
6 4.5 1.8 1.8 1.3 1.0 1.0
7 3.5 2.2 1.4 1.1 1.0 0.9
8 3.5 4.0 1.8 1.4 1.3
9 2.0 1.3 1.3 1.0 0.9 0.7
Average 
Std dev 
SEM
2.78
0.86
0.29
1.94
0.85
0.28
1.40
0.32
0.11
1.13
0.32
0.11
1.22
0.57
0.19
0.86
0.25
0.08
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Figure 6.2 Plasma MK-801 concentration analysis
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l im e  after dosing (hours)
Mean plasma MK-801 concentration following intravenous administration at 5mg/kg, 
30 minutes prior to MCA occlusion (Ozyurt et al, 1988). Data are presented as mean + 
SEM on a log scale, n = 9 at all time points except at 5 hours, where n = 8. The plasma 
half life of MK-801 is approximately 2.5 hours.
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6.2.2 Topographical analysis of APP immunoreactivity
Since diaminobenzidine was used as the chromagen in the immunocytochemistry, the 
increase in APP immunoreactivity within the white matter was brown (Fig. 6.3). An 
accurate determination of the topography in increased APP immunoreactivity for the 
two groups of cats was established using the method previously described for the rat 
(see section 4.2.4). In brief, images from 16 equivalent coronal sections from each 
animal, at defined coronal planes, were viewed on a monitor, digitised and printed. 
The images produced showed the increased APP immunoreactivity. The sections 
were also viewed using a conventional light microscope at x 2.5 magnification. Any 
increased APP immunoreactivity visible on the slides but which was not visible on 
the scanned images was manually drawn onto the image. This procedure was 
repeated for each animal at each coronal level. In this way, an accurate determination 
of the overall topography of increased APP immunoreactivity for the two groups of 
animals could be established by tracing and superimposing the increased APP 
immunoreactivity at each coronal level for the two groups of animals onto a single 
line diagram which was drawn on an acetate sheet. The superimposition of increased 
APP immunoreactivity for the animals was repeated at each of the 16 coronal levels 
(Fig. 6.4).
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Figure 6.3 APP immunoreactivity in the cat
A
A
Typical example o f increased APP immunoreactivity in the cat following MCA 
occlusion. A) Line diagram o f coronal level 6 showing the location o f the 
following micrographs, (scale bar approximately 0.5cm). B) Increase in APP 
immunoreactivity in white matter tracts x400 and C) xl,000.
Figure 6.4 Topography of APP immunoreactivity: vehicle group
Topography of the APP immunoreactivity for the 16 preselected coronal levels in the 
cats after MCA occlusion (vehicle, n = 10; MK-801, n = 6). To gain an overall 
impression of distribution of increased APP immunoreactivity for the two groups of 
cats, the APP was mapped onto line diagrams which were subsequently superimposed 
(represented as dots).
Figure 6.4 cont... Topography of APP immunoreactivity: MK-801 group
6.2.3 Quantification of APP immunoreactivity 
Semi-quantitative analysis
In order to assess the relationship of APP immunoreactivity and volume of infarction, 
each coronal section was analysed for APP by light microscopy and a semi- 
quantitative rating allocated, viz. O for no APP, 1 for some APP, 2 for a moderate 
amount of APP and 3 for large amounts of APP, the method previously described for 
the rat (section 4.2.5) (Fig. 6.5). Sections from a single coronal level from all animals 
were assessed simultaneously in order to keep the scoring system consistent for each 
animal within and between groups. The total APP immunoreactivity score for each 
animal in both the vehicle and drug treated groups, out of a maximum of 48, was the 
sum of the scores for the 16 coronal levels (Table 6.3). To assess the reproducibility 
of semi-quantitative analysis of APP immunoreactivity in the cat, the scoring system 
was repeated for two of the coronal levels three weeks after the initial assessment by 
the same scorer (for intra-rater variability) and by a different scorer (for inter-rater 
variability) (Fig. 6.6).
Quantitative analysis
For quantitative analysis, the images from 16 equivalent coronal sections, from each 
animal, showing the increased APP immunoreactivity, obtained as described in 
section 6.2.2., were analysed. A transparent counting grid, arranged in a regular 
square array, was randomly placed over each image and the number of points 
overlying the area of increased APP immunoreactivity was counted (Fig 6.7). This 
was performed on all sixteen levels for both the drug and vehicle treated animals.
The total APP score for each animal was the sum of the points on target for all 
sixteen levels (Table 6.4). The intra-rater variability was tested by repeating the count
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for a randomly selected sample from the two cat populations and comparing the two 
sets of results (Fig. 6.8A). To assess the inter-rater reliability of this technique, a 
novice was asked to use the grid system and count the number of ‘hits’ in a randomly 
selected sample of images from the two cat groups (Fig. 6.8B).
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Figure 6.5 Scoring of APP by semi-quantitative and quantitative methods
A B c
Semi-quantitative 
APP score
1 2 3
Quantitative APP
score
16 74 117
Scanned cat images at a single coronal level to show the area o f increased APP 
immunoreactivity (outline in black) following MCA occlusion. Table shows the 
semi-quantitative score for each section allocated; 0 for no APP, 1 for some APP 
(A), 2 for a moderate amount o f APP (B) and 3 for large amounts o f APP (C). 
Scores allocated using quantitative analysis by point-counting grid; 16 for (A), 74 
for (B) and 117 for (C).
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Figure 6.6 Reproducibility of the semi-quantitative APP analysis
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Semi-quantitative analysis
A random selection of cat sections were analysed to assess intra-scorer variability 
and inter-scorer variability. An APP score of 0,1, 2 or 3 was given on each 
occasion as previously described. The value allocated on the second occasion was 
deducted from that on the first occasion to give a final result ranging from -2 to +2. 
Therefore, where a section was given the same score on both occasions the value 
allocated was 0.
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Figure 6.7 Method of quantitative APP analysis in the cat
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Coronal slice o f cat brain overlaid with a point-counting grid. The image 
from a defined coronal plane, is viewed on a monitor, digitised and printed. 
The image produced shows the increased APP immunoreactivity (outline in 
red). A transparent counting grid, arranged in a regular square array, is 
randomly placed over the image and the number o f points overlying the area 
o f increased APP immunoreactivity are counted.
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Figure 6.8 Reproducibility of quantitative APP analysis
Intra-rater variability
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Assessment of the APP accumulation score by point-grid analysis resulted in both the 
intra-scorer variability (i.e. when the same images were scored on repeated occasions by 
the same person) (A), and inter-scorer variability (i.e. when the same images were 
scored by different people) (B), being minimal.
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6.3 RESULTS
6.3.1 APP immunocytochemistry after MCA occlusion
In the ipsilateral ischaemic hemisphere, all animals in both the vehicle and MK-801 
treated groups had increased APP immunoreactivity in subcortical white matter. The 
increased axonal immunoreactivity was ‘bulbous’ in appearance (Fig. 6.3), as previously 
seen in the rat subcortical white matter and myelinated tracts permeating the striatum 
(Fig. 4.5), and thought to be an early indication of axotomy (Povlishock, 1992).
6.3.2 Relationship between ischaemia and APP accumulation
The administration of MK-801 reduced the volume of ischaemic damage in the cerebral 
hemisphere by 30% compared to untreated cats and by 44% in the cortex compared to 
untreated cats following MCA occlusion (Table 6.5 and Table 6.6 and Fig. 6.9). The 
volume of ischaemic damage in the caudate nucleus was affected minimally by 
treatment with MK-801. In the cerebral hemisphere and cortex, MK-801 reduced the 
area of ischaemic damage in every coronal plane studied (Fig. 6.10A).
In the vehicle treated animals, there was an association between the volume of 
ischaemic damage and the amount of increased APP immunoreactivity as assessed by 
both semi-quantitative and quantitative analysis (Fig. 6.11A and 6.12A), the increase in 
APP immunoreactivity being greatest in cats with the largest volumes of neuronal 
necrosis.
6.3.3 Effect of MK-801 on APP accumulation
In the MK-801 treated cats, with increasing volume of ischaemic damage there was a 
general increase in APP accumulation as assessed by semi-quantitative and quantitative
analysis (Fig. 6.1 IB and 6.12B). The primary hypothesis being tested was that if MK- 
801 protects axons, the APP score should be reduced. However, despite there being a 
reduction in the volume of infarction in the MK-801 treated animals, MK-801 failed to 
significantly reduce the APP score. Using semi-quantitative analysis the mean total APP 
score for the vehicle treated group was 21 + 1 and the mean total APP score for the MK- 
801 treated group was 21 + 1. Using quantitative analysis the mean total APP score for 
the vehicle treated group was 253 + 19 and the mean total APP score for the MK-801 
treated group was 322 + 22 (Fig. 6.9 B and 6.9C) (Table 6.6). Overall, the quantitative 
mean APP score in the MK-801 treated group was significantly higher (P<0.05, two- 
tailed t-test) than the APP score in the vehicle treated group. The amount of axonal 
injury, as assessed by the quantitative APP score, was corrected for the size of ischaemic 
damage thus allowing the effect of MK-801 on the ratio of white matter:grey matter 
injury to be established (Table 6.7 and Fig. 6.13). The difference in the ratios between 
the vehicle treated animals and drug treated animals was significantly different using the 
one tailed Welch’s t-test (P < 0.05). For a given volume of infarction, the total APP 
accumulation score was the same or higher in the drug treated animals as compared to 
the vehicle treated animals (Fig. 6.1 IB and 6.12B).
In addition to looking at the total APP score, the relationship of the APP score 
and area of ischaemia at different coronal planes was assessed (Fig. 6.10). Despite a 
reduction in the area of ischaemic damage at each coronal plane following MK-801 
administration, there was not a similar reduction in APP score as assessed by either 
semi-quantitative or quantitative analysis.
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6.3.4 Semi-quantitative analysis versus point-counting technique of APP
The intra and inter-rater variability for both techniques are illustrated in Fig. 6.5 and Fig. 
6.7. Using the semi-quantitative method the intra-rater correlation, r = 0.73 and inter - 
rater correlation, r = 0.69 (Spearman rank correlation, assuming nonparametric 
correlation). Using the quantitative method of APP analysis, the intra-rater correlation, r 
= 0.99 and the inter-rater correlation, r = 0.96 (Pearson correlation assuming Gaussian 
distribution)
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Table 6.6 Influence of MK-801 upon the volume of ischaemic damage 
and APP score in the cat after MCA occlusion
Volume of ischaemic damage (mm )
Vehicle MK-801
Cerebral hemisphere 1801 ±297 1265 ±295
Cerebral cortex 1297 ±288 720 ±262
Caudate nucleus 228 ± 12 238 ±14
APP score (semi-quantitative) 21 ± 1 21 ±1
APP score (quantitative) 253 ±19 322 ±21
n 10 6
Data are presented as mean ± SEM.
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Figure 6.9 Effect of MK-801 on total volume of ischaemic damage and
total APP score following MCA occlusion
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hemisphere cortex nucleus
Volume of ischaemic brain damage in cerebral hemisphere, cerebral cortex, and caudate 
nucleus in vehicle treated control cats and in cats treated with MK-801. Each point 
represents data from a single animal. The mean value for the group is indicated by a 
solid horizontal line.
B Semi-quantitative analysis
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CEREBRAL HEMISPHERE
Total APP accumulation score as assessed by semi-quantitative (B) and quantitative 
(C) analysis in the cerebral hemisphere in vehicle treated control cats and in cats treated 
with MK-801 after MCA occlusion. Each point represents data from a single animal. 
The mean value for the group is indicated by a solid horizontal line.
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Figure 6.10 Effect of MK-801 on area of ischaemic damage and mean 
APP score at eight defined coronal levels following MCA 
occlusion in the cat
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(A) The effect of MK-801 upon the area of ischaemic damage in the cerebral cortex at 11 
defined coronal planes. (B) Mean APP accumulation score as assessed by semi- 
quantitative analysis and (C) quantitative analysis at each coronal level. Despite the 
MK-801 treated animals having a smaller area of ischaemic damage at each of the 
coronal levels (A), there was no reduction in the APP score compared to the vehicle 
treated animals when assessed by either method of analysis (B and C). Data are 
presented as mean + SEM. Vehicle (n = 10); MK-801 (n = 6).
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Figure 6.11 Volume of ischaemic damage and semi-quantitative APP
accumulation score
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The volume of ischaemic damage was compared to total accumulation of APP for each 
animal in A) Vehicle treated animals and B) MK-801 treated animals. The total APP 
accumulation was the score sum for the 16 coronal levels. Total APP accumulation 
score increased with increasing volume of infarction. Each point represents data from 
single animal. The dotted line in B represents best fit line for vehicle animals.
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Figure 6.12 Volume of ischaemic damage and quantitative APP
accumulation score
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The volume of ischaemic damage was compared to total accumulation of APP for each 
animal in the vehicle and MK-801 treated groups. The total APP accumulation score 
was the score sum for the 16 coronal levels obtained using the point grid system. (A) In 
the vehicle group, total APP accumulation score increased with increasing volume of 
infarction. (B) For a given volume of infarction, the drug treated animals had a higher 
total APP accumulation score (solid line) as compared to vehicle animals (dotted line)
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Table 6.7 White matter injuryigrey matter injury ratio following MCA
occlusion
Volume o f infarction 
(mm3)
Quantitative APP score APP score: infarct 
volume
Vehicle 1165 274 0.24
1270 164 0.13
3074 260 0.08
2282 275 0.12
759 218 0.29
1232 230 0.19
1795 208 0.12
3659 372 0.10
1687 313 0.19
1089 217 0.20
MK-801 1017 383 0.38
624 356 0.57
2440 310 0.13
728 284 0.39
923 243 0.26
1855 355 0.19
The amount of axonal injury was corrected for the size of ischaemic damage by 
generating a ratio of APP score.infarct volume for the vehicle treated and MK-801 
treated animals.
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Figure 6.13 White matter injuryrgrey matter injury ratio following MCA 
occlusion
APP score:infarct volumeInfarct volume
MK-801VehicleVehicle
Cerebral hemisphere Cerebral hemisphere
(A) Volume of ischaemic brain damage in the cerebral hemisphere in vehicle 
treated control cats and in cats treated with MK-801. (B) Ratio of APP score, as 
assessed by quantitative analysis, and infarct volume. The APP score:infarct 
volume ratio is significantly higher in the drug treated animals compared to the 
vehicle treated animals (P < 0.05, Welch’s one sided t-test) despite a reduction in 
infarction volume in the drug treated group. Data are presented as mean + SEM. 
Vehicle (n = 10); MK-801 (n = 6).
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6.4 DISCUSSION
6.4.1 The species issue
Many advantages have accrued from the use of rodent models for neuroscience research. 
The extensive normotensive data, their relatively small size and modest cost has allowed 
the conduction of a large battery of structural and functional studies to be undertaken in 
rats which would not be possible in higher order animals because of the technical as 
well as financial limitations (Povlishock et al. 1994). The lissencephalic nature of the 
rodent cortex, however, is recognised as a deficiency in that it does not allow the 
complete modelling of all changes occurring in the complex gyri and sulci of the 
gyrencephalic brain. The experiments described in previous chapters using the rat 
model, although suggestive that axons are not salvaged following the administration of 
MK-801, were not conclusive. This was due firstly to the small shifts of neuronal 
necrosis following drug administration in the rat brain, secondly, due to the difficulty of 
assessing the protective effects of MK-801 in such a small volume of white matter, and 
thirdly, due to the small variance in lesion size within the groups making separation of 
APP scores between the two groups difficult. The potential implications of the failure of 
the classic neuroprotective drug, MK-801, to save white matter following ischaemia are 
huge. The use of higher order animals, such as the cat, which more closely reflects the 
cerebral anatomy of man, was considered necessary to characterise better the pathology 
of white matter injury following therapeutic intervention.
6.4.2 Semi-quantitative versus quantitative analysis of APP
Before a new methodology can be accepted it is important to establish the reliability of 
the technique. Although the semi-quantitative method of analysis of APP has already
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been described for the rat in chapter 4, this had not previously been applied to the cat. 
One could predict that the major limitation of semi-quantitative analysis is that it is 
purely subjective and hence liable to error. However, the results show that the intra-rater 
reproducibility is quite good with the same score being allocated to approximately 80% 
of sections. The weakness of the semi-quantitative system is revealed when a different 
scorer is asked to assess the sections. In this case only 67% of sections were allocated 
the same score by the two assessors. The use of the point-grid technique was developed 
to overcome the subjectivity associated with the semi-quantitative analysis.
Quantification of APP using a fine, regular square array point-grid system was 
found to be a relatively rapid technique. The count of points is always an integer value 
and therefore an approximation. In general, the more points superimposed on any given 
outline, the more accurate the estimate of area. When used for quantification of APP in 
the cat, it was found to be a relatively sensitive scoring method since the scores between 
coronal levels ranged from 1-177 as compared to 1-3 for semi-quantitative analysis. 
Furthermore, it is a more reliable, robust and user friendly method as compared to the 
semi-quantitative analysis. This is highlighted by the fact that there were no significant 
differences between the results obtained by myself and the novice, who had had only a 
few minutes of tuition about the technique (Fig. 6.8B). Using this quantitative 
methodology, it was possible to confidently evaluate the effect of MK-801 treatment on 
the extent of APP accumulation in the white matter tracts of the cat brain following 
MCA occlusion.
6.4.3 MK-801 and the protection of axons
The experiment was designed to answer three questions. In answer to the first, the study 
demonstrated that increased APP immunoreactivity is a consistent outcome in white
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matter after focal cerebral ischaemia in the cat. Secondly, using two different scoring 
systems for APP, it was found that the larger the volume of the ischaemic lesion, the 
greater the extent of increased APP immunoreactivity. Once these two facts had been 
established, it was possible to investigate whether the classic neuroprotective drug, MK- 
801, protects axons following MCA occlusion. The results obtained strongly suggest 
that MK-801 fails to protect axons, as judged by the APP accumulation score, despite 
MK-801 reducing the volume of ischaemic injury of grey matter by 30%. Following 
MK-801 administration the axonal injury was not decreasing with infarct volume at the 
same rate as vehicle treated animals. This was established by assessing the axonal 
injury: infarct volume ratios for the drug treated and vehicle animals. The increased ratio 
in the drug treated group suggests that MK-801 results in more axonal injury relative to 
that o f grey matter injury following MCA occlusion (Fig. 6.13). Even at each coronal 
level, where the MK-801 resulted in reduced neuronal necrosis, the mean APP score 
was approximately the same or higher than that in the vehicle treated animals. It 
appeared that the APP score in the MK-801 treated animals was a value similar to that 
that would be expected if they had not received any treatment at all; the neuroprotective 
drug saved neurons but not axons. This finding has tremendous implications in the 
design and development of drugs for the treatment of stroke. The use of agents targeted 
towards the protection of grey matter alone may be inimical to the function of the brain 
as a whole. The failure of many recent drug trials, and the findings of the present study, 
suggest that the success of future strategies will be dependant on the protection of the 
brain as a whole; that is, the development of either single agents or combination therapy 
targeted at the protection of both grey and white matter. The findings and implications 
of this study will be discussed in more depth in the following chapter.
CHAPTER 7 
DISCUSSION
7.1 INTRODUCTION
The functional integrity of the CNS as a whole depends not only on the normal 
operation of neurons and their synaptic connections, but also on the axons that 
interconnect neurons with each other and carry input and output to and from the CNS. 
Classically white matter has been considered less vulnerable than grey matter to 
ischaemic injury (Marcoux et al. 1982), however recent evidence would suggest 
otherwise (Dewar and Dawson, 1997; Pantoni et al. 1996). Until recently, much less was 
known about the mechanisms of injury in white matter compared to grey matter. Since 
white matter does not contain neuronal cell bodies or synapses, it was considered likely 
that the mechanisms of injury and strategies for its protection were different from those 
in grey matter. Waxman and colleagues, using an in vitro model of isolated optic nerves 
(Waxman et al. 1991; Waxman et al. 1992), have confirmed that myelinated axons are 
susceptible to anoxia in the absence of their perikarya and that functional and structural 
impairment occurs within the axon itself, and not only as a consequence of impaired 
perikaryal function. Using this model, the excitability of CNS axons has shown to be 
critically dependent on an adequate supply of energy and that irreversible axonal injury
9+depends on energy failure and the presence of extracellular Ca (Section 1.5.3) (Stys et 
al. 1990). Although Stys has claimed that at least qualitatively, the mechanisms 
described using the in vitro optic nerve model are operative in an in vivo situation (Stys,
1996), very little work has been published on axonal injury in vivo following focal 
cerebral ischaemia to substantiate this claim. In fact most of the literature pertaining to 
axonal injury in vivo is related to traumatic brain injury.
Studies of traumatic brain injury in a non-human primate model alerted 
Neuroscientists to the importance of white matter injury; Gennarelli and colleagues in 
1982 suggested a direct link between the extent of diffuse axonal injury and the ensuing 
patient morbidity (Gennarelli et al. 1982). This experimental finding has been 
corroborated by evidence of diffuse axonal injury in man in which the most severe 
grades had the commonest association with the vegetative state and severe disability 
(Adams et al. 1989) (section 1.7.2).
Despite these findings, over the last decade the major mechanistic advances in 
the therapy of stroke have been targeted towards the protection of the neuronal cell 
body, with protection of white matter being largely neglected. Following ischaemia, the 
extracellular concentration of the excitatory neurotransmitter glutamate has been show 
to increase to levels that are toxic to neurones, and consequently, drug development has 
been targeted at the blockade of glutamate release or prevention of its action at the 
postsynaptic receptors (Wahlgren, 1997). Since the predominant pathway for calcium 
ion entry into nerve cells in ischaemic CNS tissue is via the glutamate activated NMD A 
receptor channel complex (section 1.5.2), much effort has been focused on the discovery 
and development of molecules that can inhibit the ion fluxes induced by activation of 
this receptor-channel complex. Many studies using NMDA antagonists, including MK- 
801, have been demonstrated in the experimental setting to reduce the volume of 
neuronal necrosis following an ischaemic insult (Fig. 1.8) (Park et al. 1988a and 1988b; 
Ozyurt et al. 1988) (see section 1.6.2). The reported success of these NMDA antagonists 
in the experimental setting, has permitted the progression of drugs to clinical trials in 
man (Bullock, 1998; Small and Buchan, 1997). The results of the phase III trials have 
generally been disappointing. Some of the trials have been stopped prematurely when 
interim analysis has raised concerns about the risk-benefit ratio, and others have been
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stopped when there has been no difference between active treatment and placebo (Muir 
and Lees, 1995). Even in those trials that have been completed, the results have not 
necessarily proven the clinical efficacy of the drugs concerned. The reasons for these 
drug failures are almost certainly multifactorial. However, it cannot be ignored that 
NMDA antagonists are targeted towards the salvation of grey matter and therefore will 
not be effective in cell components such as white matter which are devoid of NMDA 
receptors.
In order that the effect of therapeutic intervention on the protection of white 
matter can be assessed, a method by which white matter injury can be visualised and 
quantified is required. The work described in this thesis set out to investigate different 
markers of axonal injury, develop a suitable method for quantification of axonal injury, 
and finally, using this information, to investigate whether classic neuroprotective drugs, 
such as MK-801, protect axons following an ischaemic insult. In the following sections, 
the results described in the preceding chapters, and the implications for future drug 
development in stroke research, are discussed .
7.2 THE SEARCH FOR A MARKER OF AXONAL INJURY
7.2.1 MAP5, SNAP25, NF68kD and APP
In the era of silver impregnation techniques, axonal bulbs were thought to develop over 
a 12-18 h period (Adams et al. 1989). With the advent of a variety of markers used to 
define the responses of axons to injury, the time scale of axonal bulb visualisation seems 
to have speeded considerably with positive axonal swellings being demonstrated using 
APP at only 1.75 h after head injury (Blumbergs et al. 1995)! APP has attracted 
particular interest as a marker of axonal damage in blunt head injury since it
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accumulates at the location of disruption in axonal transport (McKenzie et al. 1996; 
Gentleman et al. 1995; Sherriff et al. 1994a and 1994c; Blumbergs et al. 1994). 
Furthermore, local neurofilament (NF) changes following blunt head injury in human 
post-mortem and experimental studies have been described using antibodies targeted 
against the 68kDa subunit. Alterations in the staining of these antibodies following head 
injury are sensitive in detecting early changes in the axon which correlate with the 
genesis of impaired axoplasmic transport (Yaghmai and Povlishock, 1992; Grady et al. 
1993; Erb and Povlishock, 1988; Povlishock et al. 1983).
Various markers of axonal injury have been investigated after cerebral ischaemic 
challenges, including APP (Yam et al. 1997; Stephenson et al. 1992; Kalaria et al.
1993). As in response to traumatic brain injury (Sherriff et al. 1994c; Gentleman et al. 
1993; Blumbergs et al. 1994), the increase in APP immunoreactivity in axons which 
occurs in response to cerebral ischaemia is bulb like in appearance and has been 
suggested to be indicative of dysfunction of axonal transport (Shigematsu and McGeer, 
1992). The dependence of axonal transport on the integrity of the cytoskeleton would 
therefore suggest that accumulation of transported proteins may be preceded by 
evidence of changes in cytoskeletal proteins. In this respect, alterations in 
immunostaining of proteins associated with axonal microtubules at 2 and 6 h after 
induction of focal cerebral ischaemia in the rat has been reported (Dewar and Dawson, 
1997). Although axonal damage can be detected in head-injured patients who survive 
only a few hours (Sherriff et al. 1994c; McKenzie et al. 1996; Gentleman et al. 1995), 
demonstration of increased APP immunoreactivity in the rat had been demonstrated, 
prior to this thesis, following at least 24 h of focal cerebral ischaemia (Stephenson et al. 
1992; Yam et al. 1997).
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The work described in Chapter 3 was undertaken to determine the time course of 
changes induced by focal cerebral ischaemia in axonal transport and proteins associated 
with the microtubular and neurofilament components of the cytoskeleton. Alterations in 
immunoreactivity of antibodies directed at an axonally transported protein, a 
microtubule associated protein and a neurofilament protein were investigated at 
different times following permanent MCA occlusion in rats. SNAP25 which plays a role 
in synaptic exocytosis and like APP, undergoes fast anterograde transport (Sollner et al. 
1993; Oyler et al. 1989), the NF68kD subunit of neurofilament protein, which has been 
extensively studied in difiuse axonal injury after traumatic brain injury (Yaghmai and 
Povlishock, 1992; Grady et al. 1993; Erb and Povlishock, 1988; Povlishock et al. 1983), 
and MAP5 which is a component of the microtubular system (Ochs, 1972) and has been 
shown to be sensitive to cerebral ischaemia (Dewar and Dawson, 1997), were all 
examined.
The study demonstrated that ischaemia results in abnormalities of axonal 
neurofilament and microtubule proteins as well as disruption of axonal transport. 
Importantly, these changes occur early in the evolution of ischaemic brain damage with 
both cytoskeletal structural abnormalities and disruption of axonal transport being 
detected within 1 h of MCA occlusion (Table 3.1). SNAP25 immunoreactivity was 
increased in a circumscribed zone in the subcortical white matter (Fig. 3.5) and in the 
white matter tracts permeating the striatum, bordering the area of infarction (Fig. 3.4). 
SNAP25 undergoes fast anterograde transport to the synapse (Hess et al. 1992) and 
therefore its presence within axons at the site of injury may be due to its accumulation 
following inhibition of axoplasmic flow. This hypothesis is supported by the fact that 
the site of its accumulation was found to be very similar to that of APP which also 
undergoes fast anterograde axonal transport (Koo et al. 1990) along microtubules by
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kinesin (Amaratunga et al. 1995), and has been previously shown to accumulate in 
similar regions after inhibition of axoplasmic flow (Yam et al. 1997; Nakamura et al. 
1992; Kawarabayashi et al. 1991; Shigematsu et al. 1992; Otsuka et al. 1991) (see 
below). In addition, the increased immunostaining with SNAP25 after focal ischaemia 
was 'bulbous' in appearance, reminiscent of axonal swellings which occur following 
traumatic brain injury and which have been suggested to be an early indicator of 
axotomy (Povlishock, 1992) (Fig. 7.1). Where microtubules remain in the intact 
axoplasm, fast axonal transport, both anterograde and retrograde, continues resulting in 
accumulation of proteins and organelles at the point or points of damage along the 
length of the axon. SNAP25 appears to be a sensitive marker of axonal injury in this 
model of focal ischaemia. Changes in the immunostaining were evident from 1 h and 
marked by 4 h post MCA occlusion.
The early onset of altered SNAP25 immunoreactivity was consistent with the 
change in NF68kD immunostaining in axons after ischaemia. NFs are composed from 
three subunit polypeptides, the so-called 'neurofilament triplet' (for review see 
Schlaepfer, 1987 and section 1.3). Antibodies to the 68kD subunit have proved to be the 
most useful for detecting reactive axonal change following traumatic brain injury in 
both man and animals (Yaghmai and Povlishock, 1992; Grady et al. 1993). NFs play a 
critical role in determining axonal calibre (Hoffman et al. 1984) and it was interesting 
that by 2 h following MCA occlusion, NF68kD immunostaining was rough and 
disorganised in appearance compared to the contralateral hemisphere and to sham 
operated animals (Fig. 3.7). Also, by 4 h, as with SNAP25, this change of pattern was 
more accentuated (Fig. 3.6 and Fig. 3.7). Furthermore, the electron microscope findings 
described in Chapter 3 support the light microscopic findings, also indicating disruption 
of axonal cytoskeletal structure following MCA occlusion. In the ipsilateral caudate
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nucleus within the core of the infarct, NF spacing in individual myelinated fibre tracts 
was more dispersed and disorganised compared to that in the contralateral hemisphere 
(Fig. 3.10). Misalignment of NFs and accumulation of organelles has previously been 
described to occur in a model of traumatic brain injury at similar time points to that 
found in this study of ischaemic brain injury (Yaghmai and Povlishock, 1992).
However, it is the microtubular component of the cytoskeleton, rather than the NFs, 
which provide the tracks for axonal transport. Microtubules are composed of a core 
cylinder of a  and p-tubulin, the stability and assembly of which is dependent on a 
variety of microtubule associated proteins including MAP la  and MAP5 (Ludin and 
Matus, 1993). Therefore it was significant to find that within 2 h of MCA occlusion, 
altered immunoreactivity was also seen with MAP5 staining. The pattern in the 
myelinated fibre tracts permeating the striatum had a clumped, globular appearance (Fig. 
3.8). Changes in MAP5 immunoreactivity were also evident in the subcortical white 
matter, where the staining was granular in appearance, as has been previously reported 
(Dewar and Dawson, 1997). Early microtubule disruption is supported by ultrastructural 
studies at 2 h after focal ischaemia in the rat (Pantoni et al. 1996) and at even earlier 
time points following axonal stretch injury in the guinea-pig (Maxwell and Graham,
1997). Loss of microtubules in the axons may provide an explanation for the focal 
perturbation of axonal transport that results in the formation of axonal swellings 
characterised by increased SNAP25 and APP immunoreactivity and aggregates of 
axonal organelles as seen by electron microscopy (Fig. 3.13).
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Figure 7.1
»
a
Axonal bulb formation following head injury and ischaemia. APP bulbs 
following diffuse axonal injury in man (a) and focal ischaemia in the rat (b). 
The presence of  axonal bulbs are also evident following focal ischaemia in 
the rat using antibodies to SNAP25 (c).
Amyloid precursor protein immunoreactivity following focal cerebral ischaemia 
was assessed in the rat and cat (Chapter 4 and Chapter 6 respectively). APP 
immunoreactivity was assessed at a single time point but in greater detail than that 
described for MAP5, SNAP25 and NF68kD as described above, with a view to possible 
quantification. APP is considered to be a sensitive marker of axonal injury following 
human head injury and ischaemic insults in man and animals (Yam et al. 1997; Suenaga 
et al. 1994; Stephenson et al. 1992; Kalaria et al. 1993; McKenzie et al. 1996; 
Gentleman et al. 1995; Sherriff et al. 1994c; Blumbergs et al. 1994). The studies using 
APP as a marker of axonal injury described in this thesis demonstrated that increased 
APP immunoreactivity is a consistent outcome in white matter after focal cerebral 
ischaemia in both the rat and cat. As with SNAP25, increased APP immunoreactivity is 
likely to reflect APP accumulation (Shigematsu and McGeer, 1992) due to disruption of 
axonal microtubules (McKenzie et al. 1996). The topographical increase in 
immunoreactivity of APP in white matter tracts is correlated with the distribution of 
infarction (Fig 4.1). In the rat, the APP accumulations were generally found in the 
corpus callosum immediately ventral to the anterior cingulate cortex, a region in which 
pallor in haematoxylin and eosin stained sections was not present after MCA occlusion. 
In addition increased APP staining was also present in white matter tracts permeating 
the caudate nucleus but only at the margin of the zones of neuronal necrosis (Fig. 4.9). 
This is similar to immunocytochemical studies in the human brain where APP 
immunoreactivity was not observed in the core of the infarct (Ohgami et al. 1992).These 
findings lend credence to the possibility that focal ischaemia results in accumulation of 
APP at the periphery of the infarct due to disturbances in axoplasmic flow. Several 
experiments in the rat support this theory; axonal APP accumulation has been reported 
to occur after cytoskeletal disruption incurred after needle stab injury (Otsuka et al.
1991) and injections of excitotoxins such as kainic acid (Kawarabayashi et al. 1991; 
Shigematsu et al. 1992) or ibotenic acid (Nakamura et al. 1992). The possibility that 
there is increased synthesis following such insults could also account for increased APP 
immunoreactivity following such insults. In situ hybridisation techniques have shown an 
increase in APP gene expression in a transectomised facial nucleus (Palacios et al. 1992) 
and ischaemic brain injuries have been shown previously to induce accumulations of 
APP in neuronal perikaiya of the rat (Stephenson et al. 1992; Kalaria et al. 1993).
In the studies undertaken in the cat and rat described in this thesis, the 
interpretation that axonal APP immunoreactivity represents damage to axons is 
supported by the fact that it was found within swollen axons (Fig. 4.8 and Fig. 6.3) and 
it occurred in the areas bordering the area of infarction where axonal disruption is likely 
to have taken place (Fig. 4.1). Since APP is transported by fast anterograde axonal 
transport (Koo et al. 1990), 6 hours in the cat and 24 hours in the rat following MCA 
occlusion appeared to be adequate time for the protein, which is synthesised in the cell 
bodies, to be delivered to and accumulate at the site of axonal injury in sufficient 
quantities for it to be detected. Electron microscope findings would support this view 
since there was evidence of axotomy with accumulation of APP and organelles 
suggestive of disrupted axonal transport (Fig. 3.13). The axons in which APP 
accumulation occurs may thus have viable cell bodies in regions not located within 
boundaries of the ischaemic lesion. The absence of APP staining within the zone of 
ischaemic necrosis reflects the intense ischaemia affecting both axons and cell bodies; 
transport and subsequent accumulation of APP does not occur due to total energy 
failure.
Until recently it was widely thought that white matter showed greater resistance 
to ischaemia-induced damage compared to grey matter. However, the results described
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above using a variety of markers targeting different structures within axons, contribute 
to the growing evidence demonstrating the acute vulnerability of axons to cerebral 
ischaemia in vivo (Dewar and Dawson, 1997; Pantoni et al. 1996). Furthermore, the 
studies described in both rat and cat models of MCA occlusion indicate that APP may 
be a useful marker of axonal injury, and, provided that a suitable method of APP 
quantification could be devised, potentially suitable for the assessment of therapeutic 
intervention in the protection of white matter following an ischaemic insult.
7.2.2 Does APP accumulation reflect irreversible injury to axons?
One could speculate that within the first few hours of MCA occlusion there exists a 
‘therapeutic window’ during which axons can be saved, however no consensus of 
opinion on this matter has yet been reached. APP ‘swellings’, where continuity of the 
axon is still maintained, may reflect a temporary disturbance in axoplasmic flow which 
has the potential for recovery. However, the development of APP positive axonal bulbs, 
whereby secondary axotomy has occurred, may indicate the evolution of irreversible 
brain damage (Maxwell et al. 1997). The time course of axonal bulb formation in the 
ischaemic rat model has yet to be established although increased SNAP25 
immunoreactivity was demonstrated following lh of MCA occlusion (Chapter 3). In 
human head injury, there appears to be a potential for recovery which is time-dependent, 
in that within the first 10 hours recovery may be possible in just under 35% of the axons 
whereas from 10 hours onwards, there is potential for recovery in less than 10% of the 
axons (McKenzie et al. 1996).
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7.2.3 Axonal injury: Common mechanisms following head injury and focal 
cerebral ischaemia
The similarities between the pathobiology of blunt head injury and cerebral ischaemia 
are increasingly recognised. As previously mentioned, axonal damage, which constitutes 
a significant feature of brain pathology resulting from blunt head injury, also occurs in 
response to cerebral ischaemia. The mechanisms underlying axonal damage after blunt 
head injury are thought to involve cytoskeletal abnormalities and disruption of axonal 
transport (Bartus, 1997). The susceptibility of axons to blunt head injury is well 
established and diffuse axonal injury makes a significant contribution to post-injury 
coma and persistent disability (Gennarelli et al. 1982; Adams et al. 1989). The 
mechanisms underlying axonal damage after blunt head injury are thought to involve 
disruption of both neurofilaments and microtubule components of the cytoskeleton 
leading to disruption of axonal transport (Maxwell et al. 1997). The study described in 
Chapter 3 using different markers of axonal injury, indicates that events described 
following head injuiy may also be features of axonal damage resulting from cerebral 
ischaemia. Certain details pertaining to axonal anoxic/ischaemic injuiy overlap with 
head trauma. Nondisruptive axonal injury causes perturbation of the axolemma, 
disruption of ionic homeostasis, and Ca overload with activation of Ca dependent 
enzymes such as calpains and kinases (Maxwell et al. 1997). Although the primary 
insults of stroke and head injury may differ, downstream events may be funnelled into a 
common progression, culminating in irreversible cellular injury (Fig. 7.2). Ischaemic 
brain damage is by far the most common secondary insult following traumatic brain 
injuiy in man and is still found in more than 80% of fatal head injury cases despite 
modem intensive management (Graham et al. 1989). Although the pathogenesis of 
ischaemic brain damage is not yet fully understood, it is thought to occur due to the
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impairment of the normal regulation of the cerebral vasculature following brain trauma. 
This then raises the possibility that axonal damage present after blunt head injury may 
be a consequence not only of the primary insult but also of secondary white matter 
ischaemia.
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Figure 7.2 Mechanisms of axonal injury following traumatic brain 
injury and ischaemia
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7.3 QUANTIFICATION OF AXONAL INJURY
Changes in the immunostaining of a variety of proteins associated with the neuronal 
cytoskeleton following cerebral ischaemia have been described in the preceding 
chapters. The quantitative assessment of acute axonal pathology would be an extremely 
important tool in studies of axonal injury following cerebral ischaemia, particularly for 
the assessment of therapeutic intervention. Of the antibodies investigated, APP seemed 
to be the most promising for this purpose for several reasons. Firstly, APP has 
previously been established as a marker of axonal injury (Gentleman et al. 1993) and 
methods for its quantification have been investigated following head trauma (section 
1.7.2). Secondly, on a more practical level, APP immunostaining was found to be 
superior in FAM fixed paraffin embedded material compared to PAM fixed material, 
the former also being compatible with the accurate delineation of neuronal necrosis. 
Thirdly, APP could be used successfully in both rat and cat material at concentrations 
that were economically viable. A variety of methods were investigated for the 
quantification of APP and are described in detail in Chapter 4, Chapter 6 and Appendix 
4. Desired criteria for a method of quantification include ease of use, reliability and 
robustness. Methods of quantification were initially developed in rat tissue and later 
refined in the cat tissue. In essence, three methods were assessed; firstly a semi- 
quantitative method in which sections were visualised by light microscopy and a score 
ranging from 0-3 allocated based on the quantity and extent of increased APP 
immunoreactivity; secondly a more complex method of quantification was developed 
using the image analyser system which measured the area of APP immunoreactivity, 
distinguishing it from background staining by differences in optical density. Finally, a 
stereotactic method for measuring area of increased APP immunoreactivity was
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developed for use in the cat material. Each method had both advantages and 
disadvantages.
The semi-quantitative analysis was relatively quick and easy to perform. Some 
of the shortfalls of this method could be related to the inherent subjectivity associated 
with it. To minimise subjectivity, all sections had to be assessed in the course of one day 
to maximise scoring consistency. When a selection of slides were re-scored on a second 
occasion the correlation was found to be poor in the rat. However, in the cat, semi- 
quantitative analysis resulted in acceptable intra and inter-rater variability. An 
explanation for this discrepancy could be that the increased APP immunoreactivity in 
the cat sections could be visualised with the naked eye rather than having to use the light 
microscope, thus allowing simultaneous assessment of sections at each coronal level.
The sensitivity of the quantification method is restricted when it is based on a 
score ranging from only 1-3. This was of particular relevance in the rat in which only 8 
coronal levels were assessed, compared to the 16 levels in the cat. The total APP score 
for each rat was dominated by the number of levels with a score of three. However in 
the cat, this effect was diluted by the increased number of levels and lower scores over 
extended distances. This may indicate that increased sensitivity in the rat material could 
be achieved by increasing the number of coronal levels assessed. The eight levels used 
in this study had simply been extrapolated from the work of Osborne et al (1987), 
describing the appropriate levels for calculating volume of infarction following MCA 
occlusion. Sensitivity of the APP score in the rat tissue could perhaps have been 
enhanced by assessing sixteen coronal levels, as was the case in the cat, rather than just 
eight. The other potential pitfall of the semi-quantitative analysis, especially in the rat 
tissue, was the danger of allocating a similar APP score for dense APP 
immunoreactivity in a restricted area as for pale APP immunoreactivity with a more
widespread distribution, i.e. inadvertently the method failed to set clear criteria for 
differentiation of intensity and extent of immunoreactivity. Despite these factors, this 
semi-quantitative method in both the cat and the rat, demonstrated that the larger the 
volume of neuronal necrosis, the greater the extent of increased APP immunoreactivity 
(Fig. 4.3, Fig. 4.10 and Fig. 6.11).
A quantitative method of APP analysis was investigated in rat tissue using the 
MCID image analyser system (Appendix 4). This was developed to measure the area of 
increased APP immunoreactivity, differentiating it from background staining by 
differences in optical density. The theoretical advantage of this technique is that of a 
more accurate and reliable quantification of APP. However, in practice there were two 
main sources of errors which reduced this expected accuracy. Firstly, threshold settings 
had to be manually set by the operator to minimise the inclusion of background staining. 
As with semi-quantitative analysis, this introduced subjectivity into the technique and 
consequently correlation of repeated measures was poor. Secondly, the method was very 
time consuming, requiring multiple steps including visualisation of APP 
immunoreactivity by light microscopy, image capture, threshold setting for each section 
and data analysis. Despite investigating a variety of analytical procedures, the methods 
remained flawed for the reasons just described. This was disappointing since previous 
reports of quantitative analysis using similar systems have been encouraging (Sutherland 
et al. 1996; McKenzie et al. 1995). However, the main difference in one of these reports 
was that the number of positive pre-oc cells in cases of Alzheimer’s disease in the 
entorhinal cortex were counted rather than having their area measured as described in 
Appendix 4. The pre-oc cells were of a uniform size and shape, a fact not true for APP 
swellings or bulbs as seen following focal ischaemia. In another paper describing the 
quantification of features of Creutzfeldt-Jakob disease (Sutherland et al. 1996), a
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completely automated microscope and motorised stage was available which doubtless 
speeded up proceedings. An algorithm was set for spongiform change recognition which 
assumed that each site of vacuolation would have a minimum specified diameter. The 
diameter represented a compromise between the false inclusion of small areas of 
artifactual tissue separation which can occur in human post mortem tissue and the 
rejection of genuine areas of fine vacuolation (Sutherland et al. 1996). Unfortunately it 
would have been difficult to set such criteria for increased APP immunoreactivity since 
the size was variable and often similar to that of tissue artefacts. However, prion protein 
analysis was measured by manual setting of image intensity criteria, the authors 
reporting confidence in the accuracy of the system but failed to verify this statistically 
(Sutherland et al. 1996).
Following 6h MCA occlusion in the cat, increased APP immunoreactivity was 
dense and widespread within the white matter. In recent years stereological techniques 
have been developed to obtain quantitative biological data. This technique could be 
readily adapted for use in the cat material to assess the area within which there was 
increased APP immunoreactivity (Fig. 6.6). Images of sections could be captured and 
printed using the MCID, and using a point square array grid, the number of points 
superimposed on the area of increased APP immunoreactivity counted. The advantages 
of this technique were that it was relatively rapid and robust. The correlation between 
both inter and intra-scorers was very high. Furthermore, the confounding effect of 
difference in intensity of immunoreactivity was removed, with results reflecting purely 
the extent of immunoreactivity. The technique was simple and could be readily 
implemented without the need for high levels of operator skills. Compared to the semi- 
quantitative methods, the potential usefulness of this method could be attributed to its 
considerable statistical power, allowing a higher probability of detecting changes in APP
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immunoreactivity following putative treatments. In the future it would be interesting to 
develop a stereologic means of assessing increased APP immunoreactivity in rat 
sections; this would inevitably be required to be undertaken at the light microscope 
level.
The other novel technique developed was the topographical mapping of 
increased APP immunoreactivity and relating this to the region and extent of infarction 
(Fig. 4.1). This confirmed that APP in white matter tracts is correlated with the 
distribution of infarction. The main weakness in the technique was that the presence of 
APP was represented as an ‘all or none event’, consequently no overall indication of 
incidence of APP immunoreactivity was captured on the diagrams. This is in contrast to 
those diagrams showing ischaemic damage where the incidence of damage had been 
successfully achieved by using a colour scale (Fig. 4.1). Nevertheless, the pictures 
obtained were very interesting, providing information which had never previously been 
captured. The development of these techniques were fundamental for the subsequent use 
of APP as a marker of axonal injury to assess therapeutic interventions in the protection 
of white matter after an ischaemic insult.
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7.4 NEUROPROTECTION: BRAIN PROTECTION?
Until recently virtually no information was available on the mechanisms of 
anoxic/ischaemic damage in central white matter tracts. Given the drastically different 
structure and function of grey matter and white matter regions of the mammalian CNS, 
it is reasonable to expect that these mechanisms may be different. This has important 
implications for the development of therapeutic intervention in diseases such as stroke 
and other conditions, such as traumatic brain injuiy, in which white matter is a 
prominent target of anoxia/ischaemia.
7.4.1 Glutamate antagonists in clinical trials
The rationale for glutamate antagonists in the treatment of stroke is due to converging 
lines of evidence from several animal studies which suggest that glutamate plays a 
pivotal role in the pathogenesis of neuronal cell death following acute focal or global 
ischaemia of the CNS (Muir and Lees, 1995) (see section 1.5.2). Perhaps the most 
powerful evidence in support of glutamate-induced neurotoxicity in focal ischaemia 
comes from many animal studies, performed with a variety of NMDA and non-NMDA 
glutamate antagonists, and glutamate release inhibitors, in which neuroprotective 
efficacy has been shown (see section 1.6). The reason that such a variety of different 
strategies for the development of neuroprotective drugs have been developed is because 
the cascade of events leading from the onset of stroke to cell damage and infarction is 
extremely complex. This has resulted in therapeutic intervention being targeted at 
different points along the injury cascade.
In the early 1990’s a wave of clinical trials testing the efficacy of NMDA 
antagonists in the treatment of cerebral ischaemia was launched (Table 7.1). The results
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have generally been disappointing with many trials being suspended. The clinical 
development of MK-801 was discontinued as a consequence of safety concerns 
including effects on the cardiovascular system and the finding of vacuolation in the rat 
brain following MK-801 administration (Wahlgren, 1997). In 1995, patient recruitment 
in all phase III clinical trials for CGS 19755, Selfotel (a competitive glutamate site 
NMD A antagonist) was terminated based on a report suggesting that the ‘benefit-to- 
risk’ was not significant to warrant continuation of the trial. An acute stroke study of 
another competitive NMDA antagonist, eliprodil (a polyamine site NMDA glutamate 
antagonist), was also recently stopped as an interim analysis revealed that, although 
there were no safety problems, the drug failed to demonstrate a statistically significant 
difference between active treatment and placebo groups. The latest drug trial to have 
been discontinued is that using the non-competitive NMDA antagonist, Aptiganel, due 
to concerns raised over the benefit to risk ratio of the drug treatment.
Two major factors are probably at least partly responsible for the chronicle of 
failed projects; firstly, the complexity of the clinical situation, and secondly, the lack of 
animal models of acute CNS injury which can predict the clinical effectiveness of the 
therapeutic intervention. Some people believe that clinical trials for NMDA antagonists 
in stroke may have been launched prematurely with less than perfect compounds (Small 
and Buchan, 1997); others believe that patient selection and imprecise physiological 
monitoring and control may be partly responsible for the lack of success of clinical trials 
(J. McCulloch, personal communication). Clearly, it is complex. Undoubtedly, the 
reasons for drug trial failure are multifactorial. The issue that has not yet been addressed 
is whether these drugs protect white matter following ischaemia. Perhaps one reason for 
drug failure is that many drugs have been designed to specifically target grey matter 
with little attention being paid to white matter.
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7.4.2 Cerebral white matter is highly vulnerable to ischaemia
White matter has classically been considered less vulnerable than grey matter to 
ischaemic injury initiated by a large artery occlusion (Marcoux et al. 1982). However, a 
recent spate of papers, in addition to the results reported in the preceding chapters of this 
thesis, suggest that cerebral white matter is in fact highly vulnerable to an ischaemic 
insult (Pantoni et al. 1996; Dewar and Dawson, 1997; Yam et al. 1997). White matter is 
critical to motor, sensory, visual and higher cerebral function (Filley, 1998). As an 
indispensable component of the neural networks, cerebral white matter contributes to 
the functional architecture of the brain. Structural or metabolic disturbances of white 
matter may result in functional impairments of the numerous networks within the brain, 
even if neurons are intact. Following most cases of stroke in man, there is infarction 
which, by definition, means pannecrosis of all cellular elements including those in both 
grey and white matter. Because of the essential role of white matter for brain function, 
the necessity for treatments to protect the brain as a whole is paramount.
7.4.3 NMDA antagonists: preservation of white matter?
In the case of ischaemic injury, one approach to treatment is to attenuate secondary 
damage propagation by blocking the NMDA receptors using suitable antagonists (for 
review see Muir and Lees, 1995). These receptor-operated channels are widely 
distributed on cell bodies of CNS neurons (section 1.5.2). Their apparent absence in 
white matter (Jones and Baughman, 1991) raises the question as to whether NMDA- 
receptor channels play a role in acute injury of CNS white matter.
In a recent study, partial crush lesion was inflicted on the optic nerve of adult 
rats and was followed immediately by an injection of MK-801 (Yoles et al. 1997). 
Protection of neurons from secondary degeneration was assessed by retrograde labelling
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of the ganglion cells and by measurement of the visual evoked potential response to 
light. Two weeks after injury, the mean number of neurons that were still intact was 
about three times higher in the MK-801 treated group than in the saline treated group, 
indicating a treatment induced protection of neurons that had escaped primary injury. A 
positive visual evoked potential was obtained in 90% of the MK-801 treated animals but 
in only 50% of injured controls. These results indicate that treatment with MK-801 
following partial crush injury of the optic nerve results in the protection of initially 
spared neurons from secondary degeneration. It is most likely that the primary site of 
action of MK-801 is at the retinal ganglion cells rather than at the lesion site itself as the 
former express high levels of NMDA receptors. It cannot be ruled out that the site of the 
MK-801 was directly on either the optic nerve fibres or on their associated astrocytes.
In the study just described, the protection of cell bodies from secondary 
degeneration following a primary lesion of the optic nerve was assessed. The question 
remains as to whether MK-801 protects both neuronal cell bodies and axonal fibres 
following a primary insult such as ischaemia. To address this question, experiments 
were undertaken in both the rat and cat and are described in this thesis. APP has been 
found to be a suitable marker of axonal injury (section 7.2.1) and a method for APP 
quantification has been developed (section 7.3). The primary hypothesis being tested 
was that if MK-801 protects axons, the APP score should be reduced. Rats were 
subjected to MCA occlusion and the axonal injury in the two groups of animals, a 
vehicle group and an MK-801 group, were compared. MK-801 resulted in a 15% 
reduction of neuronal necrosis but there was little difference in the APP score between 
the groups. Furthermore, subgroup analysis which was performed to tease out trends 
within the data, revealed no evidence of a reduced APP score following MK-801 
treatment. The cat offered a number of advantages over the rat for assessment of axonal
211
injury allowing the limitations encountered in the rat study to be overcome (section 7.3). 
Following 6h of focal cerebral ischaemia in the cat, the MK-801 treated group had a 
reduction in cerebral hemisphere neuronal necrosis of about 30%. A highly reproducible 
method of APP quantification revealed that there was no such reduction in APP 
accumulation score in the MK-801 group of animals. Overall, the quantitative mean 
APP score in the MK-801 treated group was significantly higher than the APP score in 
the vehicle treated group. In addition, the amount of axonal injury, as assessed by the 
quantitative APP score, was corrected for the size of ischaemic damage thus allowing 
the effect of MK-801 on the ratio of white matterigrey matter injury to be established 
(Table 6.7 and Fig. 6.13). The difference in the ratios between the vehicle treated 
animals and drug treated animals was significantly different. The finding that the APP 
score was not reduced following MK-801 administration suggests that MK-801 fails to 
protect axons following focal cerebral ischaemia.
Given that MK-801 has progressed to clinical trials, it is of great significance 
that MK-801 failed to reduce the APP score at any of the 16 coronal levels studied in the 
cat and failed to cause a reduction in the total APP score in drug treated animals 
compared to vehicle treated animals following MCA occlusion. The possibility that the 
drug effects were insufficient to reveal a protective effect on axonal injury as assessed 
by the APP score cannot be disregarded. Additionally it is possible that the method of 
quantification of APP was inadequate. This may be more pertinent to the studies 
undertaken in the rat tissue in which the semi-quantitative scoring method was less 
reproducible and subject to more error than that developed for the cats. Nevertheless, the 
findings described provide no evidence to suggest that MK-801 protects axons. Other 
approaches to support and verify these findings are now required.
As had been the aim, a method was developed to mark and quantify axonal 
injury and was then applied in both the cat and rat following drug intervention. The 
utility of this method in the rat will remain unclear until a positive control can be 
demonstrated whereby the APP score is reduced following MCA occlusion; in this 
regard, a drug that is markedly protective of white matter is eagerly awaited. The 
application of the technique using negative controls, is much more difficult to evaluate. 
Despite similar drawbacks in the cat experiments to that in the rat, the cat, due to its 
greater volume of white matter, provided greater value to the investigation. MK-801 
showed no evidence of axonal protection following an ischaemic insult. Based on these 
findings, it is not unreasonable to hypothesise that clinical trial failure using glutamate 
antagonists, which have been specifically tailored to exert effects on neuronal cell 
bodies, may in part be due to the lack of protection of functionally essential white matter 
tracts. With this in mind, therapeutic strategies should be aimed at the protection of both 
grey and white matter. ‘Brain protection’, rather than neuroprotection, is perhaps the key 
to future success.
7.5 THE FUTURE
Historically, the study of structural changes affecting the cerebral white matter after a 
single artery occlusion has been neglected in favour of experiments that evaluate volume 
of neuronal necrosis (Osborne et al. 1987). This outcome measure has been chosen so 
that it may be measured precisely and comparisons can then be made between studies. 
Such is the case for proximal MCA occlusion where the striatum is always infarcted 
and irreversibly damaged. However, the relationship of the outcome measure of this 
model (the reduction in volume of cortical infarct) has little correlation to functional
outcome (Rogers et al. 1992). Damage to the striatum would leave a human subject 
paralysed. Only rarely have the histological changes of white matter components during 
the first few hours after occlusion of a large cerebral artery been reported (Pantoni et al. 
1996). As yet, there is no clear consensus on the best measures of outcome but clearly 
functional recovery is the end-point most relevant to the patients. Therefore, if the 
outcome measure is the reduction in the volume of brain damage, it is also necessary to 
ascertain whether it is accompanied by improved functional outcome. Ideally the 
outcome measures after experimental stroke in animals should be multiple, and include 
morphological, biochemical, functional and behavioural assays with more emphasis 
being placed on assessing improvement in functional deficits, such as impaired 
cognition or motor co-ordination, in relation to the cerebroprotective properties of a 
drug. An alternative approach to immunocytochemistry for the assessment of axonal 
injury would be the use of the deoxyglucose method. Since glucose is almost the sole 
substrate for cerebral oxidative function, and its utilisation is stoichiometrically related 
to oxygen consumption, the analogue 2-deoxy-D-(14C) glucose, allows glucose 
metabolism to be traced and the measure of local cerebral glucose utilisation to be 
measured by the autoradiographic technique (for review see Kennedy et al. 1992). In 
addition, the development of improved imaging techniques which can be used for man 
and animals, may result in more power to pick up a drug effect in white matter than 
would various rating scales of neurological impairment of functions of daily living 
activities.
The current findings looking at axonal pathology emphasise the need for future 
drug therapies for cerebral ischaemia to target, or at least to operate so as to include 
white matter injury. With this in mind, experimental protocols which are necessary 
when evaluating potential neuroprotective drugs in order to be able to claim that the
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compound is worthy of serious evaluation as a candidate drug, must include the 
evaluation of white matter. With a greater understanding of the details of 
pathophysiology of white matter injury, we will be in a better position to design 
combinations of interventions specifically tailored to each tissue type. For example, 
glutamate antagonists for grey matter with Na+-Ca2+ exchange blockers for white matter, 
or to select common events for inhibition, such as sodium channel blockade. As 
William Holt so eloquently said, ‘Neurons are transmogrified by necrotic vicissitude or 
apoptotic predisposition into noisome nebulae that are aesthetically pleasing to only the 
nappiest of neuronecrophiliacs’ (Holt, 1997). Drug development to prevent a similar 
outcome for axons following ischaemia would be ideal.
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APPENDIX 1
SOURCES OF COMMONLY USED MATERIALS
Monoclonal Anti-MAP lb (MAP5) Sigma Product no. M-4528
Monoclonal anti-P-Tubulin Sigma Product no. T-4026
Monoclonal Anti-Neurofilament 68 Sigma Product no. N-5139
Monoclonal Anti-Alzheimer Precursor Protein Boehringer Mannheim 
(clone 22C11)
Normal Horse Serum 
Biotinylated Anti-Mouse IgG (H + L) 
(Rat adsorbed) Made in horse
Vector S-2000
Vector BA-2001
VectastainR Elite ABC Kit (Mouse IgG) 
Vectastain® Standard Peroxidase Kit
Vector PK-6102
Vector PK-4000
DAB Substrate Kit for Peroxidase Vector SK-4100
Poly-L-Lysine solution Sigma P 8920
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APPENDIX 2
STOCK SOLUTIONS AND BUFFERS 
Tris Buffer
Dissolve 24.4 g Tris in 200 ml of distilled water 
Add 148 ml of 1 N HC1 
Dilute to 41 with distilled water 
pH to 7.6 + 0.2
Tris buffered saline
1 part tris buffer to 9 parts saline
Citrate Buffer for microwaving
Citric acid 8.4 g 
4 1 of distilled water 
pH to 6.0 using 1 M NaOH 
Store in fridge
Preparation of PAM fixative
Require 200 ml per animal
Shelf life is 1 week at 4°C
Make up appropriate volume of phosphate buffer
Weigh out PAM in fume cupboard (4 g/100 ml PB)
Add PAM to buffer and heat to 60-65°C on heated stirrer in fume hood.
Once dissolved completely leave to cool
Preparation of Poly-L-Lysine slides
Clean racks in 1 % acid alcohol to remove any residual dye 
Wash well in running tap water
Load racks with slides and place in poly-L-Lysine solution.0.1 % solution diluted with
distilled water for 5 minutes at room temperature
Drain well and dry at room temperature covering to prevent dust
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MATERIALS FOR ELECTRON MICROSCOPY
Resin
A) Durcupan A/M Epoxy Resin lOg
Sigma (D-0291 Lot 74H2526)
B) Dodecenyl Succinic Anhydride (DDSA) lOg
Agar Scientific Ltd R1053
C) 2,4,6-Tri (dimethylaminomethyl) phenol (DMP-30) 0.3g
Agar Scientific Ltd R1065
D) Dibutyl Phthalate 0.3g
Agar Scientific Ltd R1071
For resin, the components A:B:C:D were mixed in a disposable plastic beaker. 
Uranyl acetate
Use a saturated solution of uranyl acetate in 50% methanol.
Filter before use.
Lead Citrate
Dissolve 1.3g lead nitrate in 30 ml distilled water and add 1.76g sodium citrate.
Shake in a 50 ml volumetric flask. Let stand for 30 minutes with intermittent shaking. 
Add 8 ml 1M NaOH to clear and dilute to 50 ml with distilled water.
Mix by inversion.
Store in well filled, tightly stoppered bottles.
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APPENDIX 3
HAEMATOXYLIN AND EOSIN STAINING FOR PARAFFIN 
SECTIONS
Histoclear 10 min
100% alcohol 2 min
95% alcohol 2 min
Wash in water
Haematoxylin 2-3 min
Wash in water
Acid alcohol seconds
Wash in water
Scot’s tap water until sections turn blue
Eosin 3 min
Wash in water
95% alcohol 2 min
100% alcohol 2 min
Histoclear
Mount in DPX
LUXOL FAST BLUE STAINING FOR PARAFFIN SECTIONS
• Histoclear lOmin
• 100% alcohol 2 min
• 95% alcohol 2 min
• Luxol fast blue 3-4 h
• Methylated spirit 5-10 min
• Wash in water 10 min
• Lithium carbonate few seconds
• 70% methylated spirits until background clear and myelin blue
• Wash in water
• Cresyl violet 5-10 min
• Wash in water
• Acid alcohol (acetic acid in methylated spirit)
• 95% alcohol 2 min
• 100% alcohol 2 min
• Histoclear
• Mount in DPX
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APPENDIX 4
DENSITOMETRIC ANALYSIS OF APP IN THE RAT 
A4.1 METHOD
In order to investigate a quantitative assessment of the relationship between increased 
APP immunoreactivity and infarction, a standard section from each animal was selected 
for evaluation. This corresponded to coronal level 3, the level of the septal nuclei, as 
previously described (Osborne et al. 1987) from the atlas of Konig and Klippel (1963). 
In total 13 sections, one from each animal, was analysed.
For the purpose of quantitative analysis of APP, the ‘Microcomputer Imaging 
Device’ (MCID), an image analysis package, proprietary to ‘Imaging Research Inc.’, 
was used. Since the images are a mosaic of pixels, and measurements based on pixel 
counts are completely dependent upon magnification, it was necessary to calibrate the 
system. Pixels were therefore calibrated to a scale using microns. A standard distance 
was captured on the computer screen with the x 2.5 objective by using a reticule which 
was provided with the MCID system. A horizontal line was drawn and the number of 
pixels for the distance counted (Fig. A4.1). The procedure was repeated for the vertical 
axis. System resolution could be increased either by increasing the number of pixels in 
an image, or by increasing the image magnification so that a smaller area fills a fixed 
number of pixels.
The simplest criterion for APP detection was optical density since APP was 
visualised as a brown precipitate. A blue filter was used when capturing images to 
enhance the contrast between the positive stain and the counterstain which had been 
used on the tissue. Increased APP immunoreactivity was recognised by the computer in
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terms of image intensity. This process involved setting an image intensity threshold so 
that increased APP immunoreactivity was defined such that all pixels darker or lighter 
than the threshold values were ignored. Pixels lying within the threshold density range 
were valid targets and the area of pixels in this threshold range measured. These 
thresholds were chosen to optimise selection of increased APP immunoreactivity whilst 
minimising inclusion of artifactual tissue. This interactive thresholding for each section, 
rather than automated image thresholding, was necessary due to the variability in 
staining of the sections.
The region of interest i.e. the scan area, was selected by the operator and the area 
of increased APP immunoreactivity (within the scan area and threshold range) was 
subsequently measured. In order to quantify the area of increased APP immunoreactivity 
in a repeatable manner, it was necessary to develop a method of analysis whereby the 
maximum area of increased APP immunoreactivity was measured whilst minimising 
tissue artefact inclusion which lay within the image intensity threshold range. Two 
different methods for achieving this were investigated and are described below.
Method 1: Contralateral and ipsilateral artefact considerations
The system was calibrated using the x 2.5 objective. Each section was viewed by light 
microscopy and digitised so that the image was seen on the monitor. An image intensity 
threshold was chosen to define the increased APP immunoreactivity on the ipsilateral 
hemisphere. In order to compensate for the inclusion of artefact within the threshold 
range in the ipsilateral hemisphere, it was assumed that there was a similar area of 
artefact within the threshold range in the contralateral hemisphere. The area of artefacts 
within the threshold range in the contralateral regions were therefore measured and 
deducted from the equivalent ipsilateral regions of interest. Consequently, in total four
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regions were analysed, namely; ipsilateral corpus callosum, contralateral corpus 
callosum, ipsilateral caudate and contralateral caudate. Since the total areas of interest 
could not be visualised on the monitor at the x 2.5 magnification, images were captured 
and ‘patched together’ so that the complete area of interest was analysed. Figure A4.2A 
and A4.2B illustrates this method of analysis for the caudate. All measurements were 
repeated on two consecutive days, the operator unaware of the prior threshold settings, 
to assess method reproducibility.
Method 2: Exclusion of artefacts in ipsilateral hemisphere
The calibration and image intensity range were set as described above. In order to 
minimise inclusion of tissue artefact, rather than selecting the whole corpus callosum 
and caudate as previously described in method 1, the scan area was selected to only 
include (as far as possible) the increased APP immunoreactivity within these regions of 
interest. Animals which did not have any increased APP immunoreactivity in the 
ipsilateral hemisphere in the coronal level 3 were not included. Since there were 
minimal tissue artefact included in the scan areas, assessment of the contralateral 
hemisphere was not required. Figure A4.2C and 2D illustrates this method of analysis.
The same procedure was repeated using the x 5 objective rather than the x 2.5 
objective to magnify the image. Each method was assessed for reproducibility by 
comparing the results obtained on two consecutive days. Graphs were plotted for each 
method and linear regression analysis performed (Fig. A4.3).
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Figure A4.1 Spatial - Distance Calibration
The spatial-distance calibration procedure allows the conversion of pixels to real 
distances. With distance calibrated, the MCID can provide fully quantitative values for 
area.
For the x 2.5 magnification:
Pixels 
Horizontal 601
Vertical 432
pm
3.000
2.000
pixels/pm : 0.200 
pixels/pm : 0.226
For the x 5 magnification: 
Pixels 
Horizontal 556
Vertical 405
pm
1,400
900
pixels/pm: 0.397 
pixels/pm: 0.450
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Figure A4.2 Quantification of APP
APP accumulation
Diffuse background staining
Scan area
Scan area
APP accumulation
Representation o f the two methods of quantification o f APP accumulation. 
Method 1: A, the entire ipsilateral caudate is scanned and threshold range 
selected. Target area in the contralateral caudate, at the same threshold, is 
deducted from ipsilateral target area. B, computer output showing scan area as 
seen in A with recognition o f artefacts and APP accumulation within the 
target range. Method 2: C, scan area in method 2 selected to include only APP 
accumulations. D, computer output showing scan area as seen in C. There is 
minimal inclusion o f tissue artefacts within the threshold range.
Figure A4.3 Assessment of reproducibility for quantitative APP analysis
Method 1- Caudate Method 1-Corpus callosum
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Relationship of APP area in the caudate nucleus and corpus callosum on day 1 and day 
2. The quantity of APP was assessed at coronal level 3 for each animal using different 
methods as described above. This analysis was repeated for each animal and the 
correlation co-efficient calculated. The line of linear regression is shown for each graph.
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A4.2 RESULTS
A4.2.1 Reproducibility of quantitative analysis
For the quantitative analysis using the MCID system, repeated measures for each 
method were drawn on scatter plots to assess reproducibility. The equation for each line
was derived by a least-squares regression method. A summary of the gradient (m),
•  0 * •correlation co-efficient (r) and (r ) for each lme is summarised m the Table A4.1. Using
method 1 (in which the entire ipsilateral hemisphere is analysed), the r2 values, 0.59 for 
the caudate nucleus and 0.64 for the corpus callosum, suggest a lack of linearity of the 
response i.e. a high accumulation score on one day may be low the next and vice versa. 
However, in method 2 (in which the scan area is selected to include only APP 
accumulations) at the lower system resolution, the m value for the corpus callosum 
indicates that the values obtained on day 1 (0.46) are approximately half the values 
obtained on day 2 (0.70). However, the r2 values of 0.82 and 0.93 indicate that by using 
this method, APP accumulation measurements remain consistent relative to each other 
(i.e. a good linearity of response). With increased system resolution, the r2 value for 
each line is 0.80 and 0.77, again suggesting that the relationship of APP accumulation 
between sections is consistent on a day to day basis. The consistency of values (as 
indicated by the slope of the line) was also good, particularly for the corpus callosum 
where m was 1.07. In conclusion, method 2 could potentially be a useful method of 
quantitative analysis of APP provided that all comparative analysis is performed in one 
sitting to ensure consistency of results.
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Table A4.1 Linear regression analysis of repeated measures
Method 1 Method 2 (x 2.5) Method 2 (x 5)
Corpus
callosum
Caudate
nucleus
Corpus
callosum
Caudate
nucleus
Corpus
callosum
Caudate
nucleus
Slope 1.15 0.89 0.46 0.70 1.07 1.50
Correlation 
co-efficient, r 0.80 0.77 0.90 0.96 0.89 0.88
r2 0.64 0.59 0.82 0.93 0.80 0.77
P 0.001 0.002 0.005 0.0001 0.02 0.009
n 13 13 13 13 13 13
The slope, correlation co-efficient, r and r2 values for the repeated measures using the 
different methods of densitometric analysis of APP accumulation. Method 1; the entire 
ipsilateral caudate is scanned and threshold range selected. The target area in the 
contralateral caudate, at the same threshold, is deducted from the ipsilateral target area. 
Method 2; the scan area is selected to only include increased APP immunoreactivity so 
that there is minimal inclusion of tissue artefact within the threshold range.
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Figure A4.4 Relationship of area of APP immunoreactivity to volume of 
infarction
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The volume of ischaemic damage was compared to area of APP immunoreactivity at 
coronal level 3 in the caudate nucleus and corpus callosum as assessed by quantitative 
analysis using method 2 (in which the scan area was selected to only include increased 
APP immunoreactivity). Each point represents data from a single animal.
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A4.2.2 Relationship between ischaemia and APP accumulation
For the quantitative analysis, based on the reproducibility findings, it was decided to 
analysis further the results obtained using method 2 (exclusion of artefacts in ipsilateral 
hemisphere) at the low system resolution. The mean area of APP immunoreactivity in 
the caudate nucleus and mean area of APP immunoreactivity in the corpus callosum 
(from measurements on day 1 and day 2) at coronal level 3 were compared to volume of 
neuronal necrosis for each rat (Fig. A4.4). In the caudate nucleus there did not appear to 
be a direct relationship between area of APP accumulation and total volume of 
ischaemic damage. However, in the corpus callosum there is a more obvious 
relationship although this does not quite reach significance. Since the values represent 
only those for coronal level 3, no firm conclusions can be drawn.
A4.3 DISCUSSION
In order to use APP as a quantitative marker of axonal injury, and to assess the potential 
beneficial effects of therapeutic intervention, a reliable method of quantifying the 
increased APP immunoreactivity is required. It is now also feasible to consider using 
quantitative image analysis techniques as a substantial part of the assessment process; 
however, as with the semi-quantitative analysis, it is necessary to test and validate these 
approaches before they are used for investigative purposes. An inherent problem with 
immunocytochemistry is that of diffuse background staining. Since APP 
immunoreactivity was defined by optical density, inclusion of artefacts and diffuse 
background staining, which were of similar optical density to the APP 
immunoreactivity, were considered to be a likely source of error. It is for this reason that 
different methods of analysis of APP immunoreactivity were developed and
investigated. In the first method, it was assumed that the area of artefact in both 
ipsilateral and contralateral hemispheres would be comparable. Therefore, at the same 
threshold setting, the contralateral target area was deducted from the ipsilateral target 
area, in order to negate the artifactual effects. In the second method the scan area was 
drawn as closely round the target areas as possible to minimise the inclusion of 
background staining and artefacts. The repeatability using this method was superior to 
that used in method 1, particularly at the higher system resolution.
Precautions were taken to try to maintain constancy throughout the experiments, 
including using the same calibration, microscope filter and light intensity. However, 
using either method, two obvious areas that required operator intervention in the 
measurement of increased APP immunoreactivity were the field selection and image 
thresholding stages. To quantify APP within the corpus callosum and caudate in a 
repeatable manner it was necessary that the delineation of anatomic boundaries was 
accurately selected from each section prior to analysis. This function was performed 
manually. This is particularly pertinent to method 1, in which the scan area was much 
larger than that used in method 2. The greater the variation in scan area, the greater the 
variation in background staining and artefacts included. Secondly, operator intervention 
in the image thresholding stage was considered a source of error since it represented a 
compromise between the false inclusion of small areas of artifactual tissue and the 
rejection of genuine areas of increased APP immunoreactivity. The two methods of 
analysis were designed in order to minimise this error. Ideally, target criteria other than 
optical density would be included, such as that of target size, to ensure that targets are 
more clearly discriminable from the background. However, this was extremely difficult 
to apply to APP staining since often the accumulations were of similar size to the 
artefacts. Furthermore, due to the differences in staining and counterstaining between
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sections, it was necessary to reset the threshold range for each section. This problem 
could potentially be overcome by staining and counterstaining all of the sections in one 
batch.
The images for both quantitative methods were captured using a monochrome 
system, each pixel being allocated a grey level value based on the brightness and 
intensity of the image. Although not undertaken, another option would have been to 
capture images using a colour system; the advantages being that the colour system is 
more sophisticated operating using red, green and blue channels. Ultimately, 
information capacity is increased and the system is better equipped for detecting subtle 
changes of the image as compared to monochrome systems (McKenzie et al. 1995).
Overall, the quantitative method of analysis was quite time consuming and 
automation of the technique would be necessary to make it more suitable for routine use. 
Method 2 appeared to be the quantitative method of choice, probably using the lower 
system resolution for speedier results. The results discussed only focus on coronal level 
3 and it would be interesting in the future to assess the other 7 coronal levels using this 
method to give a more precise measure of APP immunoreactivity for each animal. 
Because of the ease with which semi-quantitative analysis could be performed, and the 
fact that it showed that APP accumulation is determined by lesion size, the semi- 
quantitative method was chosen for the quantification of APP following therapeutic 
intervention in the rat (Chapter 5).
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